Page last updated: 2024-12-04

buspirone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Buspirone: An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

buspirone : An azaspiro compound that is 8-azaspiro[4.5]decane-7,9-dione substituted at the nitrogen atom by a 4-(piperazin-1-yl)butyl group which in turn is substituted by a pyrimidin-2-yl group at the N(4) position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2477
CHEMBL ID49
CHEBI ID3223
SCHEMBL ID16398
MeSH IDM0003077

Synonyms (127)

Synonym
BIDD:GT0519
BRD-K93461745-001-01-5
BRD-K93461745-003-03-7
gtpl36
8-[4-(4-pyrimidin-2-yl-piperazin-1-yl)-butyl]-8-aza-spiro[4.5]decane-7,9-dione
KBIO1_000921
DIVK1C_000921
CHEBI:3223 ,
buspirona
8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione
8-(4-(4-(2-pyrimidinyl)-1-piperizinyl)butyl)-8-azaspiro(4,5)decane-7,9-dione
buspironum
buspirone-mdts
SPECTRUM_001756
cas-33386-08-2
NCGC00015162-01
tocris-0962
NCGC00016820-01
lopac-b-7148
NCGC00024905-01
LOPAC0_000223
buspirone (inn)
gen-buspirone (tn)
D07593
BSPBIO_000497
BPBIO1_000547
AB00053432
ansial
buspirone [inn:ban]
brn 0964904
8-azaspiro(4,5)decane-7,9-dione, 8-(4-(4-(2-pyrimidinyl)piperizinyl)butyl)-
buspironum [inn-latin]
n-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-1-cyclopentanediacetamide
8-azaspiro(4.5)decane-7,9-dione, 8-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-
buspirona [inn-spanish]
einecs 253-072-2
buspirone
36505-84-7
C06861
DB00490
PRESTWICK3_000369
PRESTWICK2_000369
NCGC00024905-03
KBIOSS_002236
KBIO2_002236
KBIO2_004804
KBIO2_007372
PRESTWICK0_000369
PRESTWICK1_000369
NINDS_000921
SPBIO_002418
IDI1_000921
BIOMOL-NT_000108
BPBIO1_001403
NCGC00024905-02
gen-buspirone
HMS2090K19
NCGC00015162-06
L001110
bci-024
CHEMBL49 ,
(buspirone) 8-[4-(4-pyrimidin-2-yl-piperazin-1-yl)-butyl]-8-aza-spiro[4.5]decane-7,9-dione
8-[4-(4-pyrimidin-2-yl-piperazin-1-yl)-butyl]-8-aza-spiro[4.5]decane-7,9-dione; hydrochloride(buspirone)
8-[4-(4-pyrimidin-2-yl-piperazin-1-yl)-butyl]-8-aza-spiro[4.5]decane-7,9-dione : (hydrochloride)
bdbm50001859
NCGC00015162-04
AKOS002313325
8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione
8-azaspiro[4.5]decane-7,9-dione, 8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-
cas-36505-84-7
NCGC00255227-01
tox21_302371
dtxcid402707
dtxsid2022707 ,
8-{4-[4-(pyrimidin-2-yl)piperazin-1-yl]butyl}-8-azaspiro[4.5]decane-7,9-dione
STK086268
tox21_110092
CCG-204318
NCGC00015162-03
NCGC00015162-08
NCGC00015162-07
NCGC00015162-05
NCGC00015162-02
tk65wks8hl ,
unii-tk65wks8hl
FT-0621488
buspirone [mi]
buspirone [vandf]
buspirone [inn]
buspirone [who-dd]
SCHEMBL16398
NCGC00015162-10
tox21_110092_1
AB00053432-12
8-[4-[4-(pyrimidine-2-yl)-piperazine-1-yl]-butyl]-8-aza-spiro[4.5]decane-7,9-dione
8-[4-[4-(pyrimidine-2yl)-piperazine-1-yl]-butyl]-8-aza-spiro[4.5]decane-7.9-dione
8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]-butyl]-8-azaspiro[4.5]decane-7,9-dione
8-(4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl)-8-azaspiro[4.5]decane-7,9-dione #
W-106606
8-{4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl}-8-azaspiro[4.5]decane-7,9-dione
buspin
8-(4-(4-(pyrimidin-2-yl)piperazin-1-yl)butyl)-8-azaspiro[4.5]decane-7,9-dione
AB00053432_13
8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-8-azaspiro[4,5]decane-7,9-dione
SBI-0050211.P003
MRF-0000691
A924049
8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4,5]decane-7,9-dione
Q412194
116753-41-4
BRD-K93461745-003-14-4
SDCCGSBI-0050211.P004
NCGC00015162-22
8-azaspiro[4.5]decane-7,9-dione,8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-
buspirone free base
buspironehydrochloride
NCGC00015162-11
buspirone 100 microg/ml in acetonitrile
buspirone 1000 microg/ml in acetonitrile
buspirone; 8-azaspiro[4.5]decane-7,9-dione, 8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]- (9ci)
buspirona (inn-spanish)
8-(4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl)-8-azaspiro(4.5)decane-7,9-dione
n05be01
buspironum (inn-latin)
buspiron
EN300-19748949
EX-A8006F

Research Excerpts

Overview

Buspirone Hydrochloride is an anxiolytic agent and serotonin receptor agonist belonging to azaspirodecanedione class of compounds used in the treatment of anxiety disorders. Buspirone is a serotonin modulating medication and has been shown to augment esophageal peristaltic amplitude in healthy volunteers.

ExcerptReferenceRelevance
"Buspirone is an anxiolytic drug with robust serotonin receptor 1A (Htr1a) agonist activities. "( Assessing the Anti-Inflammatory Activity of the Anxiolytic Drug Buspirone Using CRISPR-Cas9 Gene Editing in LPS-Stimulated BV-2 Microglial Cells.
Al-Badri, G; Castorina, A; Faiz, A; Fisher, T; Keay, KA; Musumeci, G; Thomas Broome, S, 2021
)
2.3
"Buspirone is an effective anxiolytic drug in humans, which has been found, with acute administration, to reduce this anxiety-like response in zebrafish."( Subchronic effects of plant alkaloids on anxiety-like behavior in zebrafish.
Hawkey, AB; Hoeng, J; Koshibu, K; Levin, ED; Peitsch, MC, 2021
)
1.34
"Buspirone is a serotonin modulating medication and has been shown to augment esophageal peristaltic amplitude in healthy volunteers."( A randomized double-blind placebo-controlled crossover-style trial of buspirone in functional dysphagia and ineffective esophageal motility.
Aggarwal, N; Gabbard, S; Lopez, R; Thota, PN, 2018
)
1.44
"Buspirone is a dopamine autoreceptor and D3 receptor antagonist and partial agonist at serotonin 1A receptors, making it a logical candidate medication for methamphetamine-use disorder."( Buspirone maintenance does not alter the reinforcing, subjective, and cardiovascular effects of intranasal methamphetamine.
Lile, JA; Reynolds, AR; Rush, CR; Stoops, WW; Strickland, JC, 2017
)
2.62
"Buspirone Hydrochloride is an anxiolytic agent and serotonin receptor agonist belonging to azaspirodecanedione class of compounds used in the treatment of anxiety disorders. "( Formulation and Evaluation of Niosomal in situ Nasal Gel of a Serotonin Receptor Agonist, Buspirone Hydrochloride for the Brain Delivery via Intranasal Route.
Dua, K; Gujar, KN; Madan, JR; Mathure, D; Ranpise, HA; Tupsamundre, A, 2018
)
2.14
"Buspirone is a commonly prescribed anxiolytic drug with a favorable tolerability profile that may offer potential benefits in anxiety management for patients with HF-ASD."( A Retrospective Chart Review of Buspirone for the Treatment of Anxiety in Psychiatrically Referred Youth with High-Functioning Autism Spectrum Disorder.
Biederman, J; Ceranoglu, TA; DeLeon Fong, M; Fried, R; Galdo, M; Hoskova, B; Joshi, G; Wozniak, J, 2019
)
1.52
"Buspirone is a serotonin (5-HT)1A receptor partial agonist used in the treatment of anxiety disorders and may, therefore, have a treatment role for patients with AS."( Buspirone for the treatment of anxiety-related symptoms in Angelman syndrome: a case series.
Balaj, K; Keary, CJ; McDougle, CJ; Mullett, J; Nowinski, L; Palumbo, ML; Thibert, RL; Walsh, B, 2019
)
2.68
"Buspirone (BP) is a sensitive CYP3A probe drug that is administered through oral/intravenous routes as recommended by the U.S."( The influences of aconitine, an active/toxic alkaloid from aconitum, on the oral pharmacokinetics of CYP3A probe drug buspirone in rats.
Guo, E; Hu, M; Liu, Z; Lu, L; Wang, Y; Wu, J; Zhu, L, 2014
)
1.33
"Buspirone is a 5-HT(1A) receptor agonist with antiaggressive effects increasing prosocial behaviors."( A randomized double-blind placebo-controlled clinical trial of adjuvant buspirone for irritability in autism.
Ayoobzadehshirazi, A; Ghanizadeh, A, 2015
)
1.37
"Buspirone is an anxiolytic that activates dopaminergic and serotonergic systems and improves impulsive choice (i.e., reduces sexual risk-taking intent) in cocaine users when administered chronically."( Effects of acute buspirone administration on inhibitory control and sexual discounting in cocaine users.
Bolin, BL; Romanelli, MR; Rush, CR; Stoops, WW; Strickland, JC, 2017
)
1.52
"Buspirone is a partial 5-HT1A receptor agonist. "( Effect of buspirone on thermal sensory and pain thresholds in human volunteers.
Crozier, TA; Pavlaković, G; Tigges, J, 2009
)
2.2
"Buspirone is a partial agonist of 5-HT(1A) receptors and is used in the treatment of depression and anxiety."( Chronic buspirone treatment decreases 5-HT1B receptor densities and the serotonin transporter but increases the density of 5-HT2A receptors in the bulbectomized rat model of depression: an autoradiographic study.
Diksic, M; Sato, H; Skelin, I, 2010
)
1.52
"Buspirone is an anxiolytic drug and is a partial agonist for the serotonin 5-HT(1A) receptors as well as possessing low affinity and is an antagonist for the dopamine D(2) autoreceptors, with some evidence of a weak affinity to 5-HT(2) receptors. "( Buspirone: what is it all about?
Loane, C; Politis, M, 2012
)
3.26
"Buspirone (Buspar) is a clinically available, non-benzodiazepine anxiolytic medication that acts on both serotonin and dopamine systems."( Effects of chronic buspirone treatment on cocaine self-administration.
Bergman, J; Fivel, PA; Kohut, SJ; Mello, NK, 2013
)
1.44
"Buspirone (Buspar) is a clinically available, non-benzodiazepine anxiolytic medication that acts on serotonin and dopamine systems."( Effects of chronic buspirone treatment on nicotine and concurrent nicotine+cocaine self-administration.
Fivel, PA; Kohut, SJ; Mello, NK, 2013
)
1.44
"Buspirone, which is a partial agonist at 5HT1A receptors, increases prolactin release and may be used as a probe to examine serotonergic responses, dysfunction of which may be relevant to the pathophysiology of social phobia."( A preliminary study of buspirone stimulated prolactin release in generalised social phobia: evidence for enhanced serotonergic responsivity?
Condren, RM; Dinan, TG; Thakore, JH, 2002
)
1.35
"3. Buspirone appears to be an alternative attractive medication to traditional benzodiazepines due to its low addictive potential and lack of lethality."( The use of buspirone in primary care.
Emes, R; Khouzam, HR, 2002
)
1.22
"Buspirone was found to be a weak 5-HT2C receptor antagonist, with a low affinity for 5-HT2A and 5-HT2C receptors. "( Combined treatment with citalopram and buspirone: effects on serotonin 5-HT2A and 5-HT2C receptors in the rat brain.
Hietala, J; Laakso, A; Majasuo, H; Pälvimäki, EP; Penttilä, J; Syvälahti, E, 2006
)
2.05
"Buspirone is a serotonin 5-HT(1A) receptor agonist licensed for the treatment of anxiety. "( Lack of deleterious effects of buspirone on cognition in healthy male volunteers.
Aitken, MR; Cardinal, RN; Chamberlain, SR; Corlett, PR; Deakin, JB; Dowson, J; Müller, U; Robbins, TW; Sahakian, BJ, 2007
)
2.07
"Buspirone is a potent anxiolytic that decreases serotonin transmission. "( Dose related effects of buspirone on serum electrolyte balance, plasma osmolality and systolic blood pressure (SBP) in rats.
Farooq, R; Haleem, DJ; Haleem, MA, 2007
)
2.09
"Buspirone is a novel psychotropic drug with clear anxiolytic activity in man. "( Notes on buspirone's mechanisms of action.
Caccia, S; Garattini, S; Mennini, T, 1982
)
2.12
"Buspirone is a clinically efficacious anti-anxiety drug without any other benzodiazepine-like activity. "( Comparative neuropharmacology of buspirone and MJ-13805, a potential anti-anxiety drug.
Mattiace, LA; McMillen, BA, 1983
)
1.99
"Buspirone is a clinically effective anxiolytic with a unique structure and pharmacology which distinguishes it from the benzodiazepines. "( Neuropharmacology of buspirone.
Eison, AS; Eison, MS; Riblet, LA; Taylor, DP; Temple, DL; VanderMaelen, CP, 1984
)
2.03
"Buspirone hydrochloride is an azaspirodecanedione anxiolytic."( Buspirone, a novel nonbenzodiazepine anxiolytic.
Crismon, ML; Kastenholz, KV,
)
2.3
"Buspirone is an azaspirodecanedione that has anxiolytic actions in man and anticonflict actions in experimental animals. "( Preclinical pharmacology of buspirone hydrochloride.
Paul, SM; Skolnick, P; Weissman, BA,
)
1.87
"Buspirone is a lipophilic, dibasic heterocyclic with no structural resemblance to other anxiolytic or antipsychotic agents. "( Buspirone: chemical profile of a new class of anxioselective agents.
New, JS; Temple, DL; Yevich, JP, 1982
)
3.15
"Buspirone HCl (Buspar) is a novel anxiolytic agent unrelated to the benzodiazepines or other psychotherapeutic agents. "( Buspirone: an anxioselective alternative for the management of anxiety disorders.
Eison, AS; Eison, MS; Newton, RE; Riblet, LA; Taylor, DP; Temple, DL, 1983
)
3.15
"Buspirone is a safe, widely used drug which has a history of use in humans throughout the world."( Buspirone inhibits contact hypersensitivity in the mouse.
ChandraSekar, A; Hwang, GC; Lin, YJ; McAloon, MH; Sharpe, RJ,
)
2.3
"Buspirone is a nonsedating, nonbenzodiazepine anxiolytic with antidepressant properties."( The acute effects of nefazodone, trazodone and buspirone on sleep and sleep-related penile tumescence in normal subjects.
McBrayer, RH; Rose, FV; Ware, JC, 1994
)
1.27
"Buspirone is an anxiolytic agent that appears to have no sedative effects. "( Buspirone effect on breathlessness and exercise performance in patients with chronic obstructive pulmonary disease.
Argyropoulou, P; Georgopoulos, D; Koukou, A; Patakas, D; Vasiliadis, P, 1993
)
3.17
"Buspirone hydrochloride is a valid alternative for treating pathological anxiety in patients in which the state of alertness and good psychomotor skills must be preserved."( [Efficacy of and tolerance to buspirone hydrochloride in the treatment of psychosomatic symptoms in clinical cardiology].
Mansur, Ade P; Pileggi, F; Ramires, JA; Serrano Júnior, CV; Solimene, MC, 1993
)
2.02
"Buspirone is a selective agonist at a subtype of serotonin receptor termed 5-HT1A, whereas fluoxetine is a selective inhibitor of the reuptake of 5-HT."( Serotonin receptor specificity in anxiety disorders.
Lucki, I, 1996
)
1.02
"Buspirone is a member of the azapirone group of anxiolytic drugs and has one major metabolite, 1-(2-pyrimidinyl)piperazine (1-PP). "( Simultaneous quantitation of buspirone and its major metabolite 1-(2-pyrimidinyl)piperazine in human plasma by high-performance liquid chromatography with coulometric detection.
Franklin, M; Odontiadis, J, 1996
)
2.03
"Buspirone is a nonbenzodiazepine anxiolytic that has been effective in uncontrolled trials for treating childhood anxiety disorders. "( Buspirone treatment of anxiety associated with pharyngeal dysphagia in a four-year-old.
Albright, KJ; Feibusch, EL; Hanna, GL, 1997
)
3.18
"Buspirone acts as a partial serotonin agonist at the 5-HT1A receptor."( Weak antidepressant response after buspirone augmentation of serotonin reuptake inhibitors in refractory severe depression.
Fischer, P; Kasper, S; Küfferle, B; Tauscher, J, 1998
)
1.3
"Buspirone is an anxiolytic drug which exerts several central effects. "( Effects of buspirone on plasma neurotransmitters in healthy subjects.
Baez, S; Benaim, M; Jara, H; Lechin, A; Lechin, F; Lechin, M; Orozco, B; van der Dijs, B, 1998
)
2.13
"Buspirone is a novel anxiolytic agent that is commonly used in the treatment of generalized anxiety disorder. "( Seizures associated with buspirone overdose: case report and literature review.
Catalano, G; Catalano, MC; Hanley, PF,
)
1.88
"Buspirone is an anxiolytic drug given at a dosage of 15 mg/day. "( Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug.
Mahmood, I; Sahajwalla, C, 1999
)
2
"Buspirone is an azapirone with 5-HT1A partial agonist activity which has demonstrated efficacy in the treatment of generalized anxiety disorder, commonly referred to as persistent anxiety. "( Meta-analysis of the safety and tolerability of two dose regimens of buspirone in patients with persistent anxiety.
Cutler, NR; Hamid, S; Hong, WW; Nape, B; Sramek, JJ, 1999
)
1.98
"Buspirone is a novel agent which is clinically effective as an anxiolytic but which lacks the muscle relaxant, anticonvulsant and sedative effects of classical anxiolytics. "( Comparison of the effects of buspirone and chlordiazepoxide on differential reinforcement of low rates of response.
McNaughton, N; Panickar, KS, 1992
)
2.02
"Buspirone (BUSP) is a serotonergic (5-HT) agonist with activity at the 5-HT1A receptor. "( Buspirone induced prolactin responses in obsessive-compulsive disorder (OCD): is OCD a 5-HT2 receptor disorder?
Butcher, G; Clare, AW; Dinan, TG; Lucey, JV, 1992
)
3.17
"Buspirone is an anxiolytic drug from the azapirone family of molecules. "( Buspirone: a worldwide update.
Domantay, AG; Napoliello, MJ, 1991
)
3.17
"Buspirone is a newer anxiolytic which differs chemically and pharmacologically from the benzodiazepines. "( Can buspirone induce rebound, dependence or abuse?
Lader, M, 1991
)
2.28
"Buspirone is a novel anxiolytic which does not share the muscle relaxant, anticonvulsant and sedative properties of classical anxiolytics such as the benzodiazepines. "( Comparison of the effects of buspirone and chlordiazepoxide on successive discrimination.
McNaughton, N; Panickar, KS, 1991
)
2.02
"Buspirone is a new drug with ansiolitic properties which chemical structure and mechanism of action is different from the classical drugs traditionally used for this symptom. "( [Buspirone: a new non-benzodiazepine anxiolytic drug].
Catalán, M; Honorato, J, 1990
)
2.63
"Buspirone is a unique anxiolytic drug with established efficacy in the treatment of anxiety. "( Buspirone in the treatment of alcoholic patients.
Bruno, F, 1989
)
3.16
"Buspirone is a novel antianxiety agent with no chemical similarity to other psychotropic medications. "( Clinical effect of buspirone in autistic children.
August, GJ; Garfinkel, BD; Realmuto, GM, 1989
)
2.05
"Buspirone is an anxiolytic drug with an unknown mechanism of action. "( 1-(2-Pyrimidinyl)piperazine antagonizes GABA-activated currents in cultured spinal neurones of the rat.
Hughes, D; Smith, SM, 1989
)
1.72
"Buspirone is a member of a new class of agents known as azaspirodecanediones, and represents the first nonbenzodiazepine anxiolytic to be introduced in the U.S. "( Buspirone: a new type of anxiolytic.
DeVane, CL; Dommisse, CS, 1985
)
3.15
"Buspirone is a novel anti-anxiety drug which has neither a benzodiazepine structure nor any other benzodiazepine-like properties. "( Comparative chronic effects of buspirone or neuroleptics on rat brain dopaminergic neurotransmission.
McMillen, BA, 1985
)
2
"Buspirone is a novel anxiolytic agent unrelated to the benzodiazepines in structure or pharmacologic properties. "( Buspirone: review of its pharmacology and current perspectives on its mechanism of action.
Eison, AS; Temple, DL, 1986
)
3.16
"Buspirone is a novel anxiolytic whose pharmacological profile differs from that of the benzodiazepines and includes dopaminergic agonist effects. "( Buspirone, Parkinson's disease, and the locus ceruleus.
Bakker, K; Bruno, G; Chase, TN; Gillespie, M; LeWitt, PA; Ludwig, CL; Weinberger, DR, 1986
)
3.16
"Buspirone is a novel anxiolytic compound that does not produce the sedation often associated with the use of benzodiazepines. "( The effects of buspirone on sleep in the rat.
Dement, WC; Kaitin, KI; Lerman, JA; Peroutka, SJ, 1986
)
2.07
"Buspirone is a new antianxiety compound of a totally new type which may avoid the dependence problems of its predecessors. "( A comparison of buspirone and placebo in relieving benzodiazepine withdrawal symptoms.
Lader, M; Olajide, D, 1987
)
2.06
"Buspirone is a novel anxiolytic chemically unrelated to the benzodiazepines. "( Buspirone in the treatment of tardive dyskinesia.
Ross, CA, 1987
)
3.16
"Buspirone is an antianxiety compound that has been extensively evaluated in clinical trials: it has proved superior to placebo and comparable to diazepam in the treatment of patients with generalized anxiety disorder. "( A comparison of buspirone, diazepam, and placebo in patients with chronic anxiety states.
Lader, M; Olajide, D, 1987
)
2.06
"Buspirone is a new anxiolytic that is structurally unrelated to other psychotropic drugs. "( Azaspirodecanediones in generalized anxiety disorder: buspirone.
Gershon, S; Ortiz, A; Pohl, R,
)
1.82
"Buspirone (Buspar) is a azaspirodecanedione anxiolytic agent. "( Buspirone: an update on a unique anxiolytic agent.
Jann, MW, 1988
)
3.16
"Buspirone is a new anxiolytic agent with an original chemical structure. "( [Buspirone: pharmacological and clinical properties of the first member of a new anxiolytic drug family].
Bonvalot, T; Boulenger, JP; Zarifian, E,
)
2.48
"Buspirone is a non-benzodiazepine drug with anxiolytic properties. "( Presynaptic control of dopamine metabolism in the nucleus accumbens. Lack of effect of buspirone as demonstrated using in vivo voltammetry.
Le Moal, M; Louilot, A; Simon, H, 1987
)
1.94
"Buspirone is an atypical anxiolytic drug that exerts its action at a receptor site other than the GABA-benzodiazepine-chloride ionophore complex. "( Effect of the anxiolytic drug buspirone on prolactin and corticosterone secretion in stressed and unstressed rats.
Bethea, CL; Lorens, SA; Urban, JH; Van de Kar, LD, 1986
)
2

Effects

Buspirone has a volume of distribution of 5.3 L/kg, a systemic clearance of about 1.7 L/h/kg and an elimination half-life of about 2.5 hours. It has a low oral bioavailability because of extensive first-pass metabolism. Buspirone is potentially susceptible to drug interactions.

Buspirone has been shown to be as effective as diazepam and clorazepate and more effective than placebo in the treatment of generalized anxiety. Buspirone HCl has very low oral bioavailability (4%) due to deactivation by extensive first pass effect.

ExcerptReferenceRelevance
"Buspirone has an indication for generalized anxiety disorder though studies show only a minimal benefit."( Empirically Supported Use of Psychiatric Medications in Adolescents and Adults with IBD.
Bielefeldt, K; Szigethy, E; Thorkelson, G, 2016
)
1.16
"Buspirone has a favorable side-effects profile."( Buspirone versus methylphenidate in the treatment of attention deficit hyperactivity disorder: a double-blind and randomized trial.
Amini, H; Davari-Ashtiani, R; Mazhabdar, H; Razjouyan, K; Shahrbabaki, ME, 2010
)
2.52
"Buspirone has an extensive first-pass metabolism, which makes it potentially susceptible to drug interactions. "( Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone.
Kivistö, KT; Lamberg, TS; Neuvonen, PJ, 1998
)
1.97
"Buspirone has a low oral bioavailability because of extensive first-pass metabolism. "( Grapefruit juice substantially increases plasma concentrations of buspirone.
Backman, JT; Kivistö, KT; Lamberg, TS; Lilja, JJ; Neuvonen, PJ, 1998
)
1.98
"Buspirone has a volume of distribution of 5.3 L/kg, a systemic clearance of about 1.7 L/h/kg, an elimination half-life of about 2.5 hours and the pharmacokinetics are linear over the dose range 10 to 40 mg."( Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug.
Mahmood, I; Sahajwalla, C, 1999
)
1.28
"Buspirone has a unique structure and a pharmacologic profile which distinguishes it from the benzodiazepines."( Pharmacological and clinical effects of buspirone.
Eison, MS; Riblet, LA; Taylor, DP; Vandermaelen, CP, 1985
)
1.26
"Buspirone hydrochloride has low bioavailability of about 4% after oral administration due to first pass metabolism."( Buspirone Hydrochloride Loaded In Situ Nanovesicular Gel as an Anxiolytic Nasal Drug Delivery System: In Vitro and Animal Studies.
Abdallah, MH; Abdelnabi, DM; Elghamry, HA, 2019
)
2.68
"Buspirone HCl has very low oral bioavailability (4%) due to deactivation by extensive first pass effect. "( Transfersomal lyophilized gel of buspirone HCl: formulation, evaluation and statistical optimization.
Elsayed, I; Shamma, RN, 2013
)
2.11
"Buspirone has an indication for generalized anxiety disorder though studies show only a minimal benefit."( Empirically Supported Use of Psychiatric Medications in Adolescents and Adults with IBD.
Bielefeldt, K; Szigethy, E; Thorkelson, G, 2016
)
1.16
"Buspirone has a favorable side-effects profile."( Buspirone versus methylphenidate in the treatment of attention deficit hyperactivity disorder: a double-blind and randomized trial.
Amini, H; Davari-Ashtiani, R; Mazhabdar, H; Razjouyan, K; Shahrbabaki, ME, 2010
)
2.52
"Buspirone has demonstrated anxiolytic benefits but, like benzodiazepines, shows negligible antidepressant action."( Treating generalized anxiety disorder.
Gorman, JM, 2003
)
1.04
"Buspirone hydrochloride has several polymorphs including Form 1 and Form 2. "( Response surface analysis of solution-mediated polymorphic transformation of buspirone hydrochloride.
Murad, S; Rohani, S; Sheikhzadeh, M, 2007
)
2.01
"Buspirone has been shown to be as effective as diazepam and clorazepate and more effective than placebo in the treatment of generalized anxiety."( Buspirone, a novel nonbenzodiazepine anxiolytic.
Crismon, ML; Kastenholz, KV,
)
2.3
"Buspirone has been shown to affect dopaminergic, serotonergic and noradrenergic pathways, as well as the GABA-benzodiazepine receptor chloride ionophore complex."( Preclinical pharmacology of buspirone hydrochloride.
Paul, SM; Skolnick, P; Weissman, BA,
)
1.15
"Buspirone has demonstrated some efficacy in the treatment of a broad range of other serotonin-related disorders."( Azapirones: an alternative to benzodiazepines for anxiety.
Cadieux, RJ, 1996
)
1.02
"Buspirone has previously been reported to be effective in the augmentation of the antidepressant effect of serotonin selective re-uptake inhibitors (SSRIs) in depressed outpatients. "( Buspirone is an effective augmenting agent of serotonin selective re-uptake inhibitors in severe treatment-refractory depression.
Bouwer, C; Stein, DJ, 1997
)
3.18
"Buspirone has an extensive first-pass metabolism, which makes it potentially susceptible to drug interactions. "( Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone.
Kivistö, KT; Lamberg, TS; Neuvonen, PJ, 1998
)
1.97
"Buspirone has a low oral bioavailability because of extensive first-pass metabolism. "( Grapefruit juice substantially increases plasma concentrations of buspirone.
Backman, JT; Kivistö, KT; Lamberg, TS; Lilja, JJ; Neuvonen, PJ, 1998
)
1.98
"Buspirone has a volume of distribution of 5.3 L/kg, a systemic clearance of about 1.7 L/h/kg, an elimination half-life of about 2.5 hours and the pharmacokinetics are linear over the dose range 10 to 40 mg."( Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug.
Mahmood, I; Sahajwalla, C, 1999
)
1.28
"Buspirone has been reported to have effects on punished responding in rats which are considerably smaller and less reliable than those produced by benzodiazepines. "( Increased rates of punished responding produced by buspirone-like compounds in rats.
Sanger, DJ, 1992
)
1.98
"Buspirone has been available in the United States for over four years for the treatment of anxiety. "( Molecular basis of buspirone's anxiolytic action.
Tunnicliff, G, 1991
)
2.05
"One, buspirone, has emerged into clinical practice."( Review of buspirone's effects on human performance and related variables.
O'Hanlon, JF, 1991
)
1.14
"Buspirone has advantages in patients who can tolerate its slow onset of action, with reduced psychomotor effects, lower interactive effects with cortical depressant substances and a seeming lack of dependency or any withdrawal syndrome."( The new and newer antianxiety agents.
Tiller, JW,
)
0.85
"Buspirone has previously been demonstrated to be efficacious in the treatment of anxiety. "( Evaluation of buspirone as an antianxiety agent: buspirone and diazepam versus placebo.
Howarth, BG; Matas, M; Pecknold, JC; Ross, C; Swinson, R; Ungar, W; Vezeau, C, 1989
)
2.08
"Buspirone also has effects on dopamine, norepinephrine, and the GABA systems."( Clinical effect of buspirone in autistic children.
August, GJ; Garfinkel, BD; Realmuto, GM, 1989
)
1.33
"Buspirone has a unique structure and a pharmacologic profile which distinguishes it from the benzodiazepines."( Pharmacological and clinical effects of buspirone.
Eison, MS; Riblet, LA; Taylor, DP; Vandermaelen, CP, 1985
)
1.26
"Buspirone has been introduced as a novel non-benzodiazepine anti-anxiety agent. "( Buspirone effects in an animal conflict procedure: comparison with diazepam and phenobarbital.
Commissaris, RL; McCloskey, TC; Paul, BK, 1987
)
3.16

Actions

Buspirone did not cause the adverse effects of sedation and ataxia, which commonly are seen with diazepam treatment. Buspirone can potently increase dopaminergic impulse flow and metabolism, primarily due to inhibition of DA autoreceptors.

ExcerptReferenceRelevance
"Buspirone promotes recovery of the afferent and efferent connections of the raphe nuclei with the prefrontal cortex and spinal cord involved in integration of the anti-nociceptive and psychoemotional systems."( The Role of 5-HT1A Receptors in Long-Term Adaptation of Newborn Rats to Hypoxia.
Butkevich, IP; Mikhailenko, VA, 2016
)
1.16
"Buspirone did not produce subject-rated drug effects but dose-dependently decreased diastolic blood pressure."( Effects of acute buspirone administration on inhibitory control and sexual discounting in cocaine users.
Bolin, BL; Romanelli, MR; Rush, CR; Stoops, WW; Strickland, JC, 2017
)
1.52
"Buspirone can potently increase dopaminergic impulse flow and metabolism, primarily due to inhibition of DA autoreceptors."( Comparative neuropharmacology of buspirone and MJ-13805, a potential anti-anxiety drug.
Mattiace, LA; McMillen, BA, 1983
)
1.27
"Buspirone appears to cause less clinically significant impairment in cognition or motor performance, is less likely to potentiate the effects of brain depressants like alcohol, has little if any abuse liability, and produces no clinically identifiable physical abstinence syndrome when discontinued after long-term administration."( Clinical studies of buspirone.
Schuckit, MA, 1984
)
1.31
"Buspirone also did not cause the adverse effects of sedation and ataxia, which commonly are seen with diazepam treatment."( Effectiveness of buspirone on urine spraying and inappropriate urination in cats.
Dodman, NH; Eckstein, RA; Hart, BL; Powell, KL, 1993
)
1.35
"The buspirone-induced increase in corticosterone may have abolished the anxiolytic effects of the drug shortly after injection."( Housing conditions and the anxiolytic efficacy of buspirone: the relationship between main and side effects.
Halász, J; Haller, J; Makara, GB, 2000
)
1.04
"Buspirone did not produce vasodilation when perfusion pressure was raised with vasopressin or U46619."( Buspirone, a 5-HT(1A) receptor agonist, dilates the perfused rat uterine vascular bed through alpha(1)-adrenoceptor blockade.
Adeagbo, AS; Kadavil, EA; Oriowo, MA; Yousif, M, 2000
)
2.47
"Buspirone did not produce behavioral side effects that could lead to disability, and alprazolam had minimal side effects. "( Effects of buspirone and alprazolam on the cognitive performance of normal elderly subjects.
Colenda, CC; Hamer, RM; Hart, RP, 1991
)
2.11
"Both buspirone and gepirone enhance the acoustic startle response and gepirone's effect is attenuated in serotonin lesioned animals."( Serotonergic mechanisms in the behavioral effects of buspirone and gepirone.
Eison, AS; Eison, MS; Riblet, LA; Stanley, M, 1986
)
0.98

Treatment

Buspirone pretreatment produces significantly reduction of the lipid peroxidation level (60%) and nitrite content (44%) as well as increased the superoxide dismutase (47%) and catalase (40%) activities. Buspirone treatment also improved mitochondrial function and antioxidant activities.

ExcerptReferenceRelevance
"Buspirone treatment also improved mitochondrial function and antioxidant activities."( The Anxiolytic Drug Buspirone Prevents Rotenone-Induced Toxicity in a Mouse Model of Parkinson's Disease.
Castorina, A; Thomas Broome, S, 2022
)
1.77
"Buspirone treatment reduced the behavioral activity in both the enclosed and exposed open-field, which is generally interpreted as an anxiogenic effect."( Effect of buspirone on the behavioral regulation of rats in low versus high anxiety conditions.
Blokland, A; Esquivel, G; Griez, E; Hameleers, R; Lim, LW; Schruers, K; Steinbusch, H; Temel, Y; Visser-Vandewalle, V, 2008
)
1.47
"Buspirone pretreatment produces significantly reduction of the lipid peroxidation level (60%) and nitrite content (44%) as well as increased the superoxide dismutase (47%) and catalase (40%) activities in rat hippocampus after seizures, when compared with the pilocarpine group."( Oxidative stress in rat hippocampus caused by pilocarpine-induced seizures is reversed by buspirone.
de Freitas, RL; de Freitas, RM; de Souza, GF; Saldanha, GB; Santos, IM; Tomé, Ada R, 2010
)
1.3
"Each buspirone treatment period was followed by saline control treatment until drug- and food-maintained responding returned to baseline levels."( Effects of chronic buspirone treatment on cocaine self-administration.
Bergman, J; Fivel, PA; Kohut, SJ; Mello, NK, 2013
)
1.17
"Buspirone-treated patients had significantly lower scores on the OOWS on days thirteen (p=.040), fourteen (p=.025), fifteen (p=.035), and seventeen (p=.035)."( Effects of buspirone in withdrawal from opiates.
Branchey, M; Buydens-Branchey, L; Rose, JS; Wallach, L,
)
1.24
"Buspirone treatment did not significantly reduce anxiety symptoms in opioid-dependent patients."( A randomized, placebo-controlled trial of buspirone for the treatment of anxiety in opioid-dependent individuals.
Brady, KT; Durkalski, V; McRae, AL; Palesch, Y; Sonne, SC,
)
1.12
"Buspirone-treated group showed improvements in finger to nose and pronation-supination alternating movement test (p=0.046 and p=0.025, respectively). "( The efficacy of combined estrogen and buspirone treatment in olivopontocerebellar atrophy.
Chu, K; Heo, JH; Kim, M; Lee, ST, 2008
)
2.06
"Buspirone treatment showed feasible efficacies for OPCA, while the combined treatment of estrogen and buspirone failed to improve, suggesting estrogen may not have further benefit in cerebellar dysfunction."( The efficacy of combined estrogen and buspirone treatment in olivopontocerebellar atrophy.
Chu, K; Heo, JH; Kim, M; Lee, ST, 2008
)
2.06
"Buspirone treatment markedly increased 5-HT2A receptor mRNA levels in the DG, CA2, CA3 and CA4."( Chronic buspirone treatment differentially regulates 5-HT1A and 5-HT2A receptor mRNA and binding sites in various regions of the rat hippocampus.
Chen, H; Chuang, DM; Rubinow, DR; Zhang, L, 1995
)
1.45
"Buspirone-treated patients showed no rebound anxiety or benzodiazepine-withdrawal syndrome compared with placebo."( Assessment of the efficacy of buspirone in patients affected by generalized anxiety disorder, shifting to buspirone from prior treatment with lorazepam: a placebo-controlled, double-blind study.
Casacchia, M; Delle Chiaie, R; Kotzalidis, GD; Pancheri, P; Stratta, P; Zibellini, M, 1995
)
1.3
"Buspirone pretreatment had no effect on [3H]5-HT uptake in resting rats but prevented the noise-induced decrease in [3H]-HT uptake."( Acute noise stress reduces [3H]5-hydroxytryptamine uptake in rat brain synaptosomes: protective effects of buspirone and tianeptine.
Codegoni, A; Garattini, S; Gobbi, M; Mennini, T; Taddei, C, 1993
)
1.22
"Buspirone-treated patients averaged a 12.4-point reduction from their baseline total HAM-A score of 24.9, while their counterparts on placebo averaged a 9.5-point reduction from their mean baseline total HAM-A score of 25.6. "( Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms.
Amsterdam, JD; Cutler, NR; Hornig-Rohan, M; Sramek, JJ; Stahl, SM; Suri, A; Tansman, M; Weisler, RH, 1996
)
2.12
"Buspirone treatment prevented the loss of dendritic spines previously shown to follow 5-HT depletion with PCA."( 5-HT1a receptors mediate the neurotrophic effect of serotonin on developing dentate granule cells.
Haring, JH; Wilson, CC; Yan, W, 1997
)
1.02
"Both buspirone BID and TID treatment groups demonstrated significant reductions in mean HAM-A total scores and improvement on Clinical Global Impression measures, with no significant differences detected between the two treatment groups for either measure at any time point."( Efficacy and safety of two dosing regimens of buspirone in the treatment of outpatients with persistent anxiety.
Cutler, NR; Frackiewicz, EJ; Sramek, JJ,
)
0.84
"Buspirone pretreatment (0.5-2.0 mg/kg, I.P.) 30 min prior to cocaine (5.0 mg/kg, S.C., 30 min) conditioning had no effect on the acquisition of cocaine-induced CPP."( Buspirone fails to affect cocaine-induced conditioned place preference in the mouse.
Ali, I; Kelly, ME, 1997
)
2.46
"Buspirone treatment leads to significant changes in CD8 T-cell count and in CD4/CD8 ratio. "( Effect of the serotonin receptor agonist, buspirone, on immune function in HIV-infected individuals: a six-month randomized, double-blind, placebo-controlled trial.
Axen, TE; Benfield, T; Eugen-Olsen, J; Iversen, J; Nielsen, JO; Parner, J; Pedersen, C,
)
1.84
"One buspirone-treated and two placebo-treated patients discontinued treatment after 2 weeks because of lack of efficacy."( Buspirone therapy in anxious elderly patients: a controlled clinical trial.
Alms, DR; Böhm, C; Gammans, RE; Leroy, A; Placchi, M; Robinson, DS; Shrotriya, RC, 1990
)
2.2
"Buspirone treatment was also associated with a 57% decrease in DBI scores; statistical comparison of the DBI data with placebo was precluded by the high discontinuation rate in the placebo group."( Buspirone in the treatment of alcoholic patients.
Bruno, F, 1989
)
2.44
"Buspirone treatment was well-tolerated by all subjects even though the 45 mg/day dose was 3 times the recommended starting dose in clinical practice."( Pharmacokinetics of buspirone in elderly subjects.
Gammans, RE; LaBudde, JA; Mayol, RF; Shea, JP; Westrick, ML, 1989
)
1.32
"Buspirone-treated rats gain weight during withdrawal, suggesting that this novel anxiolytic should lack dependence liability in man."( Lack of withdrawal signs of dependence following cessation of treatment or Ro-15,1788 administration to rats chronically treated with buspirone.
Eison, MS, 1986
)
1.2
"Buspirone pretreatment (4.0 mg ."( Buspirone blocks motion sickness and xylazine-induced emesis in the cat.
Crampton, GH; Lucot, JB, 1987
)
2.44
"Treatment with buspirone (3 mg/kg p.o) was given for 4 weeks after confirmation of cachexia in animals."( Beneficial effects of buspirone in endothelin-1 induced stroke cachexia in rats.
Joshi, M; Patel, BM; Shah, D; Shah, J, 2023
)
1.56
"Treatment with buspirone was well-tolerated and resulted in sustained response in all three cases."( Buspirone for the Treatment of Generalized Anxiety Disorder in Williams Syndrome: A Case Series.
Keary, CJ; McDougle, CJ; Pober, BR; Thom, RP; Waxler, JL, 2020
)
2.34
"Treatment with buspirone was safe and well-tolerated and resulted in sustained improvement in symptoms of anxiety for a minimum of 2 years in all 3 cases."( Buspirone for the Treatment of Generalized Anxiety Disorder in Down Syndrome: 3 Cases.
Howe, YJ; McDougle, CJ; Notson, EE; Palumbo, ML; Thom, RP, 2022
)
2.52
"Treatment with buspirone, a partial 5-HT1A receptor agonist which is used in human clinic as an anxiolytic agent, boosts proliferation in the SVZ and DG in both adult and aged opossums."( The partial 5-HT1A receptor agonist buspirone enhances neurogenesis in the opossum (Monodelphis domestica).
Djavadian, RL; Grabiec, M; Turlejski, K, 2009
)
0.97
"Pretreatment with buspirone significantly reduced immobilization-induced hyperglycemia."( Inhibitory effects of the 5-HT(1A) receptor agonist buspirone on stress-induced hyperglycemia in mice: involvement of insulin and a buspirone metabolite, 1-(2-pyrimidinyl)piperazine (1-PP).
Noma, T; Sugimoto, Y; Takashima, N; Yamada, J, 2005
)
0.9
"Pretreatment with buspirone (5, 10 mg/kg, ip) and l-propranolol (10, 20 mg/kg, ip) antagonised the behavioural syndrome induced by 8-OH-DPAT and dextromethorphan."( Involvement of central serotonergic systems in dextromethorphan-induced behavioural syndrome in rats.
Balsara, JJ; Gaikwad, RV; Gaonkar, RK; Jadhav, JH; Jadhav, SA; Thorat, VM, 2005
)
0.65
"Pretreatment with buspirone (1.5 mg/kg) significantly attenuated the effects of aversive memory on c-Fos protein expression in the CA-1 and CA-3 layers of the hippocampus."( Buspirone attenuates conditioned fear-induced c-Fos expression in the rat hippocampus.
Bidziński, A; Lehner, M; Maciejak, P; Płaźnik, A; Skórzewska, A; Szyndler, J; Taracha, E; Wisłowska-Stanek, A; Zienowicz, M, 2005
)
2.09
"Treatment with buspirone resulted in a decrease of the stress-induced increase of virus titers and pulmonary vascular permeability as well as in a reduction of the mortality of mice."( Effects of buspirone on influenza A virus infection in stressed mice.
Castro-Bolaño, C; Freire-Garabal, M; Gándara, J; Losada, C; Núñez, MJ; Pereiro, D; Rey-Méndez, M; Varela-Patiño, MP, 1995
)
1.02
"pretreatment with buspirone (8 mg/kg) and 1-PP (4 mg/kg), the antinociceptive ED50 values of s.c."( Antagonism of clonidine antinociception by buspirone and 1-(2-pyrimidinyl)-piperazine.
Cao, BJ; Li, WP, 1994
)
0.87
"Pretreatment with buspirone (2.0-16 mg/kg, IP) did not attenuate the discriminative stimulus properties of 4.0 mg/kg cocaine at doses up to those that caused complete suppression of responding (16 mg/kg, IP)."( Buspirone fails to affect the discriminative stimulus effects of cocaine.
Rapoza, D, 1993
)
2.05
"Pretreatment with buspirone on the postconditioning test day also failed to affect the expression of an already established place preference response to cocaine."( Buspirone fails to affect cocaine-induced conditioned place preference in the mouse.
Ali, I; Kelly, ME, 1997
)
2.06
"Pretreatment with buspirone (0.5 mg kg(-1), i.p.), or its major metabolite 1-PP (0.5 mg kg(-1), i.p.), attenuated all SSRI-induced anti-immobility effects (P < 0.01)."( Dose-dependent influence of buspirone on the activities of selective serotonin reuptake inhibitors in the mouse forced swimming test.
Bourin, M; Redrobe, JP, 1998
)
0.92

Toxicity

Maternal buspirone protects against the adverse effects of in utero stress on depression and pain in adult rat offspring. Longer co-administration of MPH-buspirone is safe and effective for ADHD patients.

ExcerptReferenceRelevance
" Drug-related toxic signs included decreased activity and convulsions accompanied with salivation and opisthotonus in mice and rats treated with BH regardless of administration routes, and tremors and clonic convulsions accompanied with salivation in dogs treated with BH orally."( [Acute toxicity study of buspirone hydrochloride in mice, rats and dogs].
Chikazawa, H; Ishikawa, K; Kadota, T; Kai, S; Kawano, S; Kohmura, H; Kondoh, H; Kuroyanagi, K; Ohta, S; Takahashi, N, 1990
)
0.58
" Further, the side effect profile in the elderly differed little from that in the younger patients."( The safety and usefulness of buspirone as an anxiolytic drug in elderly versus young patients.
Napoliello, MJ; Robinson, D; Schenk, J, 1988
)
0.57
" In terms of acute toxicity, Pyricapirone was found to be low toxic and belongs to toxicity class IV compounds."( [The safety of pyricapirone--a new psychotropic and antiemetic agent].
Kharin, NA; Naletov, SV; Obraztsova, OG; Zin'kovskaia, LIa,
)
0.13
" The overall incidence of adverse events was similar for both treatment groups, except for a significantly greater incidence of amblyopia in patients receiving buspirone 15 mg BID."( Efficacy and safety of two dosing regimens of buspirone in the treatment of outpatients with persistent anxiety.
Cutler, NR; Frackiewicz, EJ; Sramek, JJ,
)
0.59
" The incidence of adverse events was similar between the two treatment groups, except for a significantly greater incidence of palpitations in patients receiving buspirone BID (5%) compared to buspirone TID (1%)."( Meta-analysis of the safety and tolerability of two dose regimens of buspirone in patients with persistent anxiety.
Cutler, NR; Hamid, S; Hong, WW; Nape, B; Sramek, JJ, 1999
)
0.73
" The adverse events were not essentially different between treatment groups."( Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder.
Davidson, JR; DuPont, RL; Haskins, JT; Hedges, D, 1999
)
0.54
" Selective serotonin and serotonin-noradrenaline re-uptake inhibitors have become more viable treatments for GAD than the traditionally used benzodiazepines due to greater efficacy and a more tolerable adverse event profile."( The safety of SSRIs in generalised anxiety disorder: any reason to be anxious?
Gupta, S; Masand, PS, 2003
)
0.32
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" In accord with its clinical disposition, nefazodone was the most toxic compound of the three, trazodone had relatively modest effects, whereas buspirone showed the least toxicity."( In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone.
Dunn, MC; Dykens, JA; Jamieson, JD; Marroquin, LD; Nadanaciva, S; Smith, AR; Will, Y; Xu, JJ, 2008
)
0.76
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" The present new findings demonstrate that adverse influences of prenatal stress on emotional and inflammatory pain-related behaviors can be prevented by using prenatal buspirone, which shows long-term anxiolytic, antidepressant and antinociceptive effects."( Maternal buspirone protects against the adverse effects of in utero stress on emotional and pain-related behaviors in offspring.
Butkevich, I; Makukhina, G; Mikhailenko, V; Otellin, V; Semionov, P; Vershinina, E, 2011
)
0.98
" There was no statistical significance among treatment arms in remission rates, secondary outcome measures, and adverse events."( A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression.
Calabrese, JR; Cao, L; Chen, J; Cui, X; Fang, Y; Gao, K; Hong, W; Jiang, K; Wang, Y; Wu, Z; Xu, Y; Yi, Z; Yuan, C, 2011
)
0.59
" We recently showed that maternal buspirone, a 5-HT1A receptor agonist, protects against the adverse effects of in utero stress on depression and pain in adult rat offspring."( Buspirone before prenatal stress protects against adverse effects of stress on emotional and inflammatory pain-related behaviors in infant rats: age and sex differences.
Aloisi, AM; Butkevich, IP; Mikhailenko, VA; Otellin, VA; Vershinina, EA, 2011
)
2.09
"The results suggest that compounds that indirectly facilitate 5-HT1 A receptor activation, such as citalopram, may be more effective therapeutics than direct 5-HT1 A receptor agonists because they exhibit similar anti-dyskinesia efficacy, while possessing a reduced side effect profile."( Side effect profile of 5-HT treatments for Parkinson's disease and L-DOPA-induced dyskinesia in rats.
Bishop, C; Conti, MM; Lindenbach, D; Ostock, CY; Palumbo, N; Vilceus, N, 2015
)
0.42
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016
)
0.43
" At higher doses, 50 mg/500 mg/125 mg SpinalonTM was considered to have reached maximum tolerated dose (MTD) since 3 out of 4 subjects experienced related adverse events including vomiting."( Double-Blind, Placebo-Controlled, Randomized Phase I/IIa Study (Safety and Efficacy) with Buspirone/Levodopa/Carbidopa (SpinalonTM) in Subjects with Complete AIS A or Motor-Complete AIS B Spinal Cord Injury.
Dyck, S; Guertin, PA; Kia, M; Matte, G; Mongeon, D; Prince, F; Radhakrishna, M; Roberts, M; Steuer, I; Vaillancourt, M, 2017
)
0.68
"T + S and T + B are well tolerated and safe and significantly increase the number of SSEs in different FSIAD subgroups."( Efficacy and Safety of On-Demand Use of 2 Treatments Designed for Different Etiologies of Female Sexual Interest/Arousal Disorder: 3 Randomized Clinical Trials.
Bloemers, J; Böcker, KBE; de Lange, RPJ; de Leede, L; Derogatis, LR; Eisenegger, C; Everaerd, W; Frijlink, HW; Gerritsen, J; Höhle, D; Kessels, R; Kingsberg, S; Koppeschaar, HPF; Olivier, B; Pfaus, JG; Tuiten, A; van Honk, J; van Rooij, K, 2018
)
0.48
" Secondary outcomes included adverse events, dosage reductions, motor function, dyskinesias, and anxiety."( A trial of buspirone for anxiety in Parkinson's disease: Safety and tolerability.
Auinger, P; Gil-Díaz, MC; Iourinets, J; Richard, IH; Schneider, RB; Tarolli, CG, 2020
)
0.95
" No serious adverse events occurred."( A trial of buspirone for anxiety in Parkinson's disease: Safety and tolerability.
Auinger, P; Gil-Díaz, MC; Iourinets, J; Richard, IH; Schneider, RB; Tarolli, CG, 2020
)
0.95
" Thus, results suggested that prolong co-administration of MPH-buspirone is safe and effective for ADHD patients by preventing adverse effects not only on behavioral but also on biochemical and hematological parameter."( Effect of Methylphenidate and buspirone-methylphenidate co-administration on biochemical and hematological parameters in rats: Implications for safe and confrontational use.
Alam, N; Ikram, R; Kashif, SS; Khan, SS; Khatoon, H; Naeem, S; Siddiqui, T, 2021
)
1.15
" Nonetheless, MTX-induced hippocampal neurotoxicity is a well-defined dose-limiting adverse effect that limits clinical utility."( Buspirone attenuated methotrexate-induced hippocampal toxicity in rats by regulating Nrf2/HO-1, PPAR-γ, NF-κB/nNOS, and ROS/NLRP3/caspase-1 signaling pathways.
Al-Thubiani, WS; Almohaimeed, HM; Althagafy, HS; Batawi, AH; Hassanein, EHM; Rateb, A; Sharawi, ZW, 2023
)
2.35

Pharmacokinetics

Deramciclane does not inhibit CYP3A4 activity as measured by buspirone pharmacokinetics. There were no significant differences between the young and elderly of either gender with regard to busPirone AUC, Cmax, Tmax and half-life values.

ExcerptReferenceRelevance
" The pharmacodynamic effects of buspirone and clobazam were compared in two volunteer studies."( Pharmacodynamic effects of buspirone and clobazam.
Alford, C; Bhatti, JZ; Curran, S; Hindmarch, I; McKay, G, 1991
)
0.86
" There were no significant differences between the young and elderly of either gender with regard to buspirone AUC, Cmax, Tmax and half-life values."( Pharmacokinetics of buspirone in elderly subjects.
Gammans, RE; LaBudde, JA; Mayol, RF; Shea, JP; Westrick, ML, 1989
)
0.82
" The differences between the median pharmacokinetic values of buspirone for healthy subjects, patients with mild to moderate renal impairment, and anuric patients were not statistically significant."( Clinical pharmacokinetics of oral buspirone in patients with impaired renal function.
Caccia, S; Gammans, RE; Garattini, S; Mayol, RF; Mingardi, G; Pfeffer, M; Placchi, M; Vigano, GL, 1988
)
0.79
"7 h), but mean maximum concentration Cmax was higher in patients (18."( Buspirone pharmacokinetics in patients with cirrhosis.
Dalhoff, K; Gammans, RE; Garred, P; Mayol, RF; Pfeffer, M; Placchi, M; Poulsen, HE, 1987
)
1.72
" It achieves peak serum concentrations within one hour and has a serum half-life of 2 to 5 hours."( Buspirone hydrochloride: a unique new anxiolytic agent. Pharmacokinetics, clinical pharmacology, abuse potential and clinical efficacy.
Goldberg, HL,
)
1.57
"The steady-state pharmacokinetic interaction between buspirone and alprazolam was evaluated in a parallel study with two groups of 12 male volunteers each."( A study of pharmacokinetic interaction between buspirone and alprazolam at steady state.
Barbhaiya, RH; Buch, AB; Seidehamel, RJ; Van Harken, DR, 1993
)
0.79
"The pharmacokinetic interaction between buspirone and haloperidol was evaluated in schizophrenic patients in two different groups."( Lack of pharmacokinetic interaction between buspirone and haloperidol in patients with schizophrenia.
Chang, TP; Chang, WH; Chen, JS; Chien, CP; Huang, HF; Jann, MW; Juang, DJ; Lam, YW; Lin, SK; Wei, FC, 1996
)
0.82
"The feasibility of an electrochemical detection system with on-line microdialysis coupled with sensitive microbore high-performance liquid chromatography for the measurement and brain pharmacokinetic analysis of buspirone was investigated."( Measurement and pharmacokinetic analysis of buspirone by means of brain microdialysis coupled to high-performance liquid chromatography with electrochemical detection.
Chen, CF; Tsai, TH, 1997
)
0.74
" The elimination half-life of buspirone was not changed by verapamil and diltiazem."( Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone.
Kivistö, KT; Lamberg, TS; Neuvonen, PJ, 1998
)
0.81
" Prediction of food effect response on the basis of the physicochemical and pharmacokinetic characteristics of the drug molecule or formulations is discussed."( [Role of food interaction pharmacokinetic studies in drug development. Food interaction studies of theophylline and nifedipine retard and buspirone tablets].
Drabant, S; Farsang, C; Gachályi, B; Klebovich, I; Renczes, G, 1998
)
0.5
" The half-life of buspirone was not affected."( The effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of buspirone.
Kivistö, KT; Laitila, J; Lamberg, TS; Mårtensson, K; Neuvonen, PJ,
)
0.7
" However, this pharmacokinetic interaction was not associated with impairment of psychomotor performance and it is probably of limited clinical significance."( The effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of buspirone.
Kivistö, KT; Laitila, J; Lamberg, TS; Mårtensson, K; Neuvonen, PJ,
)
0.36
"05) and the Cmax by 57% (P<0."( Interactions of buspirone with itraconazole and rifampicin: effects on the pharmacokinetics of the active 1-(2-pyrimidinyl)-piperazine metabolite of buspirone.
Kivistö, KT; Lamberg, TS; Neuvonen, PJ, 1999
)
0.65
" Plasma concentrations of buspirone were measured up to 18 hr and its pharmacodynamic effects up to 8 hr."( Lack of effect of terfenadine on the pharmacokinetics of the CYP3A4 substrate buspirone.
Kivistö, KT; Lamberg, TS; Neuvonen, PJ, 1999
)
0.83
" Examination of Cmin vs time plots revealed that the steady state was attained by day 7 except for one monkey who demonstrated much higher Cmin values."( Pharmacokinetics of buspirone following oral administration to rhesus monkeys.
Greene, DS; Marathe, PH; Markham, P; Shen, F, 1999
)
0.63
" The pharmacokinetic parameters AUC0-t, AUC0-infinity, Cmax, tmax, Ke, and t1/2 were calculated and statistically analyzed."( Pharmacokinetics of buspirone extended-release tablets: a single-dose study.
Andheria, M; Sakr, A, 2001
)
0.63
" Pharmacokinetic profiles of buspirone and its metabolite, 1-pyrimidinylpiperazine (1-PP), were obtained at steady state."( A comparative multidose pharmacokinetic study of buspirone extended-release tablets with a reference immediate-release product.
Andheria, M; Sakr, A, 2001
)
0.86
" Pharmacokinetic analysis revealed that buspirone was rapidly absorbed in all study groups, reaching peak levels at about 1 hour after administration."( Pharmacokinetics and tolerability of buspirone during oral administration to children and adolescents with anxiety disorder and normal healthy adults.
Cutler, NR; Dockens, R; Frackiewicz, EJ; Fulmor, IE; Kollia, G; Salazar, DE; Shiovitz, TM; Sramek, JJ; Tigel, PD; Uderman, HD, 2001
)
0.85
"2 ml/min and for terminal elimination half-life of 25 and 79 min, respectively."( Pharmacokinetic-pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats.
Danhof, M; Maas, HJ; Peletier, LA; Rusiç-Pavletiç, J; Van der Graaf, PH; Zuideveld, KP, 2002
)
0.58
" The secondary objective was to study the possible pharmacodynamic interaction between these two anxiolytic drugs."( Effect of the novel anxiolytic drug deramciclane on the pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug buspirone.
Ahokoski, O; Anttila, M; Björklund, H; Hänninen, J; Huupponen, R; Laine, K; Palovaara, S; Rouru, J; Ruuskanen, J, 2003
)
0.53
" Pharmacodynamic testing and measurement of plasma prolactin concentrations were carried out on day 7 and day 8 to assess the pharmacodynamic consequences of deramciclane and buspirone co-administration."( Effect of the novel anxiolytic drug deramciclane on the pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug buspirone.
Ahokoski, O; Anttila, M; Björklund, H; Hänninen, J; Huupponen, R; Laine, K; Palovaara, S; Rouru, J; Ruuskanen, J, 2003
)
0.72
"001) and 20% increase in the elimination half-life ( P=0."( Effect of the novel anxiolytic drug deramciclane on the pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug buspirone.
Ahokoski, O; Anttila, M; Björklund, H; Hänninen, J; Huupponen, R; Laine, K; Palovaara, S; Rouru, J; Ruuskanen, J, 2003
)
0.53
"Deramciclane does not inhibit CYP3A4 activity as measured by buspirone pharmacokinetics, and there were no indications of relevant pharmacodynamic interaction after multiple doses of deramciclane and a single dose of buspirone."( Effect of the novel anxiolytic drug deramciclane on the pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug buspirone.
Ahokoski, O; Anttila, M; Björklund, H; Hänninen, J; Huupponen, R; Laine, K; Palovaara, S; Rouru, J; Ruuskanen, J, 2003
)
0.77
" The present method provides an accurate, precise and sensitive tool for buspirone and was successfully applied to a pharmacokinetic study in eight subjects."( Rapid and highly sensitive liquid chromatography/electrospray ionization tandem mass spectrometry method for the quantitation of buspirone in human plasma: application to a pharmacokinetic study.
Cho, SH; Choi, YW; Im, HT; Lee, HW; Lee, KT; Park, WS; Rew, JH, 2006
)
0.77
"3 l/kg), and half-life (1."( 6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats.
Dockens, RC; Grace, JE; Li, YW; Pajor, L; Stark, AD; Taub, RA; Wong, H; Yeola, S; Yocca, FD; Zaczek, RC, 2007
)
0.76
"Based on these analyses, it is concluded that allometrically scaled mechanism based PK-PD models are promising as a means of predicting the pharmacodynamic responses in man."( Allometric scaling of pharmacodynamic responses: application to 5-Ht1A receptor mediated responses from rat to man.
Danhof, M; Peletier, LA; Van der Graaf, PH; Zuideveld, KP, 2007
)
0.34
" The method was successfully applied for pharmacokinetic study of buspirone after application of reservoir based transdermal therapeutic system of BUSP to rabbits."( Development of high performance liquid chromatography method for buspirone in rabbit serum: Application to pharmacokinetic study.
Gannu, R; Kotagiri, H; Palem, CR; Yamsani, MR; Yamsani, SK; Yamsani, VV, 2009
)
0.83
" This fully validated method was applied to a pharmacokinetic study of atractylenolide I in rats administered with 20 g/kg Atractylodis extract."( Quantitative analysis of atractylenolide I in rat plasma by LC-MS/MS method and its application to pharmacokinetic study.
Chen, B; Li, Y; Tian, Y; Wang, Z; Zhang, Y; Zhu, J, 2012
)
0.38
" After fixing three mechanism-specific pharmacodynamic parameters (I (max) and γ2 for NRI and γ1 for 5-HT(1A)) based on the model for atomoxetine and/or buspirone, the model fitted the exposure-response profiles of PF-04269339 and PF-03529936 well."( Mechanism-based pharmacokinetic/pharmacodynamic modeling of rat prefrontal cortical dopamine response to dual acting norepinephrine reuptake inhibitor and 5-HT1A partial agonist.
Barta, N; Brodfuehrer, J; Campbell, B; Dounay, A; Gray, D; Haske, T; Lepsy, C; Li, CS; Zhang, L, 2012
)
0.57
" The studies provide no evidence for concern about clinically important pharmacokinetic drug interactions of BBJ with substrate drugs metabolized by CYP3A or CYP2C9."( Effect of blueberry juice on clearance of buspirone and flurbiprofen in human volunteers.
Cancalon, PF; Court, MH; Dolnikowski, GG; Greenblatt, DJ; Hanley, MJ; Harmatz, JS; Masse, G, 2013
)
0.65
" The fully validated method was applied to a pharmacokinetic and urine excretion study for the first time."( Determination of diosbulbin B in rat plasma and urine by LC-MS/MS and its application in pharmacokinetic and urinary excretion studies.
Chen, B; Gan, L; Li, Y; Qiao, J; Tian, Y, 2013
)
0.39
" Here we tested the pharmacodynamic consequences of these properties in a P-gp deficient mouse model by studying the effects of aripiprazole and of ziprasidone on motor coordination."( Pharmacodynamic effects of aripiprazole and ziprasidone with respect to p-glycoprotein substrate properties.
Frisch, J; Hiemke, C; Holthoewer, D; Kirschbaum, KM; Schmitt, U, 2013
)
0.39
"Evidence was given that P-gp substrate properties have pharmacodynamic consequences for aripiprazole but not for ziprasidone and thus affect dopamine receptor related motor behaviour."( Pharmacodynamic effects of aripiprazole and ziprasidone with respect to p-glycoprotein substrate properties.
Frisch, J; Hiemke, C; Holthoewer, D; Kirschbaum, KM; Schmitt, U, 2013
)
0.39
" Biological investigations including pharmacokinetic studies, brain drug targeting efficiency determinations and histopathological examinations were performed on rats."( Chitosan and cyclodextrin in intranasal microemulsion for improved brain buspirone hydrochloride pharmacokinetics in rats.
Bshara, H; El-Shamy, Ael-H; Mansour, S; Osman, R, 2014
)
0.63
"The aim of this study was to elucidate the inhibition mechanism of 18β-glycyrrhetic acid (GLY) on cytochrome P450 (CYP) activity and in vivo pharmacokinetic consequences of single GLY dose in rats."( Modulation of Cytochrome P450 Activity by 18β-Glycyrrhetic Acid and its Consequence on Buspirone Pharmacokinetics in Rats.
Cho, HJ; Kim, DD; Kim, SB; Kim, YS; Yoon, IS, 2015
)
0.64

Compound-Compound Interactions

The present study aims to determine if an in vivo rat model of drug-drug interaction (DDI) could be useful to discriminate a sensitive (buspirone) from a 'non-sensitive' (verapamil) CYP3A substrate.

ExcerptReferenceRelevance
" This article reviews drug-drug interactions for an effective new non-benzodiazepine anxiolytic, buspirone."( Alcohol and drug interactions with antianxiety medications.
Schuckit, MA, 1987
)
0.49
"5 mg/70 kg), and placebo, alone and in combination with ethanol (0-0."( Acute participant-rated and behavioral effects of alprazolam and buspirone, alone and in combination with ethanol, in normal volunteers.
Griffiths, RR; Rush, CR, 1997
)
0.53
"Sixty patients with GAD were randomly assigned to treatment with buspirone or placebo, combined with anxiety management training or non-directive therapy for a period of 8 weeks."( Treatment of generalised anxiety disorder with a short course of psychological therapy, combined with buspirone or placebo.
Bond, AJ; Lader, MH; Valerie Curran, H; Wingrove, J, 2002
)
0.77
" In order to accelerate and maximise the clinical response in depressive patients, clinician should prefer to optimize the fluoxetine dose instead of in combination with buspirone."( Faster response in depressive patients treated with fluoxetine alone than in combination with buspirone.
Onder, E; Tural, U, 2003
)
0.73
" We present here an approach to determine the extent of circulating metabolites using 'metabolite standards' generated by in vitro incubations in combination with the correction for mass spectrometry response based on UV response."( Quantitative estimation of circulating metabolites without synthetic standards by ultra-high-performance liquid chromatography/high resolution accurate mass spectrometry in combination with UV correction.
Grubb, MF; Humphreys, WG; Josephs, JL; Luk, CE; Yang, Y, 2011
)
0.37
"Serotonin syndrome can be a rare but life-threatening condition that is commonly the result of a drug-drug interaction causing excessive serotonin activity."( Probable drug-drug interaction leading to serotonin syndrome in a patient treated with concomitant buspirone and linezolid in the setting of therapeutic hypothermia.
Morrison, EK; Rowe, AS, 2012
)
0.6
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38
" While grapefruit juice has been extensively studied with respect to its drug-drug interaction potential, numerous other fruit juices such as cranberry juice, orange juice, grape juice, pineapple juice and pomegranate juice have also been investigated for its potential to show drug-drug interaction of any clinical relevance."( Is pomegranate juice a potential perpetrator of clinical drug-drug interactions? Review of the in vitro, preclinical and clinical evidence.
Srinivas, NR, 2013
)
0.39
"The present study aims to determine if an in vivo rat model of drug-drug interaction (DDI) could be useful to discriminate a sensitive (buspirone) from a 'non-sensitive' (verapamil) CYP3A substrate, using ketoconazole and ritonavir as perpetrator drugs."( Assessment of CYP3A-mediated drug-drug interaction potential for victim drugs using an in vivo rat model.
Bellavance, E; Bourg, S; Duan, J; Garneau, M; Ribadeneira, MD; Rioux, N, 2013
)
0.59
" In an explorative, randomized, double-blind, placebo-controlled, crossover study we investigated the possible effects of sublingual testosterone combined with a serotonin (5-HT)1A receptor agonist, and of sublingual testosterone combined with a phosphodiesterase type 5 inhibitor (PDE5-i) on sexual functioning in women with SSRI-induced sexual dysfunction."( Efficacy of testosterone combined with a PDE5 inhibitor and testosterone combined with a serotonin (1A) receptor agonist in women with SSRI-induced sexual dysfunction. A preliminary study.
Bloemers, J; Goldstein, A; Koppeschaar, H; Olivier, B; Poels, S; Tuiten, A; van Rooij, K; Worst, P, 2015
)
0.42
"The aim of this review is to describe the rationale and main underlying reasons for undertaking, during clinical development, the study of drug candidates used separately and/or in combination with other technologies."( Rationale for Assessing Safety and Efficacy of Drug Candidates Alone and in Combination with Medical Devices: The Case Study of SpinalonTM.
Guertin, PA, 2017
)
0.46

Bioavailability

Buspirone HCl has a low oral bioavailability because of extensive first-pass metabolism. Food increases the bioavailability of buspirone by decreasing first- pass metabolism. The aim of this study was to develop Buspirone hydrochloride microemulsion formulations for intranasal administration.

ExcerptReferenceRelevance
" Thus, the ex vivo binding assay could be utilized to determine the bioavailability of the drug to the brain, and its duration of action."( Pharmacokinetics of buspirone as determined by ex vivo (3H)-DPAT binding.
Francis, JW; Sethy, VH, 1988
)
0.6
" Food increases the bioavailability of buspirone by decreasing first-pass metabolism; absorption is not markedly altered."( Metabolism and disposition of buspirone.
Gammans, RE; LaBudde, JA; Mayol, RF, 1986
)
0.83
"The oral bioavailability of buspirone is very low as a result of extensive first-pass metabolism."( Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole.
Kantola, T; Kivistö, KT; Lamberg, TS; Neuvonen, PJ, 1997
)
1.05
" Well known example, that bioavailability of theophylline can be influenced in different way (either increased, decreased or unchanged) by concomitant intake of food in the case of different sustained release products."( [Role of food interaction pharmacokinetic studies in drug development. Food interaction studies of theophylline and nifedipine retard and buspirone tablets].
Drabant, S; Farsang, C; Gachályi, B; Klebovich, I; Renczes, G, 1998
)
0.5
"Buspirone has a low oral bioavailability because of extensive first-pass metabolism."( Grapefruit juice substantially increases plasma concentrations of buspirone.
Backman, JT; Kivistö, KT; Lamberg, TS; Lilja, JJ; Neuvonen, PJ, 1998
)
1.98
" The absolute bioavailability of buspirone is approximately 4%."( Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug.
Mahmood, I; Sahajwalla, C, 1999
)
0.84
" The results indicated extended release of buspirone from the two test products in vivo with a 70% to 90% greater bioavailability in comparison with the IR formulation."( Pharmacokinetics of buspirone extended-release tablets: a single-dose study.
Andheria, M; Sakr, A, 2001
)
0.9
" The bioavailability of buspirone from the ER formulation was more than three times higher than that from the IR formulation at steady state, and that of 1-PP was about 25% less."( A comparative multidose pharmacokinetic study of buspirone extended-release tablets with a reference immediate-release product.
Andheria, M; Sakr, A, 2001
)
0.87
" No significant differences in bioavailability were observed between the IR and the three gepirone-ER formulations, indicating that any of the once-daily gepirone-ER formulations could be substituted for gepirone-IR."( Pharmacokinetic evaluation of gepirone immediate-release capsules and gepirone extended-release tablets in healthy volunteers.
Sitsen, JM; Timmer, CJ, 2003
)
0.32
" Bioavailability was higher for 6-OH-buspirone (19%) compared with that for buspirone (1."( 6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats.
Dockens, RC; Grace, JE; Li, YW; Pajor, L; Stark, AD; Taub, RA; Wong, H; Yeola, S; Yocca, FD; Zaczek, RC, 2007
)
1.03
" Thus formulations can be used to improve bioavailability of buspirone HCl."( Intranasal mucoadhesive buspirone formulation: in vitro characterization and nasal clearance studies.
Khan, SA; Patil, KS; Yeole, PG, 2008
)
0.89
"The purpose of this study was to find out whether nasal application of buspirone could increase its bioavailability and directly transport the drug from nose to brain."( Brain targeting studies on buspirone hydrochloride after intranasal administration of mucoadhesive formulation in rats.
Gaikwad, R; Khan, S; Patil, K; Yeole, P, 2009
)
0.88
"The nasal Bus-chitosan formulation improved the absolute bioavailability to 61% and the plasma concentration peaked at 30 min whereas the peak for nasal Bus-plain formulation was 60 min."( Brain targeting studies on buspirone hydrochloride after intranasal administration of mucoadhesive formulation in rats.
Gaikwad, R; Khan, S; Patil, K; Yeole, P, 2009
)
0.65
" It was found that the relative bioavailability of the drug in SLNs was significantly increased, compared to that of the drug solution."( Formulation and optimization of solid lipid nanoparticles of buspirone HCl for enhancement of its oral bioavailability.
Mohammadi, MY; Tabbakhian, M; Varshosaz, J, 2010
)
0.6
" By examination of absorption curves derived by Wagner-Nelson analysis of pharmacokinetic data it was noted that drug release in vivo correlated well with drug release observed in vitro and no marked change in rate of absorption was noted when dosage forms were located in and releasing drug in the colon."( Development of oral extended release formulations of 6-hydroxybuspirone.
Connor, A; Croop, R; Dennis, AB; Dockens, RC; Ferrie, P; Nicholson, SJ; Timmins, P; Wilding, I; Zeng, J, 2012
)
0.62
"Buspirone HCl has very low oral bioavailability (4%) due to deactivation by extensive first pass effect."( Transfersomal lyophilized gel of buspirone HCl: formulation, evaluation and statistical optimization.
Elsayed, I; Shamma, RN, 2013
)
2.11
" Combining of xanthone with piperazine moiety resulted in obtaining of compounds with increased bioavailability after oral administration."( Synthesis and evaluation of pharmacological properties of some new xanthone derivatives with piperazine moiety.
Bojarski, AJ; Gunia, A; Marona, H; Pytka, K; Satała, G; Siwek, A; Szkaradek, N; Szneler, E; Waszkielewicz, AM, 2013
)
0.39
"The aim of this study was to develop buspirone hydrochloride microemulsion formulations for intranasal administration to improve the drug bioavailability and provide high drug brain levels."( Chitosan and cyclodextrin in intranasal microemulsion for improved brain buspirone hydrochloride pharmacokinetics in rats.
Bshara, H; El-Shamy, Ael-H; Mansour, S; Osman, R, 2014
)
0.91
"6 fold increase in BH bioavailability compared to the oral commercial Buspar® tablets."( Enhanced bioavailability of buspirone hydrochloride via cup and core buccal tablets: formulation and in vitro/in vivo evaluation.
Elmeshad, AN; Fares, AR; Kassem, MA, 2014
)
0.7
" When buspirone was orally administered in rats with the 10 mg/kg intravenous puerarin coadministration, both total area under the plasma concentration-time curve from time zero to time infinity and the extent of absolute oral bioavailability were significantly increased."( In vitro and in vivo evaluation of the effect of puerarin on hepatic cytochrome p450-mediated drug metabolism.
Cho, HJ; Cho, SJ; Chong, S; Chung, SJ; Kim, DD; Kim, KS; Kim, SB; Kim, YS; Yoon, IS, 2014
)
0.88
" In vivo animal studies were performed in rabbits to study bioavailability of BS in the designed buccal discs and to establish permeation enhancement ability of carbon dioxide."( Controlled release effervescent buccal discs of buspirone hydrochloride: in vitro and in vivo evaluation studies.
Charde, SY; Jaipal, A; Pandey, MM; Prasad, RG; Sadhu, N; Srinivas, A, 2016
)
0.69
" Notably, one of these new derivatives, (E)-N-hydroxy-3-(2-oxo-1-(quinolin-2-ylmethyl)-1,2-dihydropyridin-3-yl)acrylamide (4l), significantly restored RUNX3 in a dose-dependent manner and showed high metabolic stability, a good pharmacokinetic profile with high oral bioavailability and long half-life, and strong antitumor activity."( Discovery of Orally Available Runt-Related Transcription Factor 3 (RUNX3) Modulators for Anticancer Chemotherapy by Epigenetic Activation and Protein Stabilization.
Cho, M; Choi, S; Han, G; Jeong, JH; Kang, JS; Kim, H; Kim, HJ; Kim, JH; Lee, C; Oh, SJ; Yang, JS, 2015
)
0.42
" It has short half-life (2-3h) and low oral bioavailability (4%) due to extensive first pass metabolism."( Formulation and Evaluation of Niosomal in situ Nasal Gel of a Serotonin Receptor Agonist, Buspirone Hydrochloride for the Brain Delivery via Intranasal Route.
Dua, K; Gujar, KN; Madan, JR; Mathure, D; Ranpise, HA; Tupsamundre, A, 2018
)
0.7
" Buspirone hydrochloride has low bioavailability of about 4% after oral administration due to first pass metabolism."( Buspirone Hydrochloride Loaded In Situ Nanovesicular Gel as an Anxiolytic Nasal Drug Delivery System: In Vitro and Animal Studies.
Abdallah, MH; Abdelnabi, DM; Elghamry, HA, 2019
)
2.87
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

venlafaxine XR, 75 or 150 mg/day, was significantly more efficacious than placebo at all time points. Bruxism remitted in all patients after a decrease in antidepressant dosage (N = 1) or addition of buspirone.

ExcerptRelevanceReference
" Spectral analysis of the EEG did not distinguish between the multi and single dosage schedules regarding the respective drugs in the low doses administered."( The comparison of the effects of multi and single doses of buspirone, chlordiazepoxide and hydroxyzine on psychomotor function and EEG.
Bartel, PR; Becker, PJ; Blom, MW; Sommers, DK; Van der Meyden, CH, 1992
)
0.53
" These results indicate improved reaction time and memory performance with repeated dosing of clobazam in contrast to buspirone."( Pharmacodynamic effects of buspirone and clobazam.
Alford, C; Bhatti, JZ; Curran, S; Hindmarch, I; McKay, G, 1991
)
0.79
" Comparison of the dose-response curves demonstrated a difference in the intensity of the stimulus effects."( The discriminative stimulus effects of diazepam in rats at two training doses.
Franklin, SR; Tang, AH, 1991
)
0.28
" Clinical studies in the elderly show no important difference from younger patients in safety and efficacy profile, pharmacokinetics, and dosage requirement."( Buspirone: a worldwide update.
Domantay, AG; Napoliello, MJ, 1991
)
1.72
" Rats were treated with vehicle or EEDQ (2 or 6 mg/kg) and 24 hr later dose-response curves were constructed for inhibition of 5-hydroxytrytophan (5-HTP) accumulation (after decarboxylase inhibition with NSD-1015) by the selective 5-HT1A agonists 8-hydroxy-2(di-n-propylamino)tetralin (8-OH-DPAT) (0."( Receptor reserve for 5-hydroxytryptamine1A-mediated inhibition of serotonin synthesis: possible relationship to anxiolytic properties of 5-hydroxytryptamine1A agonists.
Bohmaker, K; Goldstein, M; Meller, E, 1990
)
0.28
" Similarly, in pigeons trained to discriminate imipramine from saline, noneffective doses of CRF shifted the imipramine dose-response curve more than twofold to the left."( Interactions of corticotropin-releasing factor with antidepressant and anxiolytic drugs: behavioral studies with pigeons.
Barrett, JE; Zhang, L, 1990
)
0.28
" Acute dosing of CDP (1-27 mg/kg) produced dose-related increases in basal CS secretion but was without effect on basal NA levels."( Effects of buspirone and chlordiazepoxide on plasma catecholamine and corticosterone levels in stressed and nonstressed rats.
De Boer, SF; Slangen, JL; Van der Gugten, J, 1991
)
0.67
" For each drug, a dose-response curve was determined before (prechronic) and two weeks after (postchronic) discontinuation of chronic administration."( Behavioral effects of chronic buspirone administration in the pigeon: comparison to midazolam.
Nader, MA, 1991
)
0.57
" Mean daily diazepam dosage at entry was significantly higher in the buspirone group, but overall initial diazepam dosage was not related to outcome."( A double-blind placebo-controlled study of buspirone in diazepam withdrawal in chronic benzodiazepine users.
Ashton, CH; Rawlins, MD; Tyrer, SP, 1990
)
0.78
" A parallel shift to the right of the APO dose-response curve with buspirone was evident in 2 monkeys, indicating surmountable antagonism."( Buspirone blocks the discriminative stimulus effects of apomorphine in monkeys.
Kamien, JB; Woolverton, WL, 1990
)
1.96
" Decreases in 5-HIAA persisted throughout the chronic dosing regimen (36 days), while dopamine metabolites returned to control levels within 8 days."( Neurochemical changes in pigeon cerebrospinal fluid during chronic administration of buspirone or 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).
Barrett, JE; Nader, MA, 1989
)
0.5
") caused a parallel shift to the right of the dose-response curve for the inhibitory action of the alpha 2-receptor agonist clonidine on LC neurons."( A metabolite of buspirone increases locus coeruleus activity via alpha 2-receptor blockade.
Engberg, G, 1989
)
0.62
" With regard to all active treatments the incidence of side effects was lower on Day 7 after the subchronic dosing period--with a third of the subchronic dose--than after the first single administration."( Placebo-controlled study on acute and subchronic effects of buspirone vs bromazepam utilizing psychomotor and cognitive assessments in healthy volunteers.
Klausnitzer, W; Schaffler, K, 1989
)
0.52
" However, at higher doses the magnitude of these effects decreased and overall the dose-response curves displayed inverted U-shapes."( Effects of 5-HT1A receptor agonists and L-5-HTP in Montgomery's conflict test.
Engel, JA; Hjorth, S; Söderpalm, B, 1989
)
0.28
" For panic disorders, alprazolam is effective for short- and long-term treatment, although it needs a slow reduction in dosage and carries a risk of withdrawal reactions in about 30% of sufferers."( The new and newer antianxiety agents.
Tiller, JW,
)
0.13
" Dosage was initiated at 5 mg buspirone 3 times a day (15 mg/day), with a flexible regimen to a maximum of 30 mg/day."( Buspirone in the treatment of alcoholic patients.
Bruno, F, 1989
)
2.01
"The effects of oral buspirone (BUS, 10 mg) and diazepam (DZP, 10 mg) were studied in 12 healthy women volunteers using subjective ratings, objective tests of psychomotor and cognitive functions and urinary dosage of catecholamine output."( Buspirone and diazepam: comparison of subjective, psychomotor and biological effects.
Boulenger, JP; Herrou, M; Leymarie, P; Simon, P; Squillace, K; Zarifian, E, 1989
)
2.04
" Plasma concentrations of buspirone and 1-pyrimidinylpiperazine following both single and multiple dosing were determined by RIA and GCMS, respectively."( Pharmacokinetics of buspirone in elderly subjects.
Gammans, RE; LaBudde, JA; Mayol, RF; Shea, JP; Westrick, ML, 1989
)
0.9
" Both drugs were administered in a 1:1 dosage ratio; the daily prescribed dose did not exceed 40 mg."( Comparison of buspirone and diazepam in generalized anxiety disorder.
Dominguez, RA; Goldstein, BJ; Jacobson, AF; Steinbook, RM,
)
0.49
"Clinical trials have demonstrated that buspirone (BuSpar) is effective in the treatment of anxiety with efficacy and dosage comparable to diazepam or chlorazepate."( Pharmacological and clinical effects of buspirone.
Eison, MS; Riblet, LA; Taylor, DP; Vandermaelen, CP, 1985
)
0.81
" A shift in the gepirone dose-response curve to the left in serotonin lesioned rats suggests that this may be 5-HT-receptor mediated."( Serotonergic mechanisms in the behavioral effects of buspirone and gepirone.
Eison, AS; Eison, MS; Riblet, LA; Stanley, M, 1986
)
0.52
" These results suggest that within the normal therapeutic dosage ranges for both drugs, it is unlikely that a clinically significant interaction between them will occur."( Lack of interaction between cimetidine and buspirone.
Faulkner, HC; Gammans, RE; Goodson, PJ; Pfeffer, M; Rehm, KD; Westrick, ML, 1987
)
0.54
" No firm recommendation for specific dosage can be made based on the present data."( Clinical pharmacokinetics of oral buspirone in patients with impaired renal function.
Caccia, S; Gammans, RE; Garattini, S; Mayol, RF; Mingardi, G; Pfeffer, M; Placchi, M; Vigano, GL, 1988
)
0.55
"0 mg/kg) from saline, and then generalization tests were conducted using a cumulative dosing procedure."( Discriminative stimulus properties of buspirone in the pigeon.
Barrett, JE; Mansbach, RS, 1987
)
0.54
" Each patient took buspirone, diazepam and placebo for one week each in flexible dosage and balanced order."( Anxiety in primary care: is short-term drug treatment appropriate?
Owen, R; Tyrer, P, 1984
)
0.6
"Acute and chronic toxicities of Pyricapirone, a new psychotropic and antiemetic agent, as a substance and a dosage form (ampoule solution) were studied in experiments on animals (mice, rats, rabbits, and dogs) during various routes of administration (intraperitoneally, subcutaneously, and orally)."( [The safety of pyricapirone--a new psychotropic and antiemetic agent].
Kharin, NA; Naletov, SV; Obraztsova, OG; Zin'kovskaia, LIa,
)
0.13
" pretreatment (25 min) with morphine sulfate, 8-OH-DPAT, buspirone and 5-CT shifted the morphine sulfate dose-response curve 3- to 5-fold to the right."( Differential roles of 5-hydroxytryptamine1A and 5-hydroxytryptamine1B receptor subtypes in modulating spinal nociceptive transmission in mice.
Alhaider, AA; Wilcox, GL, 1993
)
0.53
" Side effects were assessed through the Dosage Treatment Emergent Symptoms at the same times."( Assessment of the efficacy of buspirone in patients affected by generalized anxiety disorder, shifting to buspirone from prior treatment with lorazepam: a placebo-controlled, double-blind study.
Casacchia, M; Delle Chiaie, R; Kotzalidis, GD; Pancheri, P; Stratta, P; Zibellini, M, 1995
)
0.58
" Dose-response functions for drug identifications were shifted leftward in the low-dose training phase relative to the low-dose generalization phase, suggesting that reinforcement of progressively lower doses enhances drug discriminability."( Discriminative stimulus effects of diazepam and buspirone in normal volunteers.
Critchfield, TS; Griffiths, RR; Rush, CR; Troisi, JR, 1995
)
0.55
" The dose-response curves from buspirone and tandospirone demonstrated enough dissimilarity to the dose-response curves from gepirone and ipsapirone to suggest differences in their rates of absorption, and/or differences in the production of active and inactive metabolites."( The effects of azapirones on serotonin1A neurons of the dorsal raphe.
Matheson, GK; Michel, C; Pfeifer, DM; Weiberg, MB, 1994
)
0.57
" In contrast, cumulative dosing of U-93385E (0."( Tolerance development to the vagal-mediated bradycardia produced by 5-HT1A receptor agonists.
Clement, ME; Escandon, NA; Harris, LT; McCall, RB, 1994
)
0.29
" Pharmacodynamic changes were significantly intercorrelated; all effects were maximal 1 to 2 hours after dosage but were indistinguishable from placebo by 8 hours."( Distinguishing a benzodiazepine agonist (triazolam) from a nonagonist anxiolytic (buspirone) by electroencephalography: kinetic-dynamic studies.
Gouthro, TA; Greenblatt, DJ; Harmatz, JS; Locke, J; Shader, RI, 1994
)
0.51
") showed an anticonflict activity with a bell-shaped dose-response relationship without any effect on spontaneous water consumption."( Comparison of the anticonflict effect of buspirone and its major metabolite 1-(2-pyrimidinyl)-piperazine (1-PP) in rats.
Achiha, M; Amano, M; Goto, A; Hara, C; Ogawa, N; Sakai, A; Takahashi, N, 1993
)
0.55
" One patient developed a lasting problem of cervical-cranial dystonia and tremors after treatment with buspirone at a dosage of 40 mg/day for several weeks."( Persistent movement disorders induced by buspirone.
Hening, W; LeWitt, PA; McHale, D; Walters, A, 1993
)
0.77
" Plasma samples were obtained predose and at specified time points after dosing and analyzed for gepirone and 1-PP content by a specific gas chromatographic-mass spectrometric method."( Effect of food on the bioavailability of gepirone in humans.
Farmen, RH; Pittman, KA; Sciacca, MA; Sostrin, MB; Tay, LK, 1993
)
0.29
" In drug interaction test sessions caffeine (56 mg/kg) blocked the discriminative stimulus properties of the training dose of CDP and shifted the CDP discriminative dose-response function to the right."( Perceptual masking of the chlordiazepoxide discriminative cue by both caffeine and buspirone.
Gauvin, DV; Holloway, FA; Peirce, JM, 1994
)
0.51
" Bruxism remitted in all patients after a decrease in antidepressant dosage (N = 1) or addition of buspirone (N = 3)."( SSRI-associated nocturnal bruxism in four patients.
Ellison, JM; Stanziani, P, 1993
)
0.5
" In addition, they suggest that a decrease in SSRI dosage or the addition of buspirone may relieve SSRI-associated nocturnal bruxism."( SSRI-associated nocturnal bruxism in four patients.
Ellison, JM; Stanziani, P, 1993
)
0.51
"1 mg/kg) reduced by 54% the emotional stress-induced increase of colonic spike burst frequency, while a higher dosage (1 mg/kg) of methysergide had no effect."( Comparative involvement of 5-HT1, 5-HT2 and 5-HT3 receptors in stress-induced colonic motor alterations in rats.
Alary, C; Buéno, L; Gué, M; Junien, JL; Rio-Lacheze, CD, 1993
)
0.29
" Both the U-shaped dose-response curve seen with buspirone in some animal tests of anxiety and its slow onset of clinical action could be attributed to this release of stress hormones."( The pituitary-adrenal axis and the different behavioral effects of buspirone and chlordiazepoxide.
Logan, B; McNaughton, N; Panickar, KS, 1996
)
0.78
" Plasma profiles of buspirone and 1-PP following oral dosing are presented."( Simultaneous quantitation of buspirone and its major metabolite 1-(2-pyrimidinyl)piperazine in human plasma by high-performance liquid chromatography with coulometric detection.
Franklin, M; Odontiadis, J, 1996
)
0.91
"Buspirone was given as a single high dose to six HIV-seropositive subjects, or as continuous medication with increasing dosage over 6 weeks to nine HIV-seropositive subjects, with CD4 T-cell counts of 150-300 x 10(6)/l."( Buspirone, a serotonin receptor agonist, increases CD4 T-cell counts and modulates the immune system in HIV-seropositive subjects.
Aabech, P; Afzelius, P; Benfield, T; Dybkjaer, E; Hofmann, B; Iversen, J; Kronborg, G; Nielsen, JO, 1996
)
3.18
" After 5 days of therapy the patient reported no adverse effects, and the paroxetine dosage was increased to 20 mg every morning."( Possible paroxetine-induced bruxism.
Adler, DA; Bungay, KM; Romanelli, F, 1996
)
0.29
" The findings demonstrate that buspirone, in a daily dosage varying between 20 and 50 mg, may be effective in reducing this type of behavioural disturbance and associated with an improvement in sociability."( The effect of buspirone on challenging behaviour in mentally retarded patients: an open prospective multiple-case study.
Tuinier, S; Verhoeven, WM, 1996
)
0.94
" Dosing instructions for buspirone and guidelines for switching patients from benzodiazepines to buspirone are offered."( Strategies for treatment of generalized anxiety in the primary care setting.
Rickels, K; Schweizer, E, 1997
)
0.6
"5 mg/kg) produced a leftward shift in the cocaine dose-response curve (0."( Modulation of the discriminative stimulus properties of cocaine: comparison of the effects of fluoxetine with 5-HT1A and 5-HT1B receptor agonists.
Callahan, PM; Cunningham, KA, 1997
)
0.3
" In patients who have experienced only partial treatment results, the clinician should first consider optimizing antidepressant dosage or lengthening therapy."( Practical management of treatment-resistant depression.
Cadieux, RJ, 1998
)
0.3
"Buspirone is an anxiolytic drug given at a dosage of 15 mg/day."( Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug.
Mahmood, I; Sahajwalla, C, 1999
)
2
" A change to BID dosing for buspirone may offer convenience and possibly higher compliance in patients with persistent anxiety without compromising the excellent safety and tolerability profile of the medication."( Meta-analysis of the safety and tolerability of two dose regimens of buspirone in patients with persistent anxiety.
Cutler, NR; Hamid, S; Hong, WW; Nape, B; Sramek, JJ, 1999
)
0.83
"63 mg/kg) shifted the dose-response curve of each agonist to the right in a dose-dependent manner."( Estimation of apparent pA2 values for WAY 100635 at 5-HT1A receptors regulating 5-hydroxytryptamine release in anaesthetised rats.
Assié, MB; Koek, W, 2000
)
0.31
" Based on these observations of the potential benefits of once-daily dosing with the ER product in terms of prolonged buspirone plasma concentrations, a significant increase in the ratio of buspirone to 1-PP concentration with a lower intersubject variation could be achieved that should provide an improvement in the desired therapeutic effects of buspirone."( A comparative multidose pharmacokinetic study of buspirone extended-release tablets with a reference immediate-release product.
Andheria, M; Sakr, A, 2001
)
0.77
" The dosage was increased to 150 mg SR twice a day and eventually augmented with buspirone 15 mg 3 times a day."( Bupropion-induced acute dystonia.
Detweiler, MB; Harpold, GJ, 2002
)
0.54
" The symptoms receded when the bupropion dose was returned to 150 mg SR once a day, suggesting a dose-response relationship."( Bupropion-induced acute dystonia.
Detweiler, MB; Harpold, GJ, 2002
)
0.31
" Clinicians prescribing buspirone must know its basic pharmacology, adverse effects, and dosing guidelines."( The use of buspirone in primary care.
Emes, R; Khouzam, HR, 2002
)
1.01
" A three-way crossover study in 18 healthy subjects studied a 30 mg "Fast" (12 h) and 30 mg "Slow" (24 h) formulation of buspirone hydrochloride given once a day, and 2x15 mg immediate release tablets dosed at a 12 h interval."( Development and validation of an in vitro-in vivo correlation for buspirone hydrochloride extended release tablets.
Goldberg, A; Sakr, A; Takka, S, 2003
)
0.76
" In experiment 3, rats received the same regimen of buspirone dosing as in experiment 2, before receiving in-vivo microdialysis for 5-HT and DA in the ventral hippocampus, nucleus accumbens and medial prefrontal cortex."( Effects of acute and chronic buspirone on impulsive choice and efflux of 5-HT and dopamine in hippocampus, nucleus accumbens and prefrontal cortex.
Liu, YP; Robbins, TW; Wilkinson, LS, 2004
)
0.87
"A stability indicating, reversed-phase high-performance liquid chromatographic method was developed and validated for the determination of buspirone (Bsp) in pharmaceutical dosage forms."( Development and validation of a high-performance liquid chromatographic method for the determination of buspirone in pharmaceutical preparations.
Panderi, I; Zaxariou, M, 2004
)
0.74
" The applicability of the method was evaluated through determination of BUS and PIR in tablet dosage forms."( Adsorptive stripping voltammetric behaviour of azomethine group in pyrimidine-containing drugs.
Abdel-Hay, MH; Barary, MH; Belal, TS; Sabry, SM, 2004
)
0.32
" Our results showed that buspirone exhibited an inverted-U-shaped dose-response curve in both the EPM and the VC tests."( Oral buspirone causes a shift in the dose-response curve between the elevated-plus maze and Vogel conflict tests in Long-Evans rats: relation of brain levels of buspirone and 1-PP to anxiolytic action.
Benjamin, D; Crooke, JJ; Ilyin, SE; Lang, W; Reitz, AB; Rosenthal, DI; Vaidya, AH, 2005
)
1.15
" given before test session, which was 24 h after the aversive training, significantly decreased freezing response within a limited dose range of the U-shaped dose-response relationship."( Buspirone attenuates conditioned fear-induced c-Fos expression in the rat hippocampus.
Bidziński, A; Lehner, M; Maciejak, P; Płaźnik, A; Skórzewska, A; Szyndler, J; Taracha, E; Wisłowska-Stanek, A; Zienowicz, M, 2005
)
1.77
" Oral dosing of buspirone in rats resulted in exposures (area under the concentration-time profile) of 6-OH-buspirone and 1-(2-pyrimidinyl)-piperazine (1-PP), another major metabolite of buspirone, that were approximately 12 (6-OH-buspirone)- and 49 (1-PP)-fold higher than the exposure of the parent compound."( 6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats.
Dockens, RC; Grace, JE; Li, YW; Pajor, L; Stark, AD; Taub, RA; Wong, H; Yeola, S; Yocca, FD; Zaczek, RC, 2007
)
1.1
" There was a 4-day washout between each dosing period."( Pharmacokinetics of 6-hydroxybuspirone and its enantiomers administered individually or following buspirone administration in humans.
Croop, R; Dockens, RC; Tran, AQ; Zeng, J, 2007
)
0.63
"5 mg/kg) at a dose of 375 mg/kg and exhibited a U-shaped dose-response curve."( Anxiolytic activity of a phytochemically characterized Passiflora incarnata extract is mediated via the GABAergic system.
Butterweck, V; Grundmann, O; McGregor, GP; Wang, J, 2008
)
0.35
" A total of 34 children with ADHD as defined by DSM-IV-TR were randomized to buspirone or methylphenidate dosed on weight-adjusted basis at buspirone (0."( Buspirone versus methylphenidate in the treatment of attention deficit hyperactivity disorder: a double-blind and randomized trial.
Amini, H; Davari-Ashtiani, R; Mazhabdar, H; Razjouyan, K; Shahrbabaki, ME, 2010
)
2.03
"Albino rats were dosed (subcutaneously) with AL-8309A, 8-OH DPAT, or buspirone once or three times before 6-hour exposure to blue light."( Agonists at the serotonin receptor (5-HT(1A)) protect the retina from severe photo-oxidative stress.
Collier, RJ; Dembinska, O; Hellberg, M; Kapin, MA; Krueger, DS; Martin, EA; Patel, Y; Romano, C, 2011
)
0.6
" Significant protection was measured in rats dosed once 0, 24, or 48 hours before light exposure."( Agonists at the serotonin receptor (5-HT(1A)) protect the retina from severe photo-oxidative stress.
Collier, RJ; Dembinska, O; Hellberg, M; Kapin, MA; Krueger, DS; Martin, EA; Patel, Y; Romano, C, 2011
)
0.37
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
" This observation, along with a desire to provide for once daily dosing of this compound, provided the basis for the development of an extended release formulation."( Development of oral extended release formulations of 6-hydroxybuspirone.
Connor, A; Croop, R; Dennis, AB; Dockens, RC; Ferrie, P; Nicholson, SJ; Timmins, P; Wilding, I; Zeng, J, 2012
)
0.62
"To investigate if treatment with a single dosage of T+5-HT(1A)ra will produce improvement in sexual functioning in women with Hypoactive Sexual Desire Disorder (HSDD) as the result of dysfunctional high sexual inhibition."( Toward personalized sexual medicine (part 3): testosterone combined with a Serotonin1A receptor agonist increases sexual satisfaction in women with HSDD and FSAD, and dysfunctional activation of sexual inhibitory mechanisms.
Bloemers, J; Chivers, M; Everaerd, W; Gerritsen, J; Goldstein, I; Koppeschaar, H; Olivier, B; Poels, S; Tuiten, A; van Ham, D; van Mameren, F; van Rooij, K, 2013
)
0.39
" Data were derived from an earlier study, designed to compare efficacy and tolerability of fixed dosage of extended-release venlafaxine, mitazapine, paroxetine, and risperidone, sodium valproate, buspirone, trazodone or thyroid hormone augmenting to paroxetine in those patients."( Difference in remission in a Chinese population with anxious versus nonanxious treatment-resistant depression: a report of OPERATION study.
Cao, L; Chen, J; Fang, Y; Hong, W; Peng, D; Wu, Z; Yuan, C; Zhang, C, 2013
)
0.58
"The aim of this study was to increase the transdermal permeation of buspirone HCl utilizing a stable dosage form."( Transfersomal lyophilized gel of buspirone HCl: formulation, evaluation and statistical optimization.
Elsayed, I; Shamma, RN, 2013
)
0.91
" However, the amount of acid and base used for generation of carbon dioxide should be selected with care as this may damage the integrity of bioadhesive dosage form."( Controlled release effervescent buccal discs of buspirone hydrochloride: in vitro and in vivo evaluation studies.
Charde, SY; Jaipal, A; Pandey, MM; Prasad, RG; Sadhu, N; Srinivas, A, 2016
)
0.69
"3 mg/kg/injection cocaine or MA) choice paradigm in which complete SA dose-response curves were determined each session (N = 3/group)."( Effects of buspirone and the dopamine D3 receptor compound PG619 on cocaine and methamphetamine self-administration in rhesus monkeys using a food-drug choice paradigm.
Banala, AK; John, WS; Nader, MA; Newman, AH, 2015
)
0.81
"A single injected dose of the antidepressant fluoxetine had no significant effect on animals' activity in the open-arm test, neither in a small dosage (5 mg/kgbw) nor in a higher one (10 mg/kgbw), whereas a single high dose of buspirone significantly impeded the open-arm activity of the rats."( Dose dependent effects of serotonergic agents on anxiety.
Dogaru, MT; Gáll, Z; Kolcsar, M, 2014
)
0.59
"006) and higher average dexmedetomidine dosing per patient-day (0."( Assessment of Antishivering Medication Requirements During Therapeutic Normothermia: Effect of Cooling Methods.
Kirk, A; McDaniel, C; Rincon, F; Szarlej, D, 2016
)
0.43
" Chronic buspirone dosing studies remain to be conducted, but given preclinical findings and the outcomes of this work, the utility of buspirone for treating methamphetamine use disorder appears limited."( Acute buspirone dosing enhances abuse-related subjective effects of oral methamphetamine.
Pike, E; Rush, CR; Stoops, WW,
)
1.03
" Considering previous findings with chronic dosing, these findings highlight that the behavioral effects of buspirone differ as a function of dosing conditions."( Effects of acute buspirone administration on inhibitory control and sexual discounting in cocaine users.
Bolin, BL; Romanelli, MR; Rush, CR; Stoops, WW; Strickland, JC, 2017
)
1.01
"Buspirone was evaluated in one flexibly dosed (N = 227) and one fixed-dose (N = 341) trial in children and adolescents aged 6-17 years with a primary diagnosis of GAD."( Buspirone in Children and Adolescents with Anxiety: A Review and Bayesian Analysis of Abandoned Randomized Controlled Trials.
Cornwall, GJ; Croarkin, PE; Keeshin, BR; Mills, JA; Mossman, SA; Strawn, JR; Varney, ST, 2018
)
3.37
" We report the case of a 6-year-old girl who was successfully treated with once-nightly dosing of buspirone for fluoxetine-induced sleep bruxism, which was confirmed with clear on-off-on treatment sequence."( Fluoxetine-Induced Sleep Bruxism Rapidly Treated With Once-Nightly Dosing of Buspirone in a 6-Year-Old Girl.
Akbaş, B; Bilgiç, A,
)
0.58
" All patients had been treated with a stable dosage of AAPDs for at least three months."( Co-treatment of buspirone with atypical antipsychotic drugs (AAPDs) improved neurocognitive function in chronic schizophrenia.
Deng, W; Guo, W; Li, T; Ma, X; Song, X; Tian, H; Wang, J; Wang, Q; Wang, Y; Wei, J; Wei, M; Yang, X; Zhao, L; Zheng, C, 2019
)
0.86
" We randomly assigned patients to receive buspirone or placebo for 4 weeks, with the adjusted dosage for age."( Comparison of the Efficacy of Buspirone and Placebo in Childhood Functional Abdominal Pain: A Randomized Clinical Trial.
Badihian, N; Badihian, S; Saneian, H; Shahsanai, A; Yaghini, O, 2020
)
1.11
"Individuals with PD and clinically significant anxiety were randomized 4:1 to flexible dosage buspirone or placebo for 12 weeks."( A trial of buspirone for anxiety in Parkinson's disease: Safety and tolerability.
Auinger, P; Gil-Díaz, MC; Iourinets, J; Richard, IH; Schneider, RB; Tarolli, CG, 2020
)
1.17
" When coadministered with axitinib, a lower dosage of buspirone should be defined to avoid a toxic response."( Inhibition of Axitinib on Buspirone Metabolism in vitro and in vivo.
Pang, NH; Qu, GE; Tang, CR; Xu, RA; Zhang, BW, 2022
)
1.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
anxiolytic drugAnxiolytic drugs are agents that alleviate anxiety, tension, and anxiety disorders, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions.
sedativeA central nervous system depressant used to induce drowsiness or sleep or to reduce psychological excitement or anxiety.
serotonergic agonistAn agent that has an affinity for serotonin receptors and is able to mimic the effects of serotonin by stimulating the physiologic activity at the cell receptors. Serotonin agonists are used as antidepressants, anxiolytics, and in the treatment of migraine disorders.
EC 3.4.21.26 (prolyl oligopeptidase) inhibitorAny EC 3.4.21.* (serine endopeptidase) inhibitor that interferes with the action of prolyl oligopeptidase (EC 3.4.21.26).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
azaspiro compoundAn azaspiro compound is a spiro compound in which at least one of the cyclic components is a nitrogen heterocyle.
pyrimidinesAny compound having a pyrimidine as part of its structure.
N-arylpiperazine
N-alkylpiperazine
piperidones
organic heteropolycyclic compound
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (97)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency34.42520.002541.796015,848.9004AID1347395; AID1347398
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency4.89663.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency23.89130.006038.004119,952.5996AID1159521; AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency23.85270.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency45.79120.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743042; AID743054
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency4.46680.011212.4002100.0000AID1030
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency12.58930.00137.762544.6684AID914; AID915
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency61.13060.001022.650876.6163AID1224838
progesterone receptorHomo sapiens (human)Potency6.11310.000417.946075.1148AID1346795
regulator of G-protein signaling 4Homo sapiens (human)Potency13.37140.531815.435837.6858AID504845
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency18.11020.01237.983543.2770AID1645841
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency37.80720.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency24.54120.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency27.37770.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency30.89560.375827.485161.6524AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency32.06470.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency45.32470.000229.305416,493.5996AID1259244; AID1259248; AID743075; AID743079; AID743080; AID743091
cytochrome P450 2D6Homo sapiens (human)Potency15.41360.00108.379861.1304AID1645840
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency31.91670.001019.414170.9645AID743094; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency0.19490.023723.228263.5986AID743223
arylsulfatase AHomo sapiens (human)Potency8.49211.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency12.58930.035520.977089.1251AID504332
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency20.81140.00207.533739.8107AID891
cytochrome P450 2C9 precursorHomo sapiens (human)Potency7.94330.00636.904339.8107AID883
D(1A) dopamine receptorHomo sapiens (human)Potency5.80450.02245.944922.3872AID488982
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID488953
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency17.78280.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency48.55770.000323.4451159.6830AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency23.75870.000627.21521,122.0200AID743202; AID743219
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency14.21910.031610.279239.8107AID884; AID885
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency20.08500.00106.000935.4813AID943; AID944
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency14.21911.000012.224831.6228AID885
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency68.58960.001557.789015,848.9004AID1259244
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency14.21911.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency14.21911.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency14.21911.000012.224831.6228AID885
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency68.58960.001551.739315,848.9004AID1259244
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency14.21911.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency14.21911.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency14.21911.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency14.21911.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency14.21911.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency14.21911.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency14.21911.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency7.94330.00638.235039.8107AID883
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency19.95260.009610.525035.4813AID1479145
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency14.21911.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency14.21911.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency14.21911.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency14.21911.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency14.21911.000012.224831.6228AID885
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency9.52830.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 2Homo sapiens (human)IC50 (µMol)12.00000.40003.10009.7000AID721751
Bile salt export pumpRattus norvegicus (Norway rat)IC50 (µMol)369.80000.40002.75008.6000AID1209456
Bile salt export pumpHomo sapiens (human)IC50 (µMol)88.04330.11007.190310.0000AID1209455; AID1443986; AID1449628
5-hydroxytryptamine receptor 1AHomo sapiens (human)IC50 (µMol)0.02500.00010.666410.0000AID3589
5-hydroxytryptamine receptor 1AHomo sapiens (human)Ki0.01950.00010.532610.0000AID1126944; AID1281951; AID1353521; AID1403791; AID1413422; AID1430531; AID1454764; AID1512150; AID1517957; AID1520008; AID1556424; AID1568826; AID1595143; AID1656651; AID1675981; AID1702243; AID1740897; AID1801081; AID1890359; AID265214; AID267572; AID3802; AID392707; AID460124; AID460125; AID712521; AID759366
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)IC50 (µMol)1.31500.00040.629810.0000AID4753; AID4789; AID4822; AID4823
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)Ki1.34050.00020.667710.0000AID5232; AID5291
Beta-2 adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)1.00000.00301.17839.7724AID225904
Angiotensin-converting enzyme Homo sapiens (human)IC50 (µMol)0.02400.00010.533610.0000AID3759
D(2) dopamine receptorHomo sapiens (human)IC50 (µMol)0.32300.00000.74728.0000AID625253
D(2) dopamine receptorHomo sapiens (human)Ki0.31310.00000.651810.0000AID1454763; AID1512149; AID265217; AID55594; AID625253; AID63410; AID64137
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)IC50 (µMol)3.56500.00040.908610.0000AID4789; AID4822; AID4823; AID5478
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)Ki1.05430.00010.601710.0000AID5232; AID5291; AID5556
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)7.02000.00021.874210.0000AID36710; AID36854; AID36858
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)Ki0.36700.00010.949010.0000AID35265
Beta-1 adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)1.00000.00300.07870.3250AID225904
DRattus norvegicus (Norway rat)IC50 (µMol)0.12000.00030.50267.7625AID62868
D(3) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.12000.00030.39075.4000AID62868
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)IC50 (µMol)0.18880.00031.38338.4000AID36858; AID3725; AID3745; AID3757; AID3759; AID625190
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Ki0.01620.00010.739610.0000AID3470; AID4000; AID4042; AID4062; AID4073; AID4220; AID4332; AID4411; AID625190
Alpha-2B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)7.75000.00031.09147.7625AID225902; AID36781
D(2) dopamine receptorBos taurus (cattle)IC50 (µMol)4.00000.00100.79948.0000AID62167; AID62170
Alpha-2C adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)7.75000.00031.09147.7625AID225902; AID36781
Alpha-2A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)7.75000.00031.06917.7625AID225902; AID36781
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)7.02000.00021.270410.0000AID36710; AID36854; AID36858
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)Ki0.36700.00000.575110.0000AID35265
Alpha-1D adrenergic receptorHomo sapiens (human)IC50 (µMol)1.07700.00020.75688.8970AID625200
Alpha-1D adrenergic receptorHomo sapiens (human)Ki0.52900.00000.360910.0000AID625200
D(1B) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.12000.00030.35635.4000AID62868
Beta-3 adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)1.00000.00300.07870.3250AID225904
5-hydroxytryptamine receptor 2AHomo sapiens (human)IC50 (µMol)2.28600.00010.88018.8500AID625192
5-hydroxytryptamine receptor 2AHomo sapiens (human)Ki1.58130.00000.385510.0000AID1454765; AID394122; AID625192
5-hydroxytryptamine receptor 2CHomo sapiens (human)Ki2.27000.00010.954910.0000AID4748
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)IC50 (µMol)9.00530.00051.48357.8000AID36858; AID4669; AID625190
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)Ki0.01320.00031.29679.2440AID4691; AID625190
5-hydroxytryptamine receptor 1DRattus norvegicus (Norway rat)IC50 (µMol)1.00000.00311.73607.8000AID36858
D(4) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.12000.00030.38715.4000AID62868
5-hydroxytryptamine receptor 1FRattus norvegicus (Norway rat)IC50 (µMol)1.00000.00501.79627.8000AID36858
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)IC50 (µMol)1.42000.00040.615610.0000AID4789; AID4822; AID4823
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)Ki1.34050.00020.590910.0000AID5232; AID5291
5-hydroxytryptamine receptor 7Homo sapiens (human)Ki0.42600.00030.380610.0000AID1656650; AID1801081
D(3) dopamine receptorHomo sapiens (human)IC50 (µMol)0.04400.00011.01788.7960AID625254
D(3) dopamine receptorHomo sapiens (human)Ki0.01500.00000.602010.0000AID625254
5-hydroxytryptamine receptor 2BHomo sapiens (human)IC50 (µMol)0.75000.00011.18738.9125AID625217
5-hydroxytryptamine receptor 2BHomo sapiens (human)Ki0.47700.00030.769310.0000AID625217
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)7.02000.00001.819410.0000AID36710; AID36854; AID36858
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)Ki0.25200.00000.965010.0000AID1126944; AID35265
5-hydroxytryptamine receptor 3AHomo sapiens (human)Ki10.00000.00000.74119.9000AID712522
5-hydroxytryptamine receptor 6Homo sapiens (human)Ki0.01200.00020.522910.0000AID1801081
D(2) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.20550.00010.54948.4000AID61416; AID62868; AID64287; AID64297; AID64425
D(2) dopamine receptorRattus norvegicus (Norway rat)Ki0.60950.00000.437510.0000AID65247; AID65408
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)3.98110.00091.901410.0000AID576612
Alpha-2A adrenergic receptorBos taurus (cattle)IC50 (µMol)0.02500.00200.49073.8430AID3589
DMus musculus (house mouse)Ki1.00000.00040.76232.5300AID61838
5-hydroxytryptamine receptor 2ABos taurus (cattle)Ki0.17800.00720.09260.1780AID5137
Multidrug and toxin extrusion protein 2Homo sapiens (human)IC50 (µMol)46.00000.16003.95718.6000AID721752
DBos taurus (cattle)IC50 (µMol)270.00000.00100.47208.0000AID63046
Multidrug and toxin extrusion protein 1Homo sapiens (human)IC50 (µMol)1.70000.01002.765610.0000AID721754
Sigma non-opioid intracellular receptor 1Homo sapiens (human)IC50 (µMol)0.26660.00030.70285.3660AID203852; AID203984; AID625223
Sigma non-opioid intracellular receptor 1Homo sapiens (human)Ki1.31950.00000.490110.0000AID204624; AID625223
Lysosomal alpha-glucosidaseBos taurus (cattle)IC50 (µMol)0.03000.00210.01600.0300AID3725
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 1AHomo sapiens (human)EC50 (µMol)0.07850.00010.25718.0000AID1675987; AID1675989; AID1675991; AID1675993; AID1702323; AID1702325; AID1702327; AID265221; AID392709
5-hydroxytryptamine receptor 1AHomo sapiens (human)Kd0.01000.00010.95285.0119AID438555
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)EC50 (µMol)0.08000.00132.612925.7000AID265221
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)EC50 (µMol)0.08000.00133.394625.7000AID265221
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)EC50 (µMol)0.08000.00133.394625.7000AID265221
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (337)

Processvia Protein(s)Taxonomy
activation of cysteine-type endopeptidase activity involved in apoptotic processSolute carrier family 22 member 2Homo sapiens (human)
positive regulation of gene expressionSolute carrier family 22 member 2Homo sapiens (human)
organic cation transportSolute carrier family 22 member 2Homo sapiens (human)
monoatomic cation transportSolute carrier family 22 member 2Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 2Homo sapiens (human)
serotonin transportSolute carrier family 22 member 2Homo sapiens (human)
body fluid secretionSolute carrier family 22 member 2Homo sapiens (human)
organic cation transportSolute carrier family 22 member 2Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 2Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 2Homo sapiens (human)
amine transportSolute carrier family 22 member 2Homo sapiens (human)
putrescine transportSolute carrier family 22 member 2Homo sapiens (human)
spermidine transportSolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 2Homo sapiens (human)
choline transportSolute carrier family 22 member 2Homo sapiens (human)
dopamine transportSolute carrier family 22 member 2Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 2Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 2Homo sapiens (human)
histamine transportSolute carrier family 22 member 2Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 2Homo sapiens (human)
histamine uptakeSolute carrier family 22 member 2Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 2Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
amino acid import across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 2Homo sapiens (human)
L-arginine import across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
export across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 2Homo sapiens (human)
L-alpha-amino acid transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
L-arginine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 2Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
gamma-aminobutyric acid signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of serotonin secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of vasoconstriction5-hydroxytryptamine receptor 1AHomo sapiens (human)
exploration behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of dopamine metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of hormone secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1AHomo sapiens (human)
response to hypoxiaAngiotensin-converting enzyme Homo sapiens (human)
kidney developmentAngiotensin-converting enzyme Homo sapiens (human)
blood vessel remodelingAngiotensin-converting enzyme Homo sapiens (human)
angiotensin maturationAngiotensin-converting enzyme Homo sapiens (human)
regulation of renal output by angiotensinAngiotensin-converting enzyme Homo sapiens (human)
neutrophil mediated immunityAngiotensin-converting enzyme Homo sapiens (human)
antigen processing and presentation of peptide antigen via MHC class IAngiotensin-converting enzyme Homo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensinAngiotensin-converting enzyme Homo sapiens (human)
proteolysisAngiotensin-converting enzyme Homo sapiens (human)
spermatogenesisAngiotensin-converting enzyme Homo sapiens (human)
female pregnancyAngiotensin-converting enzyme Homo sapiens (human)
regulation of blood pressureAngiotensin-converting enzyme Homo sapiens (human)
male gonad developmentAngiotensin-converting enzyme Homo sapiens (human)
response to xenobiotic stimulusAngiotensin-converting enzyme Homo sapiens (human)
embryo development ending in birth or egg hatchingAngiotensin-converting enzyme Homo sapiens (human)
post-transcriptional regulation of gene expressionAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of gene expressionAngiotensin-converting enzyme Homo sapiens (human)
substance P catabolic processAngiotensin-converting enzyme Homo sapiens (human)
bradykinin catabolic processAngiotensin-converting enzyme Homo sapiens (human)
regulation of smooth muscle cell migrationAngiotensin-converting enzyme Homo sapiens (human)
regulation of vasoconstrictionAngiotensin-converting enzyme Homo sapiens (human)
animal organ regenerationAngiotensin-converting enzyme Homo sapiens (human)
response to nutrient levelsAngiotensin-converting enzyme Homo sapiens (human)
response to lipopolysaccharideAngiotensin-converting enzyme Homo sapiens (human)
mononuclear cell proliferationAngiotensin-converting enzyme Homo sapiens (human)
response to laminar fluid shear stressAngiotensin-converting enzyme Homo sapiens (human)
angiotensin-activated signaling pathwayAngiotensin-converting enzyme Homo sapiens (human)
vasoconstrictionAngiotensin-converting enzyme Homo sapiens (human)
hormone metabolic processAngiotensin-converting enzyme Homo sapiens (human)
hormone catabolic processAngiotensin-converting enzyme Homo sapiens (human)
eating behaviorAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of apoptotic processAngiotensin-converting enzyme Homo sapiens (human)
peptide catabolic processAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of vasoconstrictionAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of glucose importAngiotensin-converting enzyme Homo sapiens (human)
regulation of synaptic plasticityAngiotensin-converting enzyme Homo sapiens (human)
lung alveolus developmentAngiotensin-converting enzyme Homo sapiens (human)
amyloid-beta metabolic processAngiotensin-converting enzyme Homo sapiens (human)
arachidonic acid secretionAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of neurogenesisAngiotensin-converting enzyme Homo sapiens (human)
heart contractionAngiotensin-converting enzyme Homo sapiens (human)
regulation of angiotensin metabolic processAngiotensin-converting enzyme Homo sapiens (human)
hematopoietic stem cell differentiationAngiotensin-converting enzyme Homo sapiens (human)
angiogenesis involved in coronary vascular morphogenesisAngiotensin-converting enzyme Homo sapiens (human)
cellular response to glucose stimulusAngiotensin-converting enzyme Homo sapiens (human)
response to dexamethasoneAngiotensin-converting enzyme Homo sapiens (human)
cell proliferation in bone marrowAngiotensin-converting enzyme Homo sapiens (human)
regulation of heart rate by cardiac conductionAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of calcium ion importAngiotensin-converting enzyme Homo sapiens (human)
response to thyroid hormoneAngiotensin-converting enzyme Homo sapiens (human)
blood vessel diameter maintenanceAngiotensin-converting enzyme Homo sapiens (human)
regulation of hematopoietic stem cell proliferationAngiotensin-converting enzyme Homo sapiens (human)
negative regulation of gap junction assemblyAngiotensin-converting enzyme Homo sapiens (human)
cellular response to aldosteroneAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of peptidyl-cysteine S-nitrosylationAngiotensin-converting enzyme Homo sapiens (human)
positive regulation of systemic arterial blood pressureAngiotensin-converting enzyme Homo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
temperature homeostasisD(2) dopamine receptorHomo sapiens (human)
response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein phosphorylationD(2) dopamine receptorHomo sapiens (human)
response to amphetamineD(2) dopamine receptorHomo sapiens (human)
nervous system process involved in regulation of systemic arterial blood pressureD(2) dopamine receptorHomo sapiens (human)
regulation of heart rateD(2) dopamine receptorHomo sapiens (human)
regulation of sodium ion transportD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(2) dopamine receptorHomo sapiens (human)
positive regulation of neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
positive regulation of receptor internalizationD(2) dopamine receptorHomo sapiens (human)
autophagyD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
neuron-neuron synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
axonogenesisD(2) dopamine receptorHomo sapiens (human)
synapse assemblyD(2) dopamine receptorHomo sapiens (human)
sensory perception of smellD(2) dopamine receptorHomo sapiens (human)
long-term memoryD(2) dopamine receptorHomo sapiens (human)
grooming behaviorD(2) dopamine receptorHomo sapiens (human)
locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
adult walking behaviorD(2) dopamine receptorHomo sapiens (human)
protein localizationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell population proliferationD(2) dopamine receptorHomo sapiens (human)
associative learningD(2) dopamine receptorHomo sapiens (human)
visual learningD(2) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(2) dopamine receptorHomo sapiens (human)
response to light stimulusD(2) dopamine receptorHomo sapiens (human)
response to toxic substanceD(2) dopamine receptorHomo sapiens (human)
response to iron ionD(2) dopamine receptorHomo sapiens (human)
response to inactivityD(2) dopamine receptorHomo sapiens (human)
Wnt signaling pathwayD(2) dopamine receptorHomo sapiens (human)
striatum developmentD(2) dopamine receptorHomo sapiens (human)
orbitofrontal cortex developmentD(2) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(2) dopamine receptorHomo sapiens (human)
adenohypophysis developmentD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell migrationD(2) dopamine receptorHomo sapiens (human)
peristalsisD(2) dopamine receptorHomo sapiens (human)
auditory behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of synaptic transmission, GABAergicD(2) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(2) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
response to histamineD(2) dopamine receptorHomo sapiens (human)
response to nicotineD(2) dopamine receptorHomo sapiens (human)
positive regulation of urine volumeD(2) dopamine receptorHomo sapiens (human)
positive regulation of renal sodium excretionD(2) dopamine receptorHomo sapiens (human)
positive regulation of multicellular organism growthD(2) dopamine receptorHomo sapiens (human)
response to cocaineD(2) dopamine receptorHomo sapiens (human)
negative regulation of circadian sleep/wake cycle, sleepD(2) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(2) dopamine receptorHomo sapiens (human)
drinking behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(2) dopamine receptorHomo sapiens (human)
response to morphineD(2) dopamine receptorHomo sapiens (human)
pigmentationD(2) dopamine receptorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(2) dopamine receptorHomo sapiens (human)
negative regulation of innate immune responseD(2) dopamine receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IID(2) dopamine receptorHomo sapiens (human)
negative regulation of insulin secretionD(2) dopamine receptorHomo sapiens (human)
acid secretionD(2) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(2) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(2) dopamine receptorHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityD(2) dopamine receptorHomo sapiens (human)
response to axon injuryD(2) dopamine receptorHomo sapiens (human)
branching morphogenesis of a nerveD(2) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(2) dopamine receptorHomo sapiens (human)
epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(2) dopamine receptorHomo sapiens (human)
release of sequestered calcium ion into cytosolD(2) dopamine receptorHomo sapiens (human)
dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of synapse structural plasticityD(2) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(2) dopamine receptorHomo sapiens (human)
excitatory postsynaptic potentialD(2) dopamine receptorHomo sapiens (human)
positive regulation of growth hormone secretionD(2) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeD(2) dopamine receptorHomo sapiens (human)
regulation of locomotion involved in locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
negative regulation of cellular response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
positive regulation of glial cell-derived neurotrophic factor productionD(2) dopamine receptorHomo sapiens (human)
positive regulation of long-term synaptic potentiationD(2) dopamine receptorHomo sapiens (human)
hyaloid vascular plexus regressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of neuron migrationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(2) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(2) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(2) dopamine receptorBos taurus (cattle)
negative regulation of prolactin secretionD(2) dopamine receptorBos taurus (cattle)
negative regulation of lactationD(2) dopamine receptorBos taurus (cattle)
positive regulation of mammary gland involutionD(2) dopamine receptorBos taurus (cattle)
hyaloid vascular plexus regressionD(2) dopamine receptorBos taurus (cattle)
G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-1D adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of vasoconstrictionAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1D adrenergic receptorHomo sapiens (human)
temperature homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytokine production involved in immune response5-hydroxytryptamine receptor 2AHomo sapiens (human)
glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytosolic calcium ion concentration5-hydroxytryptamine receptor 2AHomo sapiens (human)
memory5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2AHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
regulation of dopamine secretion5-hydroxytryptamine receptor 2AHomo sapiens (human)
artery smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
urinary bladder smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of heat generation5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of potassium ion transport5-hydroxytryptamine receptor 2AHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of neuron apoptotic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein localization to cytoskeleton5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of vasoconstriction5-hydroxytryptamine receptor 2AHomo sapiens (human)
symbiont entry into host cell5-hydroxytryptamine receptor 2AHomo sapiens (human)
sensitization5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral response to cocaine5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of inflammatory response5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergic5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of execution phase of apoptosis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of platelet aggregation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of DNA biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2AHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 2CHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
locomotory behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
feeding behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2CHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of nervous system process5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of appetite5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of corticotropin-releasing hormone secretion5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of calcium-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2CHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2CHomo sapiens (human)
smooth muscle contraction5-hydroxytryptamine receptor 7Homo sapiens (human)
circadian rhythm5-hydroxytryptamine receptor 7Homo sapiens (human)
blood circulation5-hydroxytryptamine receptor 7Homo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 7Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 7Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 7Homo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 7Homo sapiens (human)
response to ethanolD(3) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(3) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
learning or memoryD(3) dopamine receptorHomo sapiens (human)
learningD(3) dopamine receptorHomo sapiens (human)
locomotory behaviorD(3) dopamine receptorHomo sapiens (human)
visual learningD(3) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(3) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(3) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(3) dopamine receptorHomo sapiens (human)
response to histamineD(3) dopamine receptorHomo sapiens (human)
social behaviorD(3) dopamine receptorHomo sapiens (human)
response to cocaineD(3) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(3) dopamine receptorHomo sapiens (human)
response to morphineD(3) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(3) dopamine receptorHomo sapiens (human)
positive regulation of mitotic nuclear divisionD(3) dopamine receptorHomo sapiens (human)
acid secretionD(3) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(3) dopamine receptorHomo sapiens (human)
negative regulation of oligodendrocyte differentiationD(3) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(3) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(3) dopamine receptorHomo sapiens (human)
musculoskeletal movement, spinal reflex actionD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(3) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(3) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(3) dopamine receptorHomo sapiens (human)
positive regulation of dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(3) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(3) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(3) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(3) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(3) dopamine receptorHomo sapiens (human)
neural crest cell migration5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cytokine production5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of endothelial cell proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor internalization5-hydroxytryptamine receptor 2BHomo sapiens (human)
heart morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
cardiac muscle hypertrophy5-hydroxytryptamine receptor 2BHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
neural crest cell differentiation5-hydroxytryptamine receptor 2BHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphorylation5-hydroxytryptamine receptor 2BHomo sapiens (human)
calcium-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 2BHomo sapiens (human)
negative regulation of apoptotic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of MAP kinase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
embryonic morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of nitric-oxide synthase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell division5-hydroxytryptamine receptor 2BHomo sapiens (human)
ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cellular response to temperature stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 3AHomo sapiens (human)
monoatomic ion transmembrane transport5-hydroxytryptamine receptor 3AHomo sapiens (human)
excitatory postsynaptic potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
inorganic cation transmembrane transport5-hydroxytryptamine receptor 3AHomo sapiens (human)
regulation of presynaptic membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 3AHomo sapiens (human)
regulation of membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
cerebral cortex cell migration5-hydroxytryptamine receptor 6Homo sapiens (human)
positive regulation of TOR signaling5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 6Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 6Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of smooth muscle contractionAlpha-2A adrenergic receptorBos taurus (cattle)
regulation of vasoconstrictionAlpha-2A adrenergic receptorBos taurus (cattle)
platelet activationAlpha-2A adrenergic receptorBos taurus (cattle)
glycolytic process5-hydroxytryptamine receptor 2ABos taurus (cattle)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2ABos taurus (cattle)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2ABos taurus (cattle)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2ABos taurus (cattle)
protein localization to cytoskeleton5-hydroxytryptamine receptor 2ABos taurus (cattle)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2ABos taurus (cattle)
positive regulation of glycolytic process5-hydroxytryptamine receptor 2ABos taurus (cattle)
positive regulation of peptidyl-tyrosine phosphorylation5-hydroxytryptamine receptor 2ABos taurus (cattle)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2ABos taurus (cattle)
organic cation transportMultidrug and toxin extrusion protein 2Homo sapiens (human)
transmembrane transportMultidrug and toxin extrusion protein 2Homo sapiens (human)
proton transmembrane transportMultidrug and toxin extrusion protein 2Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneMultidrug and toxin extrusion protein 2Homo sapiens (human)
synaptic transmission, dopaminergicDBos taurus (cattle)
vasodilationDBos taurus (cattle)
xenobiotic transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
organic cation transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
putrescine transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
thiamine transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
amino acid import across plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine import across plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-alpha-amino acid transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
proton transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
lipid transportSigma non-opioid intracellular receptor 1Homo sapiens (human)
nervous system developmentSigma non-opioid intracellular receptor 1Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwaySigma non-opioid intracellular receptor 1Homo sapiens (human)
regulation of neuron apoptotic processSigma non-opioid intracellular receptor 1Homo sapiens (human)
protein homotrimerizationSigma non-opioid intracellular receptor 1Homo sapiens (human)
maltose metabolic processLysosomal alpha-glucosidaseBos taurus (cattle)
regulation of the force of heart contractionLysosomal alpha-glucosidaseBos taurus (cattle)
diaphragm contractionLysosomal alpha-glucosidaseBos taurus (cattle)
heart morphogenesisLysosomal alpha-glucosidaseBos taurus (cattle)
glycogen catabolic processLysosomal alpha-glucosidaseBos taurus (cattle)
locomotory behaviorLysosomal alpha-glucosidaseBos taurus (cattle)
tissue developmentLysosomal alpha-glucosidaseBos taurus (cattle)
aorta developmentLysosomal alpha-glucosidaseBos taurus (cattle)
vacuolar sequesteringLysosomal alpha-glucosidaseBos taurus (cattle)
muscle cell cellular homeostasisLysosomal alpha-glucosidaseBos taurus (cattle)
neuromuscular process controlling postureLysosomal alpha-glucosidaseBos taurus (cattle)
neuromuscular process controlling balanceLysosomal alpha-glucosidaseBos taurus (cattle)
cardiac muscle contractionLysosomal alpha-glucosidaseBos taurus (cattle)
glycophagyLysosomal alpha-glucosidaseBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (82)

Processvia Protein(s)Taxonomy
amine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
L-amino acid transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
choline transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
efflux transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
L-arginine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
receptor-receptor interaction5-hydroxytryptamine receptor 1AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
endopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
carboxypeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
metalloendopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
calmodulin bindingAngiotensin-converting enzyme Homo sapiens (human)
peptidase activityAngiotensin-converting enzyme Homo sapiens (human)
metallopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
exopeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
tripeptidyl-peptidase activityAngiotensin-converting enzyme Homo sapiens (human)
peptidyl-dipeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
zinc ion bindingAngiotensin-converting enzyme Homo sapiens (human)
chloride ion bindingAngiotensin-converting enzyme Homo sapiens (human)
mitogen-activated protein kinase kinase bindingAngiotensin-converting enzyme Homo sapiens (human)
bradykinin receptor bindingAngiotensin-converting enzyme Homo sapiens (human)
mitogen-activated protein kinase bindingAngiotensin-converting enzyme Homo sapiens (human)
metallodipeptidase activityAngiotensin-converting enzyme Homo sapiens (human)
heterocyclic compound bindingAngiotensin-converting enzyme Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(2) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(2) dopamine receptorHomo sapiens (human)
protein bindingD(2) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(2) dopamine receptorHomo sapiens (human)
dopamine bindingD(2) dopamine receptorHomo sapiens (human)
ionotropic glutamate receptor bindingD(2) dopamine receptorHomo sapiens (human)
identical protein bindingD(2) dopamine receptorHomo sapiens (human)
heterocyclic compound bindingD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(2) dopamine receptorHomo sapiens (human)
protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
identical protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1D adrenergic receptorHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
virus receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein tyrosine kinase activator activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein-containing complex binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 7Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 7Homo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 7Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(3) dopamine receptorHomo sapiens (human)
protein bindingD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(3) dopamine receptorHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
G-protein alpha-subunit binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
GTPase activator activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 3AHomo sapiens (human)
serotonin-gated monoatomic cation channel activity5-hydroxytryptamine receptor 3AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 3AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 3AHomo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity5-hydroxytryptamine receptor 3AHomo sapiens (human)
histamine receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
protein binding5-hydroxytryptamine receptor 6Homo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2ABos taurus (cattle)
protein tyrosine kinase activator activity5-hydroxytryptamine receptor 2ABos taurus (cattle)
identical protein binding5-hydroxytryptamine receptor 2ABos taurus (cattle)
serotonin binding5-hydroxytryptamine receptor 2ABos taurus (cattle)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2ABos taurus (cattle)
organic cation transmembrane transporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
antiporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
transmembrane transporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
polyspecific organic cation:proton antiporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
protein bindingMultidrug and toxin extrusion protein 1Homo sapiens (human)
organic cation transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-amino acid transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
thiamine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
antiporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
putrescine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
polyspecific organic cation:proton antiporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
G protein-coupled opioid receptor activitySigma non-opioid intracellular receptor 1Homo sapiens (human)
protein bindingSigma non-opioid intracellular receptor 1Homo sapiens (human)
alpha-1,4-glucosidase activityLysosomal alpha-glucosidaseBos taurus (cattle)
carbohydrate bindingLysosomal alpha-glucosidaseBos taurus (cattle)
maltose alpha-glucosidase activityLysosomal alpha-glucosidaseBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (71)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
membraneSolute carrier family 22 member 2Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 2Homo sapiens (human)
presynapseSolute carrier family 22 member 2Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
synapse5-hydroxytryptamine receptor 1AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1AHomo sapiens (human)
extracellular spaceAngiotensin-converting enzyme Homo sapiens (human)
extracellular regionAngiotensin-converting enzyme Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme Homo sapiens (human)
lysosomeAngiotensin-converting enzyme Homo sapiens (human)
endosomeAngiotensin-converting enzyme Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
external side of plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
basal plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
brush border membraneAngiotensin-converting enzyme Homo sapiens (human)
extracellular exosomeAngiotensin-converting enzyme Homo sapiens (human)
sperm midpieceAngiotensin-converting enzyme Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme Homo sapiens (human)
Golgi membraneD(2) dopamine receptorHomo sapiens (human)
acrosomal vesicleD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
ciliumD(2) dopamine receptorHomo sapiens (human)
lateral plasma membraneD(2) dopamine receptorHomo sapiens (human)
endocytic vesicleD(2) dopamine receptorHomo sapiens (human)
axonD(2) dopamine receptorHomo sapiens (human)
dendriteD(2) dopamine receptorHomo sapiens (human)
synaptic vesicle membraneD(2) dopamine receptorHomo sapiens (human)
sperm flagellumD(2) dopamine receptorHomo sapiens (human)
dendritic spineD(2) dopamine receptorHomo sapiens (human)
perikaryonD(2) dopamine receptorHomo sapiens (human)
axon terminusD(2) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(2) dopamine receptorHomo sapiens (human)
ciliary membraneD(2) dopamine receptorHomo sapiens (human)
non-motile ciliumD(2) dopamine receptorHomo sapiens (human)
dopaminergic synapseD(2) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(2) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(2) dopamine receptorHomo sapiens (human)
presynaptic membraneD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
Golgi membraneD(2) dopamine receptorBos taurus (cattle)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
neurofilament5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
caveola5-hydroxytryptamine receptor 2AHomo sapiens (human)
axon5-hydroxytryptamine receptor 2AHomo sapiens (human)
cytoplasmic vesicle5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
neuronal cell body5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendritic shaft5-hydroxytryptamine receptor 2AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
cell body fiber5-hydroxytryptamine receptor 2AHomo sapiens (human)
glutamatergic synapse5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 7Homo sapiens (human)
trans-Golgi network membrane5-hydroxytryptamine receptor 7Homo sapiens (human)
synapse5-hydroxytryptamine receptor 7Homo sapiens (human)
dendrite5-hydroxytryptamine receptor 7Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 7Homo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
synapseD(3) dopamine receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
nucleoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
cytoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2BHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3AHomo sapiens (human)
cleavage furrow5-hydroxytryptamine receptor 3AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 3AHomo sapiens (human)
serotonin-activated cation-selective channel complex5-hydroxytryptamine receptor 3AHomo sapiens (human)
synapse5-hydroxytryptamine receptor 3AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3AHomo sapiens (human)
transmembrane transporter complex5-hydroxytryptamine receptor 3AHomo sapiens (human)
neuron projection5-hydroxytryptamine receptor 3AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
cilium5-hydroxytryptamine receptor 6Homo sapiens (human)
synapse5-hydroxytryptamine receptor 6Homo sapiens (human)
dendrite5-hydroxytryptamine receptor 6Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
caveola5-hydroxytryptamine receptor 2ABos taurus (cattle)
axon5-hydroxytryptamine receptor 2ABos taurus (cattle)
cytoplasmic vesicle5-hydroxytryptamine receptor 2ABos taurus (cattle)
presynapse5-hydroxytryptamine receptor 2ABos taurus (cattle)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2ABos taurus (cattle)
plasma membraneMultidrug and toxin extrusion protein 2Homo sapiens (human)
apical plasma membraneMultidrug and toxin extrusion protein 2Homo sapiens (human)
membraneMultidrug and toxin extrusion protein 2Homo sapiens (human)
endoplasmic reticulum membraneDBos taurus (cattle)
dendritic spineDBos taurus (cattle)
ciliary membraneDBos taurus (cattle)
plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
basolateral plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
apical plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
nuclear envelopeSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear inner membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear outer membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulum membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
lipid dropletSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytosolSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic densitySigma non-opioid intracellular receptor 1Homo sapiens (human)
membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
growth coneSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytoplasmic vesicleSigma non-opioid intracellular receptor 1Homo sapiens (human)
anchoring junctionSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic density membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
lysosomal membraneLysosomal alpha-glucosidaseBos taurus (cattle)
autolysosome lumenLysosomal alpha-glucosidaseBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (466)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID4169Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
Derivatives of (R)- and (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin: synthesis and interactions with 5-HT1A receptors.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1443995Hepatotoxicity in human assessed as drug-induced liver injury2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID395327Dissociation constant, pKa by capillary electrophoresis2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID203984In vitro binding affinity measured on sigma opioid receptor using [3H]DTG as radioligand1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
High affinity and selectivity on 5-HT1A receptor of 1-aryl-4-[1-tetralin)alkyl]piperazines. 2.
AID460125Displacement of [3H]8-OH-DPAT from 5HT1A receptor expressed in CHO cells by liquid scintillation counting2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Synthesis of dihydrofuroaporphine derivatives: identification of a potent and selective serotonin 5-HT 1A receptor agonist.
AID5007Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB1996Journal of medicinal chemistry, Oct-11, Volume: 39, Issue:21
3-amino-3,4-dihydro-2H-1-benzopyran derivatives as 5-HT1A receptor ligands and potential anxiolytic agents. 2. Synthesis and quantitative structure-activity relationship studies of spiro[pyrrolidine- and piperidine-2,3'(2'H)-benzopyrans].
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1215127Ratio of fraction unbound in solid supported porcine brain membrane vesicles at 5 uM by TRANSIL assay to fraction unbound in Wistar rat brain homogenate at 5 uM after 5 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
AID721753Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells at 20 uM after 1.5 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID265218Selectivity for D2 receptor over 5HT1A receptor2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.
AID1454156Stability in rat liver microsomes assessed as compound remaining by mass spectrometry2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Enterovirus inhibitory activity of C-8-tert-butyl substituted 4-aryl-6,7,8,9-tetrahydrobenzo[4,5]thieno[3,2-e][1,2,4]triazolo[4,3-a]pyrimidin-5(4H)-ones.
AID4748Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
New benzocycloalkylpiperazines, potent and selective 5-HT1A receptor ligands.
AID193146Compound was tested for the induction of behavioral syndrome (forepaw treading) in rats at a dose of 1.25 mg/kg; not tested1996Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5
8-[4-[2-(1,2,3,4-Tetrahydroisoquinolinyl]butyl-8-azaspiro[4.5]decane-7,9-dione: a new 5-HT1A receptor ligand with the same activity profile as buspirone.
AID1675991Biased agonist activity at Gal4-VP16 transcription factor linked human 5-HT1A receptor expressed in human U2OS cells assessed as induction of beta-arrestin2 recruitment measured after 5 hrs by Tango assay
AID1636356Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID177716Induction of catalepsy in nonfasted male Sprague-Dawley rats (dose that produced catalepsy in 50% of the animals)1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Buspirone analogues. 1. Structure-activity relationships in a series of N-aryl- and heteroarylpiperazine derivatives.
AID3738Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)1996Journal of medicinal chemistry, Oct-11, Volume: 39, Issue:21
3-amino-3,4-dihydro-2H-1-benzopyran derivatives as 5-HT1A receptor ligands and potential anxiolytic agents. 2. Synthesis and quantitative structure-activity relationship studies of spiro[pyrrolidine- and piperidine-2,3'(2'H)-benzopyrans].
AID1702329Biased agonist activity at human recombinant 5-HT1A receptor stably expressed in CHO-K1 cells assessed as increase in calcium mobilization measured at 2 sec intervals for 180 secs by Fluo-4AM dye based fluorescence assay
AID5006Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex1994Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12
3,4-Dihydro-3-amino-2H-1-benzopyran derivatives as 5-HT1A receptor ligands and potential anxiolytic agents. 1. Synthesis and structure--activity relationship studies.
AID393946Anxiolytic activity in Wistar rat assessed as time spent into open arms at 5 mg/kg, ip administered 60 mins before evaluation and measured during 5 mins by elevated plus-maze test2009Bioorganic & medicinal chemistry, Mar-01, Volume: 17, Issue:5
Synthesis and pharmacological evaluation of new arylpiperazines N-[4-[4-(aryl) piperazine-1-yl]-phenyl]-amine derivatives: putative role of 5-HT1A receptors.
AID4789Binding affinity towards 5-hydroxytryptamine 2 receptor was determined1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Central serotonin receptors as targets for drug research.
AID4042Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-41011995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
Piperazinylalkyl heterocycles as potential antipsychotic agents.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1443986Inhibition of recombinant human BSEP expressed in baculovirus infected sf9 cell membrane vesicles assessed as reduction in ATP or AMP-dependent [3H]-taurocholic acid uptake in to vesicles preincubated for 5 mins followed by ATP/AMP addition measured after2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID193147Compound was tested for the induction of behavioral syndrome (forepaw treading) in rats at a dose of 10 mg/kg1996Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5
8-[4-[2-(1,2,3,4-Tetrahydroisoquinolinyl]butyl-8-azaspiro[4.5]decane-7,9-dione: a new 5-HT1A receptor ligand with the same activity profile as buspirone.
AID3471Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Novel 2-substituted tetrahydro-3H-benz[e]indolamines: highly potent and selective agonists acting at the 5-HT1A receptor as possible anxiolytics and antidepressants.
AID5232Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Synthesis and structure activity relationships of cis- and trans-2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-c]pyridines for 5-HT receptor subtypes.
AID1209456Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID1454764Binding affinity to 5-HT1A (unknown origin)2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID190627Social interaction time determined in vivo rat at 0.1 mg/kg of ip administration2003Bioorganic & medicinal chemistry letters, Jan-20, Volume: 13, Issue:2
Development of a presynaptic 5-HT1A antagonist.
AID61838Binding affinity against Dopamine receptor D11997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
New benzocycloalkylpiperazines, potent and selective 5-HT1A receptor ligands.
AID1222793Dissociation constant, pKa of the compound2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Which metabolites circulate?
AID265253Cmax in Beagle dog at 3 mg/kg, po2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.
AID265216Selectivity for adrenergic alpha-1 receptor over 5HT1A receptor2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.
AID1702328Biased agonist activity at human recombinant 5-HT1A receptor stably expressed in CHO-K1 cells assessed as increase in calcium mobilization measured at 2 sec intervals for 180 secs by Fluo-4AM dye based fluorescence assay relative to serotonin
AID1702274Bias factor, ratio of biased agonist activity at human recombinant 5-HT1A receptor stably expressed in CHO-K1 cells assessed as increase in ERK1/2 phosphorylation levels to biased agonist activity at human recombinant 5-HT1A receptor stably expressed in C
AID4753In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
(S)-N-tert-butyl-3-(4-(2-methoxyphenyl)-piperazin-1-yl)-2-phenylpropanamide [(S)-WAY-100135]: a selective antagonist at presynaptic and postsynaptic 5-HT1A receptors.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1512150Binding affinity to 5HT1A receptor (unknown origin)2019Bioorganic & medicinal chemistry letters, 11-01, Volume: 29, Issue:21
Design, synthesis and biological evaluation of novel serotonin and dopamine receptor ligands being 6-bromohexyl saccharine derivatives.
AID64137Binding affinity against Dopamine receptor D21997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
New benzocycloalkylpiperazines, potent and selective 5-HT1A receptor ligands.
AID41880Percent inhibition of Beta adrenergic receptor by 1 uM of compound1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Synthesis and structure-activity relationship of substituted tetrahydro- and hexahydro-1,2-benzisothiazol-3-one 1,1-dioxides and thiadiazinones: potential anxiolytic agents.
AID242352Inhibitory concentration against Alpha-1 adrenergic receptor in rat cerebral cortex membrane using [3H]prazosin as radioligand2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
New piperidinyl- and 1,2,3,6-tetrahydropyridinyl-pyrimidine derivatives as selective 5-HT1A receptor agonists with highly potent anti-ischemic effects.
AID1675988Biased agonist activity at human 5-HT1A receptor stably expressed in CHO-K1 cells assessed as inhibition of forskolin-induced cAMP accumulation after 40 mins by LANCE Ultra cAMP kit-based TR-FRET assay relative to serotonin
AID662443Chemical stability in buffer assessed as compound remaining at 1 uM after 30 mins2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors: part II.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID235588Ratio of ED50 (rotarod) to that of ED50 (fighting)1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID4171Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
Derivatives of (R)- and (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin: synthesis and interactions with 5-HT1A receptors.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1205636Metabolic stability in mouse liver microsomes assessed as compound remaining at 1 uM after 30 mins by LC-ESI/MS/MS analysis in absence of NADPH2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Discovery of Orally Available Runt-Related Transcription Factor 3 (RUNX3) Modulators for Anticancer Chemotherapy by Epigenetic Activation and Protein Stabilization.
AID4220Binding affinity against rat 5-hydroxytryptamine 1A receptor1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
New benzocycloalkylpiperazines, potent and selective 5-HT1A receptor ligands.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID65908Binding affinity towards dopamine receptor D2 by displacing [3H]spiperone radioligand in rat striatum1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Pyrrole mannich bases as potential antipsychotic agents.
AID193144Compound was tested for the induction of behavioral syndrome(flat body posture) in rats at a dose of 2.5 mg/kg; not tested1996Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5
8-[4-[2-(1,2,3,4-Tetrahydroisoquinolinyl]butyl-8-azaspiro[4.5]decane-7,9-dione: a new 5-HT1A receptor ligand with the same activity profile as buspirone.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID193155Effect on the 8-OH-DPAT-Induced Behavior(flat body posture) in Reserpine Pretreated Rats at a dose of 5 mg/kg1996Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5
8-[4-[2-(1,2,3,4-Tetrahydroisoquinolinyl]butyl-8-azaspiro[4.5]decane-7,9-dione: a new 5-HT1A receptor ligand with the same activity profile as buspirone.
AID1675993Biased agonist activity at human 5-HT1A receptor stably expressed in CHO-K1 cells co-expressing Galpha16/GPCR assessed as increase in calcium mobilization measured for 30 secs in presence of coelenterazine by aequorin-reporter gene based luminescence assa
AID193148Compound was tested for the induction of behavioral syndrome (forepaw treading) in rats at a dose of 2.5 mg/kg; not tested1996Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5
8-[4-[2-(1,2,3,4-Tetrahydroisoquinolinyl]butyl-8-azaspiro[4.5]decane-7,9-dione: a new 5-HT1A receptor ligand with the same activity profile as buspirone.
AID4821Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Mixed 5-HT1A/D-2 activity of a new model of arylpiperazines: 1-aryl-4-[3-(1,2-dihydronaphthalen-4-yl)-n-propyl]piperazines. 1. Synthesis and structure-activity relationships.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID3768Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
New benzocycloalkylpiperazines, potent and selective 5-HT1A receptor ligands.
AID1211296Unbound fraction in plasma (unknown origin) under normal atmospheric condition at pH 7.72 after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID1434365Stability in mouse liver microsomes assessed as parent compound remaining at 1 mM in absence of NADPH measured after 30 mins by LC-ESI-MS/MS method2017European journal of medicinal chemistry, Jan-27, Volume: 126Improving potency and metabolic stability by introducing an alkenyl linker to pyridine-based histone deacetylase inhibitors for orally available RUNX3 modulators.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1766987Metabolic stability in human liver microsomes assessed as compound remaining at 10 mM incubated for 30 mins by LC/MS/MS analysis
AID4015Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT1996Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5
8-[4-[2-(1,2,3,4-Tetrahydroisoquinolinyl]butyl-8-azaspiro[4.5]decane-7,9-dione: a new 5-HT1A receptor ligand with the same activity profile as buspirone.
AID63046Displacement of [3H]raclopride from Dopamine receptor D1 of calf striatum1996Journal of medicinal chemistry, Oct-11, Volume: 39, Issue:21
3-amino-3,4-dihydro-2H-1-benzopyran derivatives as 5-HT1A receptor ligands and potential anxiolytic agents. 2. Synthesis and quantitative structure-activity relationship studies of spiro[pyrrolidine- and piperidine-2,3'(2'H)-benzopyrans].
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1766985Metabolic stability in mouse liver microsomes assessed as compound remaining at 10 mM incubated for 30 mins by LC/MS/MS analysis
AID4822In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
High affinity and selectivity on 5-HT1A receptor of 1-aryl-4-[1-tetralin)alkyl]piperazines. 2.
AID265223Oral bioavailability in Sprague-Dawley rat at 3 mg/kg, po and 1 mg/kg, iv2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.
AID5291Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Synthesis and SAR of adatanserin: novel adamantyl aryl- and heteroarylpiperazines with dual serotonin 5-HT(1A) and 5-HT(2) activity as potential anxiolytic and antidepressant agents.
AID1656652Selectivity ratio of Ki for displacement of [3H]-5-carboxamidotryptamine from human 5-HT1A receptor expressed in HEK293T cell membranes to Ki for displacement of [3H]-5-carboxamidotryptamine from human 5-HT7 receptor expressed in HEK293 cell membranes2020Bioorganic & medicinal chemistry, 02-01, Volume: 28, Issue:3
Synthesis of novel 5-substituted-2-aminotetralin analogs: 5-HT
AID184831Compound was tested for the induction of lower lip retraction in rats at a dose of 1.25 mg/kg1996Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5
8-[4-[2-(1,2,3,4-Tetrahydroisoquinolinyl]butyl-8-azaspiro[4.5]decane-7,9-dione: a new 5-HT1A receptor ligand with the same activity profile as buspirone.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID4076In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Synthesis and structure-activity relationship of substituted tetrahydro- and hexahydro-1,2-benzisothiazol-3-one 1,1-dioxides and thiadiazinones: potential anxiolytic agents.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID4399Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Graphics computer-aided receptor mapping as a predictive tool for drug design: development of potent, selective, and stereospecific ligands for the 5-HT1A receptor.
AID3725Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand1996Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25
Structure-activity relationship studies on the 5-HT(1A) receptor affinity of 1-phenyl-4-[omega-(alpha- or beta-tetralinyl)alkyl]piperazines. 4.
AID27922Calculated partition coefficient (clogP)2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
trans-4-[4-(Methoxyphenyl)cyclohexyl]-1-arylpiperazines: a new class of potent and selective 5-HT(1A) receptor ligands as conformationally constrained analogues of 4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]-1-arylpiperazines.
AID1675987Biased agonist activity at human 5-HT1A receptor stably expressed in CHO-K1 cells assessed as increase in ERK1/2 phosphorylation after 15 mins by Alphalisa assay
AID1737996Metabolic stability in mouse liver microsomes assessed as percentage of compound remaining after 30 mins2020European journal of medicinal chemistry, Jul-01, Volume: 197Synthesis and evaluation of butein derivatives for in vitro and in vivo inflammatory response suppression in lymphedema.
AID193149Compound was tested for the induction of behavioral syndrome (forepaw treading) in rats at a dose of 5 mg/kg1996Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5
8-[4-[2-(1,2,3,4-Tetrahydroisoquinolinyl]butyl-8-azaspiro[4.5]decane-7,9-dione: a new 5-HT1A receptor ligand with the same activity profile as buspirone.
AID1220559Fraction unbound in cynomolgus monkey brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID1823850Anxiolytic activity in stress-induced anxiety ip dosed Wistar rat model assessed as increase in open arm entry measured after 30 mins by elevated plus maze test
AID781326pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1454765Binding affinity to 5-HT2A (unknown origin)2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry.
AID47962Dose required to reduce sympathetic nerve discharge in cat following intravenous administration1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Novel 2-substituted tetrahydro-3H-benz[e]indolamines: highly potent and selective agonists acting at the 5-HT1A receptor as possible anxiolytics and antidepressants.
AID395325Lipophilicity, log P by microemulsion electrokinetic chromatography2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID63814In vitro ability to inhibit binding of radioligand [3H]spiroperidol to dopamine D2 receptor in rat striatal membrane1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Mixed 5-HT1A/D-2 activity of a new model of arylpiperazines: 1-aryl-4-[3-(1,2-dihydronaphthalen-4-yl)-n-propyl]piperazines. 1. Synthesis and structure-activity relationships.
AID545728Displacement of [3H]DPAT from 5HT1A receptor in Wistar rat hippocampus using 2 x 10' -8 by liquid scintillation counting2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Antiarrhythmic, serotonin antagonist and antianxiety activities of novel substituted thiophene derivatives synthesized from 2-amino-4,5,6,7-tetrahydro-N-phenylbenzo[b]thiophene-3-carboxamide.
AID194642Neuronal protective effect of compound against ischemic brain damage in rat t-MCAO model2001Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4
New 5-HT1A receptor agonists possessing 1,4-benzoxazepine scaffold exhibit highly potent anti-ischemic effects.
AID1636357Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID3168Dose to reduce neuronal firing against 5-HT cells in rats (iv)1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Novel 2-substituted tetrahydro-3H-benz[e]indolamines: highly potent and selective agonists acting at the 5-HT1A receptor as possible anxiolytics and antidepressants.
AID3474Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
Dopaminergic and serotonergic activities of imidazoquinolinones and related compounds.
AID62343Inhibition of [3H]raclopride binding to Dopamine receptor D2 of bovine striatum1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
New benzocycloalkylpiperazines, potent and selective 5-HT1A receptor ligands.
AID1220554Fraction unbound in Wistar Han rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID721752Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID1675998Bias factor, ratio of biased agonist activity at human 5-HT1A receptor stably expressed in CHO-K1 cells assessed as inhibition of forskolin-induced cAMP accumulation to biased agonist activity at human 5-HT1A receptor stably expressed in CHO-K1 cells co-e
AID1536198Metabolic stability in rat liver microsomes assessed as parent compound remaining after 30 mins by LC-MS/MS analysis2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Discovery of Novel Pyruvate Dehydrogenase Kinase 4 Inhibitors for Potential Oral Treatment of Metabolic Diseases.
AID177895Inhibition of conditioned avoidance response (CAR) in fasted male Sprague-Dawley rats.1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Buspirone analogues. 1. Structure-activity relationships in a series of N-aryl- and heteroarylpiperazine derivatives.
AID460124Binding affinity to 5HT1A receptor2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Synthesis of dihydrofuroaporphine derivatives: identification of a potent and selective serotonin 5-HT 1A receptor agonist.
AID130883Inhibition of apomorphine induced stereotyped behavior in mice after intraperitoneal administration; Inactive1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Polycyclic aryl- and heteroarylpiperazinyl imides as 5-HT1A receptor ligands and potential anxiolytic agents: synthesis and structure-activity relationship studies.
AID35845Binding affinity against alpha-1 adrenergic receptor in calf frontal cortex1994Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12
3,4-Dihydro-3-amino-2H-1-benzopyran derivatives as 5-HT1A receptor ligands and potential anxiolytic agents. 1. Synthesis and structure--activity relationship studies.
AID193150Effect on the 8-OH-DPAT-Induced Behavior(flat body posture) in Reserpine Pretreated Rats at a dose of 1.25 mg/kg1996Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5
8-[4-[2-(1,2,3,4-Tetrahydroisoquinolinyl]butyl-8-azaspiro[4.5]decane-7,9-dione: a new 5-HT1A receptor ligand with the same activity profile as buspirone.
AID438555Binding affinity to 5HT1A receptor2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Physical binding pocket induction for affinity prediction.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1656650Displacement of [3H]-5-carboxamidotryptamine from human 5-HT7A receptor expressed in HEK293 cell membranes incubated for 90 mins by scintillation counting method2020Bioorganic & medicinal chemistry, 02-01, Volume: 28, Issue:3
Synthesis of novel 5-substituted-2-aminotetralin analogs: 5-HT
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID235587Ratio of ED50 (hexobarbital) to that of ED50 (fighting)1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
AID64287Inhibition of binding of radioligand [3H]spiroperidol to dopamine D2 receptor in rat striatal membranes1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Mixed 5-HT1A/D-2 activity of a new model of arylpiperazines: 1-aryl-4-[3-(1,2-dihydronaphthalen-4-yl)-n-propyl]piperazines. 1. Synthesis and structure-activity relationships.
AID169428Concentration required to produce 50% block in avoidance responding in conditioned avoidance response test in rat following peroral administration1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Polycyclic aryl- and heteroarylpiperazinyl imides as 5-HT1A receptor ligands and potential anxiolytic agents: synthesis and structure-activity relationship studies.
AID130880Inhibition of apomorphine induced climbing behavior in mice after intraperitoneal administration; Inactive1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Polycyclic aryl- and heteroarylpiperazinyl imides as 5-HT1A receptor ligands and potential anxiolytic agents: synthesis and structure-activity relationship studies.
AID1454155Stability in human liver microsomes assessed as compound remaining by mass spectrometry2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Enterovirus inhibitory activity of C-8-tert-butyl substituted 4-aryl-6,7,8,9-tetrahydrobenzo[4,5]thieno[3,2-e][1,2,4]triazolo[4,3-a]pyrimidin-5(4H)-ones.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID5009Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
New benzocycloalkylpiperazines, potent and selective 5-HT1A receptor ligands.
AID1702325Biased agonist activity at human recombinant 5-HT1A receptor stably expressed in CHO-K1 cells assessed as inhibition of forskolin-induced cAMP accumulation after 40 mins by LANCE Ultra cAMP kit-based TR-FRET assay
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID759366Displacement of [3H]8-OH-DPAT from human 5HT1A receptor expressed in HEK293 cells after 1 hr2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Synthesis and evaluation of pharmacological properties of some new xanthone derivatives with piperazine moiety.
AID1675996Bias factor, ratio of biased agonist activity at human 5-HT1A receptor stably expressed in CHO-K1 cells assessed as increase in ERK1/2 phosphorylation levels to biased agonist activity at human 5-HT1A receptor stably expressed in CHO-K1 cells co-expressin
AID193152Effect on the 8-OH-DPAT-Induced Behavior(flat body posture) in Reserpine Pretreated Rats at a dose of 10 mg/kg1996Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5
8-[4-[2-(1,2,3,4-Tetrahydroisoquinolinyl]butyl-8-azaspiro[4.5]decane-7,9-dione: a new 5-HT1A receptor ligand with the same activity profile as buspirone.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID350167Metabolic stability in human liver microsomes assessed as half life2009Journal of medicinal chemistry, May-28, Volume: 52, Issue:10
Anti-AIDS agents. 78. Design, synthesis, metabolic stability assessment, and antiviral evaluation of novel betulinic acid derivatives as potent anti-human immunodeficiency virus (HIV) agents.
AID1675986Biased agonist activity at human 5-HT1A receptor stably expressed in CHO-K1 cells assessed as increase in ERK1/2 phosphorylation levels after 15 mins by Alphalisa assay relative to serotonin
AID36868Inhibition of [3H]WB-4101 binding to alpha-1-adrenergic receptor from rat cerebral cortex membranes1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Buspirone analogues. 1. Structure-activity relationships in a series of N-aryl- and heteroarylpiperazine derivatives.
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
AID1702323Biased agonist activity at human recombinant 5-HT1A receptor stably expressed in CHO-K1 cells assessed as increase in ERK1/2 phosphorylation levels incubated for 15 mins by Alphalisa assay
AID1443992Total Cmax in human administered as single dose2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID65744In vitro inhibition of [3H]spiperone binding to Dopamine receptor D2 from rat brain limbic tissue1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Polycyclic aryl- and heteroarylpiperazinyl imides as 5-HT1A receptor ligands and potential anxiolytic agents: synthesis and structure-activity relationship studies.
AID298032Acid dissociation constant, pKa of the compound2007Journal of medicinal chemistry, Sep-20, Volume: 50, Issue:19
High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
AID4073In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.1995Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8
New (2-methoxyphenyl)piperazine derivatives as 5-HT1A receptor ligands with reduced alpha 1-adrenergic activity. Synthesis and structure-affinity relationships.
AID265217Binding affinity to D2 receptor by radioligand binding assay2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.
AID113671Effect on hexobarbital induced sleep was determined in hexobarbital potentiation test; Range1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
AID113660Effect on alcohol induced sleep was determined in ethanol potentiation test; Range1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
AID4691Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Synthesis and structure activity relationships of cis- and trans-2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-c]pyridines for 5-HT receptor subtypes.
AID1737998Metabolic stability in human liver microsomes assessed as percentage of compound remaining after 30 mins2020European journal of medicinal chemistry, Jul-01, Volume: 197Synthesis and evaluation of butein derivatives for in vitro and in vivo inflammatory response suppression in lymphedema.
AID3734Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes1994Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12
3,4-Dihydro-3-amino-2H-1-benzopyran derivatives as 5-HT1A receptor ligands and potential anxiolytic agents. 1. Synthesis and structure--activity relationship studies.
AID1675994Bias factor, ratio of biased agonist activity at human 5-HT1A receptor stably expressed in CHO-K1 cells assessed as increase in ERK1/2 phosphorylation levels to biased agonist activity at human 5-HT1A receptor stably expressed in CHO-K1 cells assessed as
AID235586Ratio of ED50 (ethanol) to that of ED50 (fighting)1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
AID1126944Displacement of [3H]-8-OH-DPAT from human recombinant 5-HT1A receptor expressed in HEK293 cell membrane after 1 hr by Microbeta scintillation counting analysis2014European journal of medicinal chemistry, May-06, Volume: 78SAR-studies on the importance of aromatic ring topologies in search for selective 5-HT(7) receptor ligands among phenylpiperazine hydantoin derivatives.
AID1517957Displacement of [3H]-8-OH-DPAT from human 5HT1A receptor expressed in CHO-K1 cell membranes incubated for 60 mins by microbeta scintillation counting analysis
AID1702242Displacement of [3H]-methylspiperone from recombinant human D2 receptor stably expressed in CHO-K1 cell membranes measured after 60 mins by microbeta2 scintillation counting method
AID394123Displacement of [3H]8-OH-DPAT from 5HT1A receptor in rat hippocampal membranes2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Synthesis and serotonin receptor activity of the arylpiperazine alkyl/propoxy derivatives of new azatricycloundecanes.
AID4095Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Arylpiperazine derivatives as high-affinity 5-HT1A serotonin ligands.
AID242983Ratio of dopamine receptor D2 to that of 5-hydroxytryptamine 1A receptor2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
New piperidinyl- and 1,2,3,6-tetrahydropyridinyl-pyrimidine derivatives as selective 5-HT1A receptor agonists with highly potent anti-ischemic effects.
AID55594Binding affinity for DA2 receptor1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
(R)-1,2,3,4-tetrahydro[1]benzothieno[2,3-c]pyridines: novel optically active compounds with strong 5-HT1A receptor binding ability exhibiting anticonflict activity and lessening of memory impairment.
AID3745In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.1999Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3
1-aryl-4-[(5-methoxy-1,2,3, 4-tetrahydronaphthalen-1-yl)alkyl]piperazines and their analogues: influence of the stereochemistry of the tetrahydronaphthalen-1-yl nucleus on 5-HT1A receptor affinity and selectivity versus alpha1 and D2 receptors. 5.
AID1568826Displacement of [3H]-8-OH-DPAT from human 5-HT1A expressed in human HEK293 cells assessed as inhibitory constant incubated for 1 hr by radioligand binding assay2019European journal of medicinal chemistry, Sep-15, Volume: 178Synthesis and computer-aided SAR studies for derivatives of phenoxyalkyl-1,3,5-triazine as the new potent ligands for serotonin receptors 5-HT
AID204624Binding affinity against sigma receptor.1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
New benzocycloalkylpiperazines, potent and selective 5-HT1A receptor ligands.
AID576612Inhibition of human ERG2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
AID4420In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Mixed 5-HT1A/D-2 activity of a new model of arylpiperazines: 1-aryl-4-[3-(1,2-dihydronaphthalen-4-yl)-n-propyl]piperazines. 1. Synthesis and structure-activity relationships.
AID1443991Induction of mitochondrial dysfunction in Sprague-Dawley rat liver mitochondria assessed as inhibition of mitochondrial respiration per mg mitochondrial protein measured for 20 mins by A65N-1 oxygen probe based fluorescence assay2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID373867Hepatic clearance in human hepatocytes in absence of fetal calf serum2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
AID1211295Unbound fraction in plasma (unknown origin) at pH 7.63 after 6 hrs by equilibrium dialysis method in presence of 5% CO22011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID1413422Displacement of [3H]-8-OH-DPAT from human 5-HT1A receptor expressed in HEK293 cell membranes after 1 hr by microbeta counting method
AID1702322Biased agonist activity at human recombinant 5-HT1A receptor stably expressed in CHO-K1 cells assessed as increase in ERK1/2 phosphorylation levels incubated for 15 mins by Alphalisa assay relative to serotonin
AID1442393Anxiolytic-like activity in iv dosed ICR mouse assessed as increase in marbles left uncovered measured after 30 mins by marble burying assay2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
The 2014 Philip S. Portoghese Medicinal Chemistry Lectureship: The "Phenylalkylaminome" with a Focus on Selected Drugs of Abuse.
AID5452The compound was tested for binding affinity against 5-HT2A receptor1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.
AID625277FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID62167Binding affinity against D2 receptor in calf caudate nucleus1994Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12
3,4-Dihydro-3-amino-2H-1-benzopyran derivatives as 5-HT1A receptor ligands and potential anxiolytic agents. 1. Synthesis and structure--activity relationship studies.
AID712522Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by filter binding assay2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.
AID4173Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
Derivatives of (R)- and (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin: synthesis and interactions with 5-HT1A receptors.
AID1403791Agonist activity at 5HT1A receptor (unknown origin)
AID545724Displacement of [3H]DPAT from 5HT1A receptor in Wistar rat hippocampus using 2 x 10' -7 by liquid scintillation counting2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Antiarrhythmic, serotonin antagonist and antianxiety activities of novel substituted thiophene derivatives synthesized from 2-amino-4,5,6,7-tetrahydro-N-phenylbenzo[b]thiophene-3-carboxamide.
AID64425In vitro binding affinity towards the dopamine receptor D2 at 10 e-6 M1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
(S)-N-tert-butyl-3-(4-(2-methoxyphenyl)-piperazin-1-yl)-2-phenylpropanamide [(S)-WAY-100135]: a selective antagonist at presynaptic and postsynaptic 5-HT1A receptors.
AID49574Maximum decrease in sympathetic nerve discharge(SND) observed at 1 mg/kg dose in cat1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Novel 2-substituted tetrahydro-3H-benz[e]indolamines: highly potent and selective agonists acting at the 5-HT1A receptor as possible anxiolytics and antidepressants.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID193153Effect on the 8-OH-DPAT-Induced Behavior(flat body posture) in Reserpine Pretreated Rats at a dose of 2.5 mg/kg1996Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5
8-[4-[2-(1,2,3,4-Tetrahydroisoquinolinyl]butyl-8-azaspiro[4.5]decane-7,9-dione: a new 5-HT1A receptor ligand with the same activity profile as buspirone.
AID4023Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
Derivatives of (R)- and (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin: synthesis and interactions with 5-HT1A receptors.
AID545727Acute toxicity in rat2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Antiarrhythmic, serotonin antagonist and antianxiety activities of novel substituted thiophene derivatives synthesized from 2-amino-4,5,6,7-tetrahydro-N-phenylbenzo[b]thiophene-3-carboxamide.
AID176370Conditioned avoidance response activity was determined by the ability to block the conditioned avoidance of a foot shock (ip)1995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
Piperazinylalkyl heterocycles as potential antipsychotic agents.
AID194961In vivo ability (10.0 mg/kg) was to elicit serotonin syndrome in rat1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Synthesis and structure-activity relationship of substituted tetrahydro- and hexahydro-1,2-benzisothiazol-3-one 1,1-dioxides and thiadiazinones: potential anxiolytic agents.
AID5478Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand1996Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25
Structure-activity relationship studies on the 5-HT(1A) receptor affinity of 1-phenyl-4-[omega-(alpha- or beta-tetralinyl)alkyl]piperazines. 4.
AID36854In vitro binding affinity measured on alpha-1 adrenergic receptor using [3H]prazosin as radioligand.1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
High affinity and selectivity on 5-HT1A receptor of 1-aryl-4-[1-tetralin)alkyl]piperazines. 2.
AID1675981Displacement of [3H]8-OH-DPAT from human 5-HT1A receptor stably expressed in CHO-K1 cell membranes measured after 60 mins by Microbeta2 scintillation counting method
AID1556424Displacement of [3H]-8-OH-DPAT from human 5HT1A receptor expressed in HEK293 cells incubated for 1 hr by liquid scintillation counter method2019European journal of medicinal chemistry, Oct-01, Volume: 1792-Aminoimidazole-based antagonists of the 5-HT
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1220555Fraction unbound in Sprague-Dawley rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID19006Calculated membrane partition coefficient (Kmemb)2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
AID526528Metabolic stability of the compound in ICR mouse liver microsome assessed as compound remaining at 1 uM2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Property based optimization of δ-lactam HDAC inhibitors for metabolic stability.
AID1656651Displacement of [3H]-5-carboxamidotryptamine from human 5-HT1A receptor expressed in HEK293T cell membranes incubated for 90 mins by scintillation counting method2020Bioorganic & medicinal chemistry, 02-01, Volume: 28, Issue:3
Synthesis of novel 5-substituted-2-aminotetralin analogs: 5-HT
AID1211298Dissociation constant, pKa of the compound2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID3589In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay2004Bioorganic & medicinal chemistry letters, Apr-05, Volume: 14, Issue:7
The design and preparation of metabolically protected new arylpiperazine 5-HT1A ligands.
AID1766986Metabolic stability in rat liver microsomes assessed as compound remaining at 10 mM incubated for 30 mins by LC/MS/MS analysis
AID1893568Stability in human liver microsomes assessed as parent compound remaining at 1 uM measured after 30 mins in presence of NADPH regeneration system by LC-MS/MS analysis2022ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7
Novel Thioxothiazolo[3,4-
AID265214Displacement of [3H]8-OH-DPAT from human 5HT1A receptor in HEK293 cells2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.
AID4177Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
Derivatives of (R)- and (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin: synthesis and interactions with 5-HT1A receptors.
AID386623Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID1570076Half life in human liver microsomes at 1 uM measured for 5 to 60 mins under shaking condition in presence of NADPH by LCMS analysis2019European journal of medicinal chemistry, Oct-15, Volume: 180Synthesis of new 5,6,7,8-tetrahydropyrido[1,2-c]pyrimidine derivatives with rigidized tryptamine moiety as potential SSRI and 5-HT
AID64803Inhibition of [3H]spiperone binding to Dopamine receptor D3 in bovine cortex1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
New benzocycloalkylpiperazines, potent and selective 5-HT1A receptor ligands.
AID172061Percent change in DOPA levels in rat brain following 1 mg/kg administration.1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
Dopaminergic and serotonergic activities of imidazoquinolinones and related compounds.
AID712521Displacement of [3H]5-carboxamidotryptamine to human 5HT1A expressed in HEK293 cells by filter binding assay2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.
AID4024Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
trans-4-[4-(Methoxyphenyl)cyclohexyl]-1-arylpiperazines: a new class of potent and selective 5-HT(1A) receptor ligands as conformationally constrained analogues of 4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]-1-arylpiperazines.
AID343003Displacement of [3H]prazosin from adrenergic receptor alpha1 in CRL:CD(SD)BR-COBS rat brain cortex2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Synthesis of new arylpiperazinylalkylthiobenzimidazole, benzothiazole, or benzoxazole derivatives as potent and selective 5-HT1A serotonin receptor ligands.
AID1211294Unbound fraction in plasma (unknown origin) at pH 7.4 after 6 hrs by equilibrium dialysis method in presence of 5% CO22011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID526530Metabolic stability of the compound in ICR mouse liver microsome assessed as compound remaining at 1 uM in presence of buffer2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Property based optimization of δ-lactam HDAC inhibitors for metabolic stability.
AID1707826Stability in human liver microsomes assessed as parent compound remaining level after 30 mins2021Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2
Peripheral Selective Oxadiazolylphenyl Alanine Derivatives as Tryptophan Hydroxylase 1 Inhibitors for Obesity and Fatty Liver Disease.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID681116TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing MDCKII cells2002The Journal of pharmacology and experimental therapeutics, Dec, Volume: 303, Issue:3
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
AID4005Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
(R)-1,2,3,4-tetrahydro[1]benzothieno[2,3-c]pyridines: novel optically active compounds with strong 5-HT1A receptor binding ability exhibiting anticonflict activity and lessening of memory impairment.
AID1281951Displacement of [3H]-8-OH-DPAT from human 5-HT1A receptor expressed in HEK293 cells2016European journal of medicinal chemistry, Apr-13, Volume: 112Rational design in search for 5-phenylhydantoin selective 5-HT7R antagonists. Molecular modeling, synthesis and biological evaluation.
AID225904In vitro binding affinity towards the noradrenergic beta receptor at 10 e-6 M1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
(S)-N-tert-butyl-3-(4-(2-methoxyphenyl)-piperazin-1-yl)-2-phenylpropanamide [(S)-WAY-100135]: a selective antagonist at presynaptic and postsynaptic 5-HT1A receptors.
AID61417Binding affinity against Dopamine receptor D2 in rat striatal membrane using [3H]spiroperidol as radioligand1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
1-aryl-4-[(1-tetralinyl)alkyl]piperazines: alkylamido and alkylamino derivatives. Synthesis, 5-HT1A receptor affinity, and selectivity. 3.
AID1172029Displacement of [3H]-8-OH-DPAT from 5-HT1AR in rat hippocampus2015Bioorganic & medicinal chemistry, Jan-01, Volume: 23, Issue:1
Antidepressant- and anxiolytic-like activity of 7-phenylpiperazinylalkyl-1,3-dimethyl-purine-2,6-dione derivatives with diversified 5-HT₁A receptor functional profile.
AID265220Activity against 5HT1A receptor relative to 5-HT by Gi-[35S]GTP-gamma-S binding assay2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID393955Anxiolytic activity in Wistar rat assessed as total number of entries at 5 mg/kg, ip administered 60 mins before evaluation and measured during 5 mins by elevated plus-maze test2009Bioorganic & medicinal chemistry, Mar-01, Volume: 17, Issue:5
Synthesis and pharmacological evaluation of new arylpiperazines N-[4-[4-(aryl) piperazine-1-yl]-phenyl]-amine derivatives: putative role of 5-HT1A receptors.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID226485Hill coefficient in rat brain 5-hydroxytryptamine 1A assay1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Arylpiperazine derivatives as high-affinity 5-HT1A serotonin ligands.
AID190415Compound was tested for the induction of behavioral syndrome(flat body posture) in rats at a dose of 10 mg/kg1996Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5
8-[4-[2-(1,2,3,4-Tetrahydroisoquinolinyl]butyl-8-azaspiro[4.5]decane-7,9-dione: a new 5-HT1A receptor ligand with the same activity profile as buspirone.
AID1675989Biased agonist activity at human 5-HT1A receptor stably expressed in CHO-K1 cells assessed as inhibition of forskolin-induced cAMP accumulation after 40 mins by LANCE Ultra cAMP kit-based TR-FRET assay
AID1675992Biased agonist activity at human 5-HT1A receptor stably expressed in CHO-K1 cells co-expressing Galpha16/GPCR assessed as increase in calcium mobilization measured for 30 secs in presence of coelenterazine by aequorin-reporter gene based luminescence assa
AID65408Binding affinity towards dopamine receptor D2 using [3H]-raclopride radioligand.1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Synthesis and structure-activity relationships of a new model of arylpiperazines. 1. 2-[[4-(o-methoxyphenyl)piperazin-1-yl]methyl]-1, 3-dioxoperhydroimidazo[1,5-alpha]pyridine: a selective 5-HT1A receptor agonist.
AID392709Agonist activity at human 5HT1A receptor expressed in CHO cells by FLIPR2009Bioorganic & medicinal chemistry letters, Feb-15, Volume: 19, Issue:4
Synthesis and pharmacological evaluation of aminopyrimidine series of 5-HT1A partial agonists.
AID184832Compound was tested for the induction of lower lip retraction in rats at a dose of 2.5 mg/kg1996Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5
8-[4-[2-(1,2,3,4-Tetrahydroisoquinolinyl]butyl-8-azaspiro[4.5]decane-7,9-dione: a new 5-HT1A receptor ligand with the same activity profile as buspirone.
AID1636440Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID177885Inhibition of apomorphine induced stereotypy in nonfasted male Sprague-Dawley rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Buspirone analogues. 1. Structure-activity relationships in a series of N-aryl- and heteroarylpiperazine derivatives.
AID1205637Metabolic stability in mouse liver microsomes assessed as compound remaining at 1 uM after 30 mins byLC-ESI/MS/MS analysis in presence of NADPH2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Discovery of Orally Available Runt-Related Transcription Factor 3 (RUNX3) Modulators for Anticancer Chemotherapy by Epigenetic Activation and Protein Stabilization.
AID1536199Metabolic stability in human liver microsomes assessed as parent compound remaining at 1 uM after 30 mins by LC-MS/MS analysis2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Discovery of Novel Pyruvate Dehydrogenase Kinase 4 Inhibitors for Potential Oral Treatment of Metabolic Diseases.
AID65247Binding affinity was determined against Dopamine receptor D2 using [3H]spiperone1995Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21
Piperazinylalkyl heterocycles as potential antipsychotic agents.
AID188348Antiaggressive anxiolytic activity in the hexagonal maze test in rat; No effect1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
AID169427Concentration required to produce 50% block in avoidance responding in conditioned avoidance response test in rat1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Polycyclic aryl- and heteroarylpiperazinyl imides as 5-HT1A receptor ligands and potential anxiolytic agents: synthesis and structure-activity relationship studies.
AID1520008Displacement of [3H]-8-OH-DPAT from human 5-HT1A receptor expressed in HEK293 cells after 1 hr by microbeta plate reader analysis
AID65434In vitro ability to inhibit [3H]spiperone binding to dopamine receptor D2 of rat limbic structures1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Synthesis and structure-activity relationship of substituted tetrahydro- and hexahydro-1,2-benzisothiazol-3-one 1,1-dioxides and thiadiazinones: potential anxiolytic agents.
AID1675990Biased agonist activity at Gal4-VP16 transcription factor linked human 5-HT1A receptor expressed in human U2OS cells assessed as induction of beta-arrestin2 recruitment measured after 5 hrs by Tango assay relative to serotonin
AID712520Inhibition of SERT-mediated [3H]5HT uptake in rat synaptosomes by scintillation counting2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.
AID1654713Stability in rat liver microsomes assessed as parent compound remaining measured after 30 mins2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design, Synthesis, and Biological Evaluation of New Peripheral 5HT
AID243004Ratio of alpha-1 adrenergic receptor to that of 5-hydroxytryptamine 1A receptor2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
New piperidinyl- and 1,2,3,6-tetrahydropyridinyl-pyrimidine derivatives as selective 5-HT1A receptor agonists with highly potent anti-ischemic effects.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1222786Oral bioavailability in patient with renal impairment at 20 mg, po2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Which metabolites circulate?
AID473744Half life in human liver microsomes by LC/MS/MS analysis2010Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7
Synthesis and evaluation of tricyclic derivatives containing a non-aromatic amide as inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1).
AID4332Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Buspirone analogues as ligands of the 5-HT1A receptor. 1. The molecular structure of buspirone and its two analogues.
AID1595143Displacement of [3H]-8-OH-DPAT from human recombinant 5-HT1A receptor expressed in HEK293 cells after 1 hr by microbeta scintillation counting method
AID5556Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Synthesis and structure-activity relationships of a new model of arylpiperazines. 1. 2-[[4-(o-methoxyphenyl)piperazin-1-yl]methyl]-1, 3-dioxoperhydroimidazo[1,5-alpha]pyridine: a selective 5-HT1A receptor agonist.
AID392707Displacement of [3H]8-OH-DPAT from human 5HT1A receptor2009Bioorganic & medicinal chemistry letters, Feb-15, Volume: 19, Issue:4
Synthesis and pharmacological evaluation of aminopyrimidine series of 5-HT1A partial agonists.
AID203852The compound was tested for affinity towards sigma-3 receptor1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
Conformational analysis, pharmacophore identification, and comparative molecular field analysis of ligands for the neuromodulatory sigma 3 receptor.
AID35897Binding affinity against alpha-2 adrenergic receptor in calf frontal cortex1994Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12
3,4-Dihydro-3-amino-2H-1-benzopyran derivatives as 5-HT1A receptor ligands and potential anxiolytic agents. 1. Synthesis and structure--activity relationship studies.
AID1675999Bias factor, ratio of biased agonist activity at Gal4-VP16 transcription factor linked human 5-HT1A receptor expressed in human U2OS cells assessed as induction of beta-arrestin2 recruitment to biased agonist activity at human 5-HT1A receptor stably expre
AID1434364Stability in mouse liver microsomes assessed as parent compound remaining at 1 mM in presence of NADPH preincubated for 5 mins followed by NADPH addition measured after 30 mins by LC-ESI-MS/MS method2017European journal of medicinal chemistry, Jan-27, Volume: 126Improving potency and metabolic stability by introducing an alkenyl linker to pyridine-based histone deacetylase inhibitors for orally available RUNX3 modulators.
AID1737997Metabolic stability in rat liver microsomes assessed as percentage of compound remaining after 30 mins2020European journal of medicinal chemistry, Jul-01, Volume: 197Synthesis and evaluation of butein derivatives for in vitro and in vivo inflammatory response suppression in lymphedema.
AID1454763Displacement of [3H]methylspiperone from human D2 receptor expressed in HEK cells2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry.
AID35265Binding affinity towards alpha-1 adrenergic receptor using [3H]prazosin radioligand.1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Synthesis and structure-activity relationships of a new model of arylpiperazines. 1. 2-[[4-(o-methoxyphenyl)piperazin-1-yl]methyl]-1, 3-dioxoperhydroimidazo[1,5-alpha]pyridine: a selective 5-HT1A receptor agonist.
AID172182Percent change in 5-HT levels in rat brain following 1 mg/kg administration.1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
Dopaminergic and serotonergic activities of imidazoquinolinones and related compounds.
AID4869The compound was tested for binding affinity against 5-HT1D receptor1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.
AID468443Inhibition of human FAAH at 1 uM2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors.
AID1702243Displacement of [3H]8-OH-DPAT from recombinant human 5HT1A receptor stably expressed in CHO-K1 cell membranes measured after 60 mins by microbeta2 scintillation counting method
AID1702244Displacement of [3H]-prazosin from alpha1 adrenergic receptor in rat cortex measured after 30 mins by microbeta2 scintillation counting method
AID1430531Displacement of [3H]-8-OH-DPAT from 5HT1A receptor (unknown origin)
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1211297Drug recovery in plasma (unknown origin)2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID3472Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
New benzocycloalkylpiperazines, potent and selective 5-HT1A receptor ligands.
AID193145Compound was tested for the induction of behavioral syndrome(flat body posture) in rats at a dose of 5 mg/kg1996Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5
8-[4-[2-(1,2,3,4-Tetrahydroisoquinolinyl]butyl-8-azaspiro[4.5]decane-7,9-dione: a new 5-HT1A receptor ligand with the same activity profile as buspirone.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID55589Dose to reduce neuronal firing against DA cells (antagonist) in rats (iv)1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Novel 2-substituted tetrahydro-3H-benz[e]indolamines: highly potent and selective agonists acting at the 5-HT1A receptor as possible anxiolytics and antidepressants.
AID4669Binding affinity towards 5-HT1B was determined1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Central serotonin receptors as targets for drug research.
AID3759In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
(S)-N-tert-butyl-3-(4-(2-methoxyphenyl)-piperazin-1-yl)-2-phenylpropanamide [(S)-WAY-100135]: a selective antagonist at presynaptic and postsynaptic 5-HT1A receptors.
AID1209455Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID395324Lipophilicity, log D at pH 7.4 by liquid chromatography2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID204612Inhibition of [3H]DTG binding to sigma receptor in rat hippocampus1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
New benzocycloalkylpiperazines, potent and selective 5-HT1A receptor ligands.
AID1365307Anxiolytic-like activity in Swiss albino mouse assessed as increase in time spent in open arms at 5 mg/kg measured for 5 mins test period by elevated plus maze test2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
New 5-HT
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID5137Binding affinity against 5-hydroxytryptamine 2 receptor1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
New benzocycloalkylpiperazines, potent and selective 5-HT1A receptor ligands.
AID343004Ratio of Ki for 5HT1A receptor to Ki for adrenergic receptor alpha1 in CRL:CD(SD)BR-COBS rat brain2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Synthesis of new arylpiperazinylalkylthiobenzimidazole, benzothiazole, or benzoxazole derivatives as potent and selective 5-HT1A serotonin receptor ligands.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID395328Lipophilicity, log P of the compound2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID36858In vitro binding affinity towards the noradrenergic alpha-1 receptor at 10 e-6 M1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
(S)-N-tert-butyl-3-(4-(2-methoxyphenyl)-piperazin-1-yl)-2-phenylpropanamide [(S)-WAY-100135]: a selective antagonist at presynaptic and postsynaptic 5-HT1A receptors.
AID5307The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Pyrrole mannich bases as potential antipsychotic agents.
AID114465Ataxic activity in mice by rotarod test; Range (64.3-92.1)1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
AID176133Decrease in hippocampal level of 5-HT at preinjection of 1 mg/kg, sc1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
(S)-N-tert-butyl-3-(4-(2-methoxyphenyl)-piperazin-1-yl)-2-phenylpropanamide [(S)-WAY-100135]: a selective antagonist at presynaptic and postsynaptic 5-HT1A receptors.
AID36782Binding affinity against Alpha-2 adrenergic receptor in rat brain membrane using [3H]yohimbine as radioligand1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
1-aryl-4-[(1-tetralinyl)alkyl]piperazines: alkylamido and alkylamino derivatives. Synthesis, 5-HT1A receptor affinity, and selectivity. 3.
AID1740897Displacement of [3H]8-OH-DPAT from human 5HT1A receptor expressed in HEK293 cells measured after 1 hr by microbeta counting method
AID4331Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Synthesis and SAR of adatanserin: novel adamantyl aryl- and heteroarylpiperazines with dual serotonin 5-HT(1A) and 5-HT(2) activity as potential anxiolytic and antidepressant agents.
AID3751In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Mixed 5-HT1A/D-2 activity of a new model of arylpiperazines: 1-aryl-4-[3-(1,2-dihydronaphthalen-4-yl)-n-propyl]piperazines. 1. Synthesis and structure-activity relationships.
AID242367Inhibitory concentration against 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]-8-OH-DPAT as radioligand2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
New piperidinyl- and 1,2,3,6-tetrahydropyridinyl-pyrimidine derivatives as selective 5-HT1A receptor agonists with highly potent anti-ischemic effects.
AID63044Binding affinity towards dopamine receptor D1 in calf striatum1994Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12
3,4-Dihydro-3-amino-2H-1-benzopyran derivatives as 5-HT1A receptor ligands and potential anxiolytic agents. 1. Synthesis and structure--activity relationship studies.
AID3757In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
High affinity and selectivity on 5-HT1A receptor of 1-aryl-4-[1-tetralin)alkyl]piperazines. 2.
AID205269Inhibition of binding of Batrachotoxinin [3H]BTX-B to high-affinity sites on voltage-dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 100 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID265287Toxicity in po dosed Sprague-Dawley rat2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.
AID265215Displacement of [3H]prazosin from adrenergic alpha-1 receptor in rat cerebral cortex cells2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID3726Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
1-aryl-4-[(1-tetralinyl)alkyl]piperazines: alkylamido and alkylamino derivatives. Synthesis, 5-HT1A receptor affinity, and selectivity. 3.
AID1353521Displacement of [3H]-8-OH-DPAT from human 5HT1AR expressed in HEK293 cell membranes after 1 hr by Microbeta scintillation counting method2018European journal of medicinal chemistry, Mar-10, Volume: 147Computer-aided insights into receptor-ligand interaction for novel 5-arylhydantoin derivatives as serotonin 5-HT
AID662442Metabolic stability in mouse liver microsomes assessed as compound remaining at 1 uM after 30 mins in the absence of NADPH2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors: part II.
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID113276Antiaggressive anxiolytic activity in the electroshock-induced fighting test in mice (po); Range (10.32-18.72)1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Chemistry and pharmacology of the non-benzodiazepine anxiolytic enciprazine and related compounds.
AID4322In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Polycyclic aryl- and heteroarylpiperazinyl imides as 5-HT1A receptor ligands and potential anxiolytic agents: synthesis and structure-activity relationship studies.
AID63410Displacement of [3H]U-86170 from human D2-dopamine receptor expressed in CHO K1 cells1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Novel 2-substituted tetrahydro-3H-benz[e]indolamines: highly potent and selective agonists acting at the 5-HT1A receptor as possible anxiolytics and antidepressants.
AID1220556Fraction unbound in CD-1 mouse brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID393949Anxiolytic activity in Wistar rat assessed as number of entries into open arms at 5 mg/kg, ip administered 60 mins before evaluation and measured during 5 mins by elevated plus-maze test2009Bioorganic & medicinal chemistry, Mar-01, Volume: 17, Issue:5
Synthesis and pharmacological evaluation of new arylpiperazines N-[4-[4-(aryl) piperazine-1-yl]-phenyl]-amine derivatives: putative role of 5-HT1A receptors.
AID36711Binding affinity against Alpha-1 adrenergic receptor in rat brain membrane using [3H]prazosin as radioligand1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
1-aryl-4-[(1-tetralinyl)alkyl]piperazines: alkylamido and alkylamino derivatives. Synthesis, 5-HT1A receptor affinity, and selectivity. 3.
AID124449Maximum obtainable hypothermic effect up to 30 mg/kg dose in mice expressed as temperature decrease in degree Centigrade1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Novel 2-substituted tetrahydro-3H-benz[e]indolamines: highly potent and selective agonists acting at the 5-HT1A receptor as possible anxiolytics and antidepressants.
AID392708Metabolic stability in human liver microsomes assessed as intrinsic clearance2009Bioorganic & medicinal chemistry letters, Feb-15, Volume: 19, Issue:4
Synthesis and pharmacological evaluation of aminopyrimidine series of 5-HT1A partial agonists.
AID1707825Stability in rat liver microsomes assessed as parent compound remaining level after 30 mins2021Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2
Peripheral Selective Oxadiazolylphenyl Alanine Derivatives as Tryptophan Hydroxylase 1 Inhibitors for Obesity and Fatty Liver Disease.
AID265288Toxicity in po dosed Beagle dog2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.
AID35714Percent inhibition of Alpha-1 adrenergic receptor by 1 uM of compound1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Synthesis and structure-activity relationship of substituted tetrahydro- and hexahydro-1,2-benzisothiazol-3-one 1,1-dioxides and thiadiazinones: potential anxiolytic agents.
AID1702326Biased agonist activity at Gal4-VP16 transcription factor linked human 5-HT1A receptor expressed in human U2OS cells assessed as stimulation of beta-arrestin recruitment measured after 5 hrs by Tango assay relative to serotonin
AID1220557Fraction unbound in Hartley guinea pig brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID4062Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Synthesis and structure-activity relationships of a new model of arylpiperazines. 1. 2-[[4-(o-methoxyphenyl)piperazin-1-yl]methyl]-1, 3-dioxoperhydroimidazo[1,5-alpha]pyridine: a selective 5-HT1A receptor agonist.
AID4823In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
(S)-N-tert-butyl-3-(4-(2-methoxyphenyl)-piperazin-1-yl)-2-phenylpropanamide [(S)-WAY-100135]: a selective antagonist at presynaptic and postsynaptic 5-HT1A receptors.
AID1675982Displacement of [3H]prazosin from alpha1 adrenergic receptor in rat cortex membranes measured after 30 mins by Microbeta2 scintillation counting method
AID679774TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: ? uM, Buspirone: 100 uM) in MDR1-expressing MDCKII cells2002The Journal of pharmacology and experimental therapeutics, Dec, Volume: 303, Issue:3
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
AID65879Inhibitory activity against rat limbic tissue Dopamine receptor D21999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Synthesis and SAR of adatanserin: novel adamantyl aryl- and heteroarylpiperazines with dual serotonin 5-HT(1A) and 5-HT(2) activity as potential anxiolytic and antidepressant agents.
AID64297In vitro binding affinity measured on dopamine receptor D2 using [3H]spiroperidol as radioligand.1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
High affinity and selectivity on 5-HT1A receptor of 1-aryl-4-[1-tetralin)alkyl]piperazines. 2.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID267572Affinity for 5HT1A receptor2006Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13
Arylpiperazines with N-acylated amino acids as 5-HT1A receptor ligands.
AID184542In vivo motor activity determined in rat at 0.1 mg/kg of ip administration2003Bioorganic & medicinal chemistry letters, Jan-20, Volume: 13, Issue:2
Development of a presynaptic 5-HT1A antagonist.
AID4175Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
Derivatives of (R)- and (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin: synthesis and interactions with 5-HT1A receptors.
AID1706015Metabolic stability in mouse liver microsomes assessed as compound remaining at 1 uM after 30 mins in presence of NADPH-regenerating system2020European journal of medicinal chemistry, Dec-15, Volume: 208Design and characterization of cereblon-mediated androgen receptor proteolysis-targeting chimeras.
AID225902In vitro binding affinity towards the noradrenergic alpha-2 receptor at 10 e-6 M1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
(S)-N-tert-butyl-3-(4-(2-methoxyphenyl)-piperazin-1-yl)-2-phenylpropanamide [(S)-WAY-100135]: a selective antagonist at presynaptic and postsynaptic 5-HT1A receptors.
AID63197Inhibition of [3H]SCH-23390 binding to Dopamine receptor D1 of bovine striatum1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
New benzocycloalkylpiperazines, potent and selective 5-HT1A receptor ligands.
AID265252Oral bioavailability in Beagle dog at 3 mg/kg, po and 1 mg/kg, iv2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID5065Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
1-aryl-4-[(1-tetralinyl)alkyl]piperazines: alkylamido and alkylamino derivatives. Synthesis, 5-HT1A receptor affinity, and selectivity. 3.
AID3802Binding affinity against human 5-hydroxytryptamine 1A receptor1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
New benzocycloalkylpiperazines, potent and selective 5-HT1A receptor ligands.
AID1654714Stability in human liver microsomes assessed as parent compound remaining measured after 30 mins2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design, Synthesis, and Biological Evaluation of New Peripheral 5HT
AID4389Ratio of binding affinity to 5-HT 1A and D2 receptor2001Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4
New 5-HT1A receptor agonists possessing 1,4-benzoxazepine scaffold exhibit highly potent anti-ischemic effects.
AID242119Inhibitory concentration against Dopamine receptor D2 in rat striatum membrane using [3H]raclopride as radioligand2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
New piperidinyl- and 1,2,3,6-tetrahydropyridinyl-pyrimidine derivatives as selective 5-HT1A receptor agonists with highly potent anti-ischemic effects.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID4411Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement1996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
Binding of arylpiperazines, (aryloxy)propanolamines, and tetrahydropyridylindoles to the 5-HT1A receptor: contribution of the molecular lipophilicity potential to three-dimensional quantitative structure-affinity relationship models.
AID1222792Clearance in iv dosed patient with renal impairment2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Which metabolites circulate?
AID36710Binding affinity towards rat Alpha-1 adrenergic receptor was evaluated using [3H]- prazosin as radioligand1996Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25
Structure-activity relationship studies on the 5-HT(1A) receptor affinity of 1-phenyl-4-[omega-(alpha- or beta-tetralinyl)alkyl]piperazines. 4.
AID1512149Displacement of [3H]methylspiperone from human D2 receptor expressed in HEK-GIRK-M4 cell membrane by radioligand binding assay2019Bioorganic & medicinal chemistry letters, 11-01, Volume: 29, Issue:21
Design, synthesis and biological evaluation of novel serotonin and dopamine receptor ligands being 6-bromohexyl saccharine derivatives.
AID184966Compound was tested for the induction of lower lip retraction in rats at a dose of 5 mg/kg1996Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5
8-[4-[2-(1,2,3,4-Tetrahydroisoquinolinyl]butyl-8-azaspiro[4.5]decane-7,9-dione: a new 5-HT1A receptor ligand with the same activity profile as buspirone.
AID705591Lipophilicity, log D of the compound2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.
AID539464Solubility of the compound in 0.1 M phosphate buffer at 600 uM at pH 7.4 after 24 hrs by LC/MS/MS analysis2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
AID1702330Bias factor, ratio of biased agonist activity at human recombinant 5-HT1A receptor stably expressed in CHO-K1 cells assessed as increase in ERK1/2 phosphorylation levels to biased agonist activity at Gal4-VP16 transcription factor linked human 5-HT1A rece
AID61418Binding affinity to Dopamine receptor D2 in of rat striatum membrane with [3H]- raclopride as radioligand2001Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4
New 5-HT1A receptor agonists possessing 1,4-benzoxazepine scaffold exhibit highly potent anti-ischemic effects.
AID113319Dose required to obtain hypothermic effect in mice following subcutaneous administration1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Novel 2-substituted tetrahydro-3H-benz[e]indolamines: highly potent and selective agonists acting at the 5-HT1A receptor as possible anxiolytics and antidepressants.
AID265251Half life in Beagle dog at 3 mg/kg, po2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.
AID298031Lipophilicity, log D at pH7.42007Journal of medicinal chemistry, Sep-20, Volume: 50, Issue:19
High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1459790Metabolic stability in human liver microsomes assessed as compound remaining at 1 uM preincubated for 5 mins followed by NADPH addition measured after 30 mins by LC-ESI/MS/MS analysis relative to control2017European journal of medicinal chemistry, Jan-05, Volume: 125Design, synthesis, and biological evaluation of structurally modified isoindolinone and quinazolinone derivatives as hedgehog pathway inhibitors.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID35964Displacement of [3H]-prazosin from Alpha-1 adrenergic receptor of bovine frontal cortex1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
New benzocycloalkylpiperazines, potent and selective 5-HT1A receptor ligands.
AID1384982Metabolic stability in rat liver microsomes assessed as parent compound remaining at 1 uM after 30 mins in presence of NADPH by LC/MS/MS analysis2018ACS medicinal chemistry letters, Jul-12, Volume: 9, Issue:7
3-Aryl-1,2,4-oxadiazole Derivatives Active Against Human Rhinovirus.
AID8189CYP3A4 metabolism half-life (t1/2)2004Bioorganic & medicinal chemistry letters, Apr-05, Volume: 14, Issue:7
The design and preparation of metabolically protected new arylpiperazine 5-HT1A ligands.
AID265219Elimination half life in human2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.
AID265221Activity against 5HT1A receptor by Gi-[35S]GTP-gamma-S binding assay2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.
AID5075Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Graphics computer-aided receptor mapping as a predictive tool for drug design: development of potent, selective, and stereospecific ligands for the 5-HT1A receptor.
AID1823848Anti-conflict activity in ip dosed Wistar rat assessed as number of shocks measured during 5 mins experimental period by measuring minimum effective dose by Vogel conflict drinking test
AID36282Antagonistic activity at Alpha-1 adrenergic receptor was performed on ring segments of rabbit thoracic aorta contracted by noradrenaline.1995Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8
New (2-methoxyphenyl)piperazine derivatives as 5-HT1A receptor ligands with reduced alpha 1-adrenergic activity. Synthesis and structure-affinity relationships.
AID1459791Metabolic stability in human liver microsomes assessed as compound remaining at 1 uM in absence of NADPH incubated for 5 mins by LC-ESI/MS/MS analysis relative to control2017European journal of medicinal chemistry, Jan-05, Volume: 125Design, synthesis, and biological evaluation of structurally modified isoindolinone and quinazolinone derivatives as hedgehog pathway inhibitors.
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID62868Inhibition of [3H]spiperone binding to dopamine receptor from rat corpus striatal membranes1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Buspirone analogues. 1. Structure-activity relationships in a series of N-aryl- and heteroarylpiperazine derivatives.
AID184967Compound was tested for the induction of lower lip retraction in rats at a dose of 5 mg/kg; not tested1996Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5
8-[4-[2-(1,2,3,4-Tetrahydroisoquinolinyl]butyl-8-azaspiro[4.5]decane-7,9-dione: a new 5-HT1A receptor ligand with the same activity profile as buspirone.
AID180162Antipsychotic activity at a dose 10 times the ED50 value for CAR block for production of catalepsy in the rat (following i.p. dosing)1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Pyrrole mannich bases as potential antipsychotic agents.
AID40083Percent inhibition of GABA-A benzodiazepine receptor at 1 uM1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Synthesis and structure-activity relationship of substituted tetrahydro- and hexahydro-1,2-benzisothiazol-3-one 1,1-dioxides and thiadiazinones: potential anxiolytic agents.
AID61416Binding affinity towards rat Dopamine receptor D2 was evaluated using [3H]- spiroperidol as radioligand1996Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25
Structure-activity relationship studies on the 5-HT(1A) receptor affinity of 1-phenyl-4-[omega-(alpha- or beta-tetralinyl)alkyl]piperazines. 4.
AID1215121Fraction unbound in Wistar rat brain homogenate at 5 uM after 5 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
AID194834In vivo ability (10.0 mg/kg) was to antagonize serotonin syndrome in rat1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Synthesis and structure-activity relationship of substituted tetrahydro- and hexahydro-1,2-benzisothiazol-3-one 1,1-dioxides and thiadiazinones: potential anxiolytic agents.
AID1220560Fraction unbound in human occipital cortex at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID62170Displacement of [3H]SDZ-205-501 from Dopamine receptor D2 in calf caudate nucleus.1996Journal of medicinal chemistry, Oct-11, Volume: 39, Issue:21
3-amino-3,4-dihydro-2H-1-benzopyran derivatives as 5-HT1A receptor ligands and potential anxiolytic agents. 2. Synthesis and quantitative structure-activity relationship studies of spiro[pyrrolidine- and piperidine-2,3'(2'H)-benzopyrans].
AID4000Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Synthesis and structure activity relationships of cis- and trans-2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-c]pyridines for 5-HT receptor subtypes.
AID1209457Unbound Cmax in human plasma2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1702324Biased agonist activity at human recombinant 5-HT1A receptor stably expressed in CHO-K1 cells assessed as inhibition of forskolin-induced cAMP accumulation after 40 mins by LANCE Ultra cAMP kit-based TR-FRET assay relative to serotonin
AID4362Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Pyrrole mannich bases as potential antipsychotic agents.
AID1384983Metabolic stability in human liver microsomes assessed as parent compound remaining at 1 uM after 30 mins in presence of NADPH by LC/MS/MS analysis2018ACS medicinal chemistry letters, Jul-12, Volume: 9, Issue:7
3-Aryl-1,2,4-oxadiazole Derivatives Active Against Human Rhinovirus.
AID392710Intrinsic activity at human 5HT1A receptor expressed in CHO cells by FLIPR relative to control2009Bioorganic & medicinal chemistry letters, Feb-15, Volume: 19, Issue:4
Synthesis and pharmacological evaluation of aminopyrimidine series of 5-HT1A partial agonists.
AID190414Compound was tested for the induction of behavioral syndrome(flat body posture) in rats at a dose of 1.25 mg/kg; not tested1996Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5
8-[4-[2-(1,2,3,4-Tetrahydroisoquinolinyl]butyl-8-azaspiro[4.5]decane-7,9-dione: a new 5-HT1A receptor ligand with the same activity profile as buspirone.
AID1211293Unbound fraction in plasma (unknown origin) under normal atmospheric condition at pH 7.22 after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID343002Displacement of [3H]8-OH-DPAT from 5HT1A receptor in CRL:CD(SD)BR-COBS rat hippocampus2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Synthesis of new arylpiperazinylalkylthiobenzimidazole, benzothiazole, or benzoxazole derivatives as potent and selective 5-HT1A serotonin receptor ligands.
AID1675983Displacement of [3H]methylspiperone from human D2 receptor stably expressed in CHO-K1 cell membranes measured after 60 mins by Microbeta2 scintillation counting method
AID265222Half life in Sprague-Dawley rat at 3 mg/kg, po2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.
AID3470Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
New benzocycloalkylpiperazines, potent and selective 5-HT1A receptor ligands.
AID416912Displacement of [3H]8-OH-DPAT from 5HT1A receptor in rat hippocampal membrane2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
The influence of an ethylene spacer on the 5-HT(1A) and 5-HT(2A) receptor affinity of arylpiperazine derivatives of amides with N-acylated amino acids and 3-differently substituted pyrrolidine-2,5-diones.
AID526529Metabolic stability of the compound in ICR mouse liver microsome assessed as compound remaining at 1 uM in presence of NADPH2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Property based optimization of δ-lactam HDAC inhibitors for metabolic stability.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1675997Bias factor, ratio of biased agonist activity at human 5-HT1A receptor stably expressed in CHO-K1 cells assessed as inhibition of forskolin-induced cAMP accumulation to biased agonist activity at Gal4-VP16 transcription factor linked human 5-HT1A receptor
AID393952Anxiolytic activity in Wistar rat assessed as number of entries into closed arms at 5 mg/kg, ip administered 60 mins before evaluation and measured during 5 mins by elevated plus-maze test2009Bioorganic & medicinal chemistry, Mar-01, Volume: 17, Issue:5
Synthesis and pharmacological evaluation of new arylpiperazines N-[4-[4-(aryl) piperazine-1-yl]-phenyl]-amine derivatives: putative role of 5-HT1A receptors.
AID36781Binding affinity towards rat Alpha-2 adrenergic receptor was evaluated using [3H]- yohimbine as radioligand1996Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25
Structure-activity relationship studies on the 5-HT(1A) receptor affinity of 1-phenyl-4-[omega-(alpha- or beta-tetralinyl)alkyl]piperazines. 4.
AID721751Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID1220558Fraction unbound in Beagle dog brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID1823851Sedative activity in ip dosed Wistar rat assessed as effect on spontaneous locomotor activity measured for 10 mins by social interaction test
AID265250Cmax in Sprague-Dawley rat at 3 mg/kg, po2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.
AID1890359Displacement of [3H]-8-OH-DAPT from human 5-HT1A receptor expressed in CHO-K1 cells membrane by scintillation counter analysis2022European journal of medicinal chemistry, Apr-05, Volume: 233Design, synthesis, and behavioral evaluation of dual-acting compounds as phosphodiesterase type 10A (PDE10A) inhibitors and serotonin ligands targeting neuropsychiatric symptoms in dementia.
AID3729Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand2001Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4
New 5-HT1A receptor agonists possessing 1,4-benzoxazepine scaffold exhibit highly potent anti-ischemic effects.
AID394122Displacement of [3H]ketanserin from 5HT2A receptor2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Synthesis and serotonin receptor activity of the arylpiperazine alkyl/propoxy derivatives of new azatricycloundecanes.
AID169282Antipsychotic activity was evaluated from the ability to block discrete trial conditioned avoidance response (CAR) of rats1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Synthesis and structure-activity relationship of substituted tetrahydro- and hexahydro-1,2-benzisothiazol-3-one 1,1-dioxides and thiadiazinones: potential anxiolytic agents.
AID4713Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Graphics computer-aided receptor mapping as a predictive tool for drug design: development of potent, selective, and stereospecific ligands for the 5-HT1A receptor.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID35435The compound was tested for its binding affinity towards Alpha-1 adrenergic receptor by displacing [3H]WB-4101 radioligand in rat cerebral cortex1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Pyrrole mannich bases as potential antipsychotic agents.
AID1675995Bias factor, ratio of biased agonist activity at human 5-HT1A receptor stably expressed in CHO-K1 cells assessed as increase in ERK1/2 phosphorylation levels to biased agonist activity at Gal4-VP16 transcription factor linked human 5-HT1A receptor express
AID1702332Bias factor, ratio of biased agonist activity at human recombinant 5-HT1A receptor stably expressed in CHO-K1 cells assessed as inhibition of forskolin-induced cAMP accumulation to biased agonist activity at Gal4-VP16 transcription factor linked human 5-H
AID721754Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID569584Displacement of [3H]-8-OH-DPAT from 5-HT1A receptor in rat hippocampal membranes by liquid scintillation counting2011Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3
Pharmacophore models based studies on the affinity and selectivity toward 5-HT1A with reference to α1-adrenergic receptors among arylpiperazine derivatives of phenytoin.
AID1215122Percentage unbound in solid supported porcine brain membrane vesicles at 5 uM by TRANSIL assay2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
AID1702327Biased agonist activity at Gal4-VP16 transcription factor linked human 5-HT1A receptor expressed in human U2OS cells assessed as stimulation of beta-arrestin recruitment measured after 5 hrs by Tango assay
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID662441Metabolic stability in mouse liver microsomes assessed as compound remaining at 1 uM after 30 mins in the presence of NADPH2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors: part II.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1801081Radioligand Binding Assays from Article 10.1111/cbdd.12394: \\Synthesis and evaluation of antidepressant-like activity of some 4-substituted 1-(2-methoxyphenyl)piperazine derivatives.\\2015Chemical biology & drug design, Mar, Volume: 85, Issue:3
Synthesis and evaluation of antidepressant-like activity of some 4-substituted 1-(2-methoxyphenyl)piperazine derivatives.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID624210Agonists at Human 5-Hydroxytryptamine receptor 5-HT1A1998Naunyn-Schmiedeberg's archives of pharmacology, Mar, Volume: 357, Issue:3
Labelling of recombinant human and native rat serotonin 5-HT1A receptors by a novel, selective radioligand, [3H]-S 15535: definition of its binding profile using agonists, antagonists and inverse agonists.
AID1345615Human 5-HT1A receptor (5-Hydroxytryptamine receptors)1998European journal of pharmacology, Aug-21, Volume: 355, Issue:2-3
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.
AID1345615Human 5-HT1A receptor (5-Hydroxytryptamine receptors)1998Naunyn-Schmiedeberg's archives of pharmacology, Mar, Volume: 357, Issue:3
Labelling of recombinant human and native rat serotonin 5-HT1A receptors by a novel, selective radioligand, [3H]-S 15535: definition of its binding profile using agonists, antagonists and inverse agonists.
AID624210Agonists at Human 5-Hydroxytryptamine receptor 5-HT1A1998European journal of pharmacology, Aug-21, Volume: 355, Issue:2-3
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.
AID1345215Mouse 5-HT7 receptor (5-Hydroxytryptamine receptors)1993Molecular pharmacology, Aug, Volume: 44, Issue:2
Molecular cloning of a mammalian serotonin receptor that activates adenylate cyclase.
AID624210Agonists at Human 5-Hydroxytryptamine receptor 5-HT1A1992The Biochemical journal, Aug-01, Volume: 285 ( Pt 3)High-level stable expression of recombinant 5-HT1A 5-hydroxytryptamine receptors in Chinese hamster ovary cells.
AID1345235Rat 5-HT7 receptor (5-Hydroxytryptamine receptors)1993Proceedings of the National Academy of Sciences of the United States of America, Sep-15, Volume: 90, Issue:18
Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation.
AID1345615Human 5-HT1A receptor (5-Hydroxytryptamine receptors)1992The Biochemical journal, Aug-01, Volume: 285 ( Pt 3)High-level stable expression of recombinant 5-HT1A 5-hydroxytryptamine receptors in Chinese hamster ovary cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,980)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990339 (17.12)18.7374
1990's789 (39.85)18.2507
2000's421 (21.26)29.6817
2010's355 (17.93)24.3611
2020's76 (3.84)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 125.36

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index125.36 (24.57)
Research Supply Index7.80 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index236.42 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (125.36)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials351 (16.75%)5.53%
Reviews213 (10.16%)6.00%
Case Studies182 (8.68%)4.05%
Observational1 (0.05%)0.25%
Other1,349 (64.36%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (60)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Buspirone in Reducing Shortness of Breath in Patients With Cancer [NCT00053846]Phase 2/Phase 3432 participants (Actual)Interventional2002-11-30Completed
A Randomized, Placebo-controlled, Double-masked Clinical Trial of Buspirone in the Treatment of 2- 6 Year Old Children With Autistic Disorder [NCT00873509]Phase 2/Phase 3166 participants (Actual)Interventional2009-05-31Completed
Transformation of Paraplegic Paralysis to Overground Stepping in Humans [NCT04105114]Early Phase 115 participants (Anticipated)Interventional2019-09-30Recruiting
Evaluating a Mechanistically-Supported Pharmacotherapy to Treat Opioid Withdrawal [NCT05511909]Phase 2100 participants (Anticipated)Interventional2022-12-15Recruiting
Hybrid Functional Electrical Stimulation Exercise to Prevent Cardiopulmonary Declines in High-level Spinal Cord Injury [NCT04458324]Phase 270 participants (Anticipated)Interventional2020-12-22Recruiting
A Pilot Study of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders [NCT03432065]Phase 215 participants (Anticipated)Interventional2023-12-31Not yet recruiting
"Study of Abdominal Massage Therapy for Generalized Anxiety Disorder Based on the Essence Fosters Spirit Theory" [NCT02186366]140 participants (Anticipated)Interventional2014-09-30Recruiting
The Effect of Oral Buspirone Hydrochloride on Esophageal Motility, Bolus Transit and Symptoms of Dysphagia, in Patients With Poor Esophageal Motility: A Randomized, Double-blind, Placebo Controlled, Cross-over Trial With HRiM [NCT05629325]Phase 425 participants (Anticipated)Interventional2021-07-06Recruiting
Improving Driving in Young People With Autism Spectrum Disorders [NCT03538431]Phase 426 participants (Actual)Interventional2018-10-31Completed
Buspirone Plus Omeprazole for Functional Dyspepsia: A Randomised Placebo Clinical Trial [NCT03444831]Phase 470 participants (Actual)Interventional2016-03-01Completed
Buspirone as an Adjunctive Medication for Opioid Tapering [NCT03521960]Phase 118 participants (Actual)Interventional2018-05-30Completed
A Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Investigate the Safety and Efficacy of Lybridos in the Domestic Setting in Healthy Female Subjects With Hypoactive Sexual Desire Disorder and Maladaptive Activity of Sexual Inhibitory M [NCT02101203]Phase 280 participants (Actual)Interventional2013-07-31Completed
Buspirone for the Treatment of Anxiety in Williams Syndrome [NCT04807517]Phase 420 participants (Actual)Interventional2021-08-01Completed
A Relative Bioavailability Study of 30 mg Buspirone Hydrochloride Tablets Under Non-Fasting Conditions [NCT00840398]Phase 124 participants (Actual)Interventional2001-12-31Completed
Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia [NCT02589340]Phase 16 participants (Actual)Interventional2016-01-31Terminated(stopped due to Low enrollment)
Enabling Forelimb Function With Agonist Drug and Epidural Stimulation in SCI [NCT02313194]Phase 1/Phase 212 participants (Anticipated)Interventional2013-07-31Active, not recruiting
Central Sleep Apnea: Physiologic Mechanisms to Inform Treatment [NCT04118387]Phase 4200 participants (Anticipated)Interventional2021-01-07Recruiting
Buspirone for Early Satiety and Symptoms of Gastroparesis: A Multicenter, Randomized, Placebo-Controlled, Double-Masked Trial (BESST) [NCT03587142]Phase 296 participants (Actual)Interventional2019-08-27Completed
Buspirone Treatment of Iatrogenic Dyskinesias in Advanced Parkinson' Disease. Multicenter, International, Placebo-controlled, Randomised, Double Blind Trial [NCT02617017]Phase 399 participants (Actual)Interventional2016-06-17Completed
Comparative, Randomized, 3-Way Crossover Bioavailability Study of Par and Bristol-Myers Squibb (Buspar)15 mg Buspirone HCl Tablets Following Administration of a 30 mg Dose in Healthy Adult Males Under Fed and Fasting Conditions [NCT00652730]Phase 121 participants (Actual)Interventional1998-07-31Completed
Brain Research in Aggression and Irritability Network (BRAIN): Building Evidence-Based Approaches to Managing Traumatic Brain Injury [NCT01821690]74 participants (Anticipated)Interventional2013-05-31Recruiting
Effects of Buspirone in Withdrawal From Opiates [NCT00326235]Phase 40 participants Interventional2002-01-31Completed
Comparative, Randomized, Single-Dose, 2-Way Crossover Bioavailability Study of Par and Bristol-Myers Squibb (Buspar) 15 mg Buspirone HCl Tablets in Healthy Adult Males Under Fasting Conditions Following Administration of a 30 mg Dose [NCT00653419]Phase 148 participants (Actual)Interventional1998-06-30Completed
Double-blind Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders [NCT01395953]Phase 20 participants (Actual)Interventional2011-11-30Withdrawn(stopped due to This study was withdrawn due to competing research interests and slow recruitment.)
An Open-label Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders [NCT01850355]9 participants (Actual)Interventional2013-07-31Active, not recruiting
Serotonin-receptor Agonism in Reward Processing [NCT05357547]Phase 263 participants (Actual)Interventional2022-05-13Completed
A Relative Bioavailability Study of 30 mg Buspirone Hydrochloride Tablets Under Fasting Conditions [NCT00840606]Phase 170 participants (Actual)Interventional2001-12-31Completed
The Tolerability of Buspirone for the Treatment of Anxiety in Parkinson's Disease [NCT02803749]Phase 221 participants (Actual)Interventional2016-10-31Completed
[NCT02273154]Phase 4240 participants (Anticipated)Interventional2014-08-31Recruiting
A Phase Two Clinical Trial of Buspirone Therapy in Localization-Related Epilepsy [NCT01496612]Phase 29 participants (Actual)Interventional2011-11-22Terminated
EuroHYP-1: European Multicentre, Randomised, Phase III Clinical Trial of Therapeutic Hypothermia Plus Best Medical Treatment Versus Best Medical Treatment Alone for Acute Ischaemic Stroke [NCT01833312]Phase 398 participants (Actual)Interventional2013-07-31Terminated(stopped due to Slow recruitment, cessation of funding)
Tri-therapy (SPINALON)-Elicited Spinal Locomotor Network Activation: Phase I-IIa Clinical Trial in Patients With Chronic Spinal Cord Injury [NCT01484184]Phase 1/Phase 250 participants (Actual)Interventional2013-07-31Completed
Do Dexmedetomidine and Buspirone Synergistically Reduce the Threshold, Gain, and Maximum Intensity of Shivering? [NCT00334360]Phase 48 participants (Actual)Interventional2004-09-30Completed
Buspirone, Stress, and Attentional Bias to Marijuana Cues [NCT02132832]Phase 245 participants (Actual)Interventional2013-06-30Completed
Serotonin 1A Agonists and Cognition in Schizophrenia [NCT00178971]Phase 360 participants (Actual)Interventional2003-01-31Completed
[NCT01546896]Phase 40 participants (Actual)Interventional2012-03-31Withdrawn
Sequenced Treatment Alternatives to Relieve Depression [NCT00021528]Phase 44,000 participants Interventional2001-07-31Completed
Career Training in Marijuana Dependence [NCT00149617]Phase 281 participants (Actual)Interventional2004-04-30Completed
Early Pharmacotherapy Aimed at Neuroplasticity in Autism : Safety and Efficacy [NCT00166621]Phase 1/Phase 220 participants Interventional2004-03-31Completed
Eight-Week, Double-Blind, 3-Arm Parallel, Placebo-Controlled, Randomized Efficacy And Safety Trial Of Atomoxetine, Atomoxetine Plus Buspirone, And Placebo In Adults With Attention Deficit Hyperactivity Disorder [NCT00174226]Phase 2241 participants (Actual)Interventional2004-11-30Completed
Acute Effects of Pharmacological Neuromodulation on Leg Motor Activity in Patients With Spinal Cord Injury Treated With Epidural Electrical Stimulation [NCT04052776]Phase 13 participants (Actual)Interventional2020-09-11Completed
Exploring Occupancy of Dopamine D3 Receptor by Buspirone in Humans Using PET [NCT01699828]Phase 1/Phase 26 participants (Actual)Interventional2012-10-31Completed
A Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Investigate the Safety and Efficacy of Lybridos in the Domestic Setting in Healthy Female Subjects With Hypoactive Sexual Desire Disorder and Maladaptive Activity of Sexual Inhibitory M [NCT01743235]Phase 2207 participants (Actual)Interventional2012-07-31Completed
[NCT02483598]Phase 412 participants (Anticipated)Interventional2015-06-30Terminated(stopped due to Initial analysis of results warranted a study re-design and work on the study was suspended.)
Psychopharmacology of Novel Medications for Cocaine Dependence - Buspirone [NCT01267292]Phase 250 participants (Actual)Interventional2011-03-31Completed
Long Term Effect of Buspirone on Esophageal Function and Esophageal Symptoms in Patients With Systematic Sclerosis (SSc) [NCT02363478]Early Phase 122 participants (Actual)Interventional2014-12-31Completed
A Placebo-Controlled Trial of Buspirone for Treatment of Marijuana Dependence [NCT00360191]Phase 281 participants (Actual)Interventional2004-04-30Completed
Buspirone Treatment for Marijuana Dependence [NCT00875836]Phase 4175 participants (Actual)Interventional2009-09-30Completed
A Randomized Controlled Evaluation of Buspirone for Relapse-Prevention in Adults With Cocaine Dependence (BRAC) [NCT01641159]Phase 262 participants (Actual)Interventional2012-08-31Completed
Pathogenesis of Sleep Disordered Breathing in Spinal Cord Injury Patients [NCT02458469]Phase 215 participants (Actual)Interventional2015-05-14Completed
Measurement of the Hippocampal Theta Rhythm From the Outer Ear Canal [NCT03954483]42 participants (Anticipated)Interventional2023-02-14Recruiting
Improving Ventilatory Capacity in Those With Chronic High Level SCI [NCT05041322]Phase 230 participants (Anticipated)Interventional2020-11-29Recruiting
Placebo-controlled, Randomized, Double-blind, Cross-over Style Trial of Buspirone in Functional Dysphagia [NCT02674412]10 participants (Actual)Interventional2016-02-29Completed
Gastric Glitch: a New Functional Disease Treated With Prucalopride and Buspirone in a N-of-1 Double-blind Clinical Trial [NCT05377619]Phase 1/Phase 21 participants (Actual)Interventional2022-01-06Completed
Pharmacovigilance in Gerontopsychiatric Patients [NCT02374567]Phase 3407 participants (Actual)Interventional2015-01-31Terminated
A Double-Blind, Placebo-Controlled Study of a Combination Product (BCI-024 and BCI-049) in Patients With Major Depressive Disorder (MDD) [NCT00705003]Phase 2142 participants (Actual)Interventional2008-05-31Completed
Human Laboratory Study of the Impact of Buspirone Maintenance on the Reinforcing, Subjective and Performance Effects of Cocaine [NCT01639157]9 participants (Actual)Interventional2012-09-30Completed
Effects of Serotonin Agonist Buspirone on Multimodal Esophageal Stimulation in Healthy Volunteers [NCT04352686]10 participants (Actual)Interventional2012-02-29Completed
Double-blind Placebo-controlled Multicenter Randomized Clinical Trial to Evaluate the Efficacy and Safety of Buspirone, Sustained-release Tablets, 15 mg (JSC Valenta Pharm, Russia) in Patients With Autonomic Dysfunction Syndrome Accompanied by Vertigo [NCT05430217]Phase 3268 participants (Actual)Interventional2022-01-28Completed
Buspirone as a Potential Treatment for Recurrent Central Apneas [NCT00746954]Phase 38 participants (Actual)Interventional2008-09-30Terminated(stopped due to Patient recruitment and Funding inadequate to finish trial)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00053846 (1) [back to overview]Dyspnea as Measured by Oxygen Cost Diagram (OCD)
NCT00705003 (5) [back to overview]The Score on the Clinical Global Impression-Improvement (CGI-I) at Week 6
NCT00705003 (5) [back to overview]The Change From Baseline on the HAM-A at Week 6
NCT00705003 (5) [back to overview]The Change From Baseline in the Quick Inventory of Depressive Symptomatology - 16 Item Self-Report (QIDS-SR16) at Week 6
NCT00705003 (5) [back to overview]The Change From Baseline in the IDS-C30 at Week 6
NCT00705003 (5) [back to overview]The Change From Baseline in the CGI-S at Week 6
NCT00746954 (1) [back to overview]Apnea-hypopnea Index (Number of Central and Mixed Apneas/Hour of Sleep)
NCT00875836 (3) [back to overview]Retention in the Study
NCT00875836 (3) [back to overview]Percent Marijuana-negative Urine Drug Screens (UDS)
NCT00875836 (3) [back to overview]Marijuana Craving
NCT01267292 (14) [back to overview]Reversal Learning as Assessed by Number of Perseverative Errors on the Reversal Learning Task
NCT01267292 (14) [back to overview]Reversal Learning as Assessed by Number of Perseverative Errors on the Reversal Learning Task
NCT01267292 (14) [back to overview]Systolic Blood Pressure
NCT01267292 (14) [back to overview]Reversal Learning as Assessed by Number of Perseverative Errors on the Reversal Learning Task
NCT01267292 (14) [back to overview]Rapid Response Inhibition as Assessed by the Immediate Memory Task (IMT)
NCT01267292 (14) [back to overview]Rapid Response Inhibition as Assessed by the Immediate Memory Task (IMT)
NCT01267292 (14) [back to overview]Rapid Response Inhibition as Assessed by the Immediate Memory Task (IMT)
NCT01267292 (14) [back to overview]Diastolic Blood Pressure
NCT01267292 (14) [back to overview]Attentional Bias as Assessed by Score on the Stroop Task
NCT01267292 (14) [back to overview]"Subjective Effects as Assessed by the Elated Subscale of the Visual Analogue Scale (VAS)"
NCT01267292 (14) [back to overview]"Subjective Effects as Assessed by Score on the Feel High Subscale of the Drug Effects Questionnaire (DEQ)"
NCT01267292 (14) [back to overview]Subjective Effects as Assessed by Score on the Vigor Subscale of the Profile of Mood States (POMS)
NCT01267292 (14) [back to overview]Risky Decision Making as Assessed by Score on the Risky Decision Making Task
NCT01267292 (14) [back to overview]Heart Rate
NCT01496612 (7) [back to overview]Mean Score on the Hamilton Depression Rating Scale (HAM-D) at the End of the Active and Placebo Periods
NCT01496612 (7) [back to overview]Mean Score on the Trail Making Test-A (TMT-A) Following 3 Months on Active Drug and 3 Months on Placebo
NCT01496612 (7) [back to overview]Mean Score on the Trail Making Test-B (TMT-B) Following 3 Months on Active Drug and 3 Months on Placebo
NCT01496612 (7) [back to overview]Seizure Frequency in the Buspirone (Active) and Placebo Periods
NCT01496612 (7) [back to overview]Mean Score on the Hamilton Anxiety Rating Scale (HAM-A) at the End of the Active and Placebo Periods.
NCT01496612 (7) [back to overview]Mean Score on the Beck Depression Inventory (BDI) at the End of the Active and Placebo Periods
NCT01496612 (7) [back to overview]Mean Score on the Cancellation Task Following 3 Months on Active Drug and 3 Months on Placebo
NCT01639157 (27) [back to overview]"Peak Ratings of Good Effects on the Visual Analog Scale"
NCT01639157 (27) [back to overview]"Peak Ratings of Euphoric on the Visual Analog Scale"
NCT01639157 (27) [back to overview]"Peak Ratings of Bad Effects on the Visual Analog Scale"
NCT01639157 (27) [back to overview]"Peak Ratings of Any Effect on the Visual Analog Scale"
NCT01639157 (27) [back to overview]"Peak Ratings of Active, Alert, Energetic on the Visual Analog Scale"
NCT01639157 (27) [back to overview]"Peak Ratings of Restless on the Visual Analog Scale"
NCT01639157 (27) [back to overview]Peak Systolic Blood Pressure
NCT01639157 (27) [back to overview]Peak Score on Stimulant Subscale of the Adjective Rating Scale
NCT01639157 (27) [back to overview]Peak Score on Sedative Subscale of the Adjective Rating Scale
NCT01639157 (27) [back to overview]"Peak Ratings of Stimulated on the Visual Analog Scale"
NCT01639157 (27) [back to overview]Peak Oral Temperature
NCT01639157 (27) [back to overview]Peak Heart Rate
NCT01639157 (27) [back to overview]Peak Diastolic Blood Pressure
NCT01639157 (27) [back to overview]Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative
NCT01639157 (27) [back to overview]"Peak Ratings of Willing to Take Again on the Visual Analog Scale"
NCT01639157 (27) [back to overview]"Peak Ratings of Willing to Pay For on the Visual Analog Scale"
NCT01639157 (27) [back to overview]"Peak Ratings of Talkative, Friendly on the Visual Analog Scale"
NCT01639157 (27) [back to overview]"Peak Ratings of Sluggish, Fatigued, Lazy on the Visual Analog Scale"
NCT01639157 (27) [back to overview]"Peak Ratings of Shaky, Jittery on the Visual Analog Scale"
NCT01639157 (27) [back to overview]"Peak Ratings of Rush on the Visual Analog Scale"
NCT01639157 (27) [back to overview]"Peak Ratings of Performance Improved on the Visual Analog Scale"
NCT01639157 (27) [back to overview]"Peak Ratings of Performance Impaired on the Visual Analog Scale"
NCT01639157 (27) [back to overview]"Peak Ratings of Nervous, Anxious on the Visual Analog Scale"
NCT01639157 (27) [back to overview]"Peak Ratings of Nauseated, Queasy, Sick to Stomach on the Visual Analog Scale"
NCT01639157 (27) [back to overview]"Peak Ratings of Like Drug on the Visual Analog Scale"
NCT01639157 (27) [back to overview]"Peak Ratings of Irregular/Racing Heartbeat on the Visual Analog Scale"
NCT01639157 (27) [back to overview]"Peak Ratings of High on the Visual Analog Scale"
NCT01641159 (2) [back to overview]Maximum Days of Continuous Cocaine Abstinence
NCT01641159 (2) [back to overview]Cocaine-use Days
NCT02132832 (12) [back to overview]Attentional Bias to Marijuana Specific Stimuli Measured Via Analysis of Eye Movements
NCT02132832 (12) [back to overview]Attentional Bias to Marijuana Specific Stimuli Measured Via Analysis of Eye Movements
NCT02132832 (12) [back to overview]Attentional Bias to Marijuana Specific Stimuli Measured Via Analysis of Eye Movements
NCT02132832 (12) [back to overview]Anxiety as Assessed by the Zung Self-Rated Anxiety Scale
NCT02132832 (12) [back to overview]Anxiety as Assessed by the Zung Self-Rated Anxiety Scale
NCT02132832 (12) [back to overview]Anxiety as Assessed by the Zung Self-Rated Anxiety Scale
NCT02132832 (12) [back to overview]Stress as Assessed by the Visual Analogue Stress Scale-Current (VASS-C)
NCT02132832 (12) [back to overview]Stress as Assessed by the Visual Analogue Stress Scale-Current (VASS-C)
NCT02132832 (12) [back to overview]Stress as Assessed by the Visual Analogue Stress Scale-Current (VASS-C)
NCT02132832 (12) [back to overview]Stress as Assessed by the Perceived Stress Scale
NCT02132832 (12) [back to overview]Stress as Assessed by the Perceived Stress Scale
NCT02132832 (12) [back to overview]Stress as Assessed by the Perceived Stress Scale
NCT02363478 (4) [back to overview]Changes From Baseline in Manometric Parameters: Duration of Contractions at the Distal Part of the Esophagus at Week 4
NCT02363478 (4) [back to overview]Changes From Baseline in Manometric Parameters: Velocity of Contractions at the Distal Part of the Esophagus at Week 4
NCT02363478 (4) [back to overview]Changes From Baseline in Manometric Parameters: i) Amplitude of Contractions at the Distal Part of the Esophagus and ii) Resting and Residual (Lower Esophageal Pressure) LES Pressure and IRP (Integrated Relaxation Pressure) at Week 4
NCT02363478 (4) [back to overview]Changes in the Severity of Esophageal Symptoms at Week 4
NCT02458469 (2) [back to overview]Apnea-Hypopnea Index (AHI)
NCT02458469 (2) [back to overview]CO2 Reserve (Delta-PETCO2-AT)
NCT02674412 (3) [back to overview]Change in Gastroesophageal Reflux Disease - Health Related Quality Questionnaire Score
NCT02674412 (3) [back to overview]Change in Percentage of Normal Swallows Recorded in a Series of 10 Measured Swallows.
NCT02674412 (3) [back to overview]Change in Distal Contractile Index (DCI) on High Resolution Esophageal Manometry
NCT02803749 (8) [back to overview]Mean Change in Hamilton Anxiety Rating Scale (HAM-A) From Baseline to 12 Weeks
NCT02803749 (8) [back to overview]"Number of Much Improved or Very Much Improved on Patient Global Impressions-Improvement (PGI-I) at 12 Weeks"
NCT02803749 (8) [back to overview]"Number of Much Improved or Very Much Improved on Clinical Global Impressions-Improvement (CGI-I) at 12 Weeks"
NCT02803749 (8) [back to overview]Mean Change in Hospital Anxiety and Depression Scale (HADS) - Depression From Baseline to 12 Weeks
NCT02803749 (8) [back to overview]The Number of Participants Who Fail to Complete the 12-week Study on Study Drug.
NCT02803749 (8) [back to overview]Mean Change in Anxiety Using the Hospital Anxiety and Depression Scale (HADS)
NCT02803749 (8) [back to overview]Mean Change in Unified Dyskinesia Rating Scale (UDysRS) From Baseline to 12 Weeks
NCT02803749 (8) [back to overview]Number of Responders (>50% Reduction From Baseline or Reduction to ≤7 on HAM-A) at 12 Weeks
NCT03538431 (2) [back to overview]Heart Rate
NCT03538431 (2) [back to overview]Driving Performance - Measured by Mean Off-Road Glance Duration
NCT03587142 (35) [back to overview]4-Week Cardiac Rhythm
NCT03587142 (35) [back to overview]4-Week Change in Anxiety
NCT03587142 (35) [back to overview]4-Week Change in Aspartate Aminotransferase (ALT)
NCT03587142 (35) [back to overview]4-Week Change in Bloating and Stomach Distention Symptoms Severity
NCT03587142 (35) [back to overview]4-Week Change in Bloating Symptom Severity
NCT03587142 (35) [back to overview]Assessment of the Severity of Adverse Events Over 4-Weeks
NCT03587142 (35) [back to overview]Adverse Events by Body Classification System by Treatment Group During the Trial
NCT03587142 (35) [back to overview]Total Number of Hospitalizations Over 4-weeks of Treatment
NCT03587142 (35) [back to overview]Serious Adverse Events
NCT03587142 (35) [back to overview]Change From Baseline at 4-weeks in the Water Load Satiety Test (WLST)
NCT03587142 (35) [back to overview]Change at 4-weeks in the Intragastric Meal Distribution (IMD)
NCT03587142 (35) [back to overview]Assessment of Adverse Events Over 4-Weeks
NCT03587142 (35) [back to overview]4-Week Change Overall Quality of Health Due to Gastroparesis Issues
NCT03587142 (35) [back to overview]4-Week Change in Weight
NCT03587142 (35) [back to overview]4-Week Change in Vomiting Symptom Severity
NCT03587142 (35) [back to overview]4-Week Change in Upper Abdominal Pain Symptom Severity
NCT03587142 (35) [back to overview]4-Week Change in Upper Abdominal Pain and Discomfort Symptoms Severity
NCT03587142 (35) [back to overview]4-Week Change in Total Overall GCSI Symptom Severity
NCT03587142 (35) [back to overview]4-Week Change in the Postprandial Fullness and Early Satiety Symptoms Severity
NCT03587142 (35) [back to overview]4-Week Change in Inability to Finish a Normal-sized Meal Symptom Severity
NCT03587142 (35) [back to overview]4-Week Change in Stomach Fullness Symptom Severity
NCT03587142 (35) [back to overview]4-Week Change in Severity of Somatic Symptoms
NCT03587142 (35) [back to overview]4-Week Change in Participant's Rating of Symptom Relief
NCT03587142 (35) [back to overview]4-Week Change in Gastric Retention
NCT03587142 (35) [back to overview]4-Week Change in Overall Physical Quality of Life (QOL)
NCT03587142 (35) [back to overview]4-Week Change in Overall Mental Quality of Life (QOL)
NCT03587142 (35) [back to overview]4-Week Change in Nausea, Vomiting and Retching Symptoms Severity
NCT03587142 (35) [back to overview]4-Week Change in Nausea Symptom Severity
NCT03587142 (35) [back to overview]4-Week Change in Loss of Appetite Symptom Severity
NCT03587142 (35) [back to overview]4-Week Change in Gastrointestinal Symptoms Rating Scale (GSRS) Global Score
NCT03587142 (35) [back to overview]4-Week Change in Gastroesophageal (GERD) Symptoms Severity
NCT03587142 (35) [back to overview]4-Week Change in Fasting Glucose
NCT03587142 (35) [back to overview]4-Week Change in Excessive Fullness Symptom Severity
NCT03587142 (35) [back to overview]4-Week Change in Depression
NCT03587142 (35) [back to overview]4-Week Change in Creatinine

Dyspnea as Measured by Oxygen Cost Diagram (OCD)

OCD was used to evaluate dyspnea on exertion and activities of daily living. OCD is a visual analog scale for quantifying a patient's evaluation of tolerance of exertion, which corresponds to oxygen requirements at different activity levels. It is measured as a score of 2 (sleeping) to 14 (brisk walking uphill). HIgher scores indicate fewer limitations due to dyspnea. (NCT00053846)
Timeframe: 28 days after beginning study drug or placebo

Interventionunits on a scale (Mean)
Buspirone Hydrochloride8.98
Placebo9.32

[back to top]

The Score on the Clinical Global Impression-Improvement (CGI-I) at Week 6

"Clinical Global Impression (CGI) is a standardized, clinician-rated assessment designed to allow the clinician to rate severity of illness, change over time, and pharmacologic treatment effects with consideration of the patient's clinical condition and the severity of side effects experienced (Guy 1976). Specifically, it consists of two global subscales: Global Improvement (CGI-I) Severity of Illness (CGI-S)~The CGI-I was administered at Weeks 2, 4 and 6. The CGI-I evaluation was performed with instruction to Rate the patient's total improvement whether or not, in your judgment, it is due entirely to drug treatment. The Investigator was asked Compared to the patient's condition at the Baseline visit, please assign a rating to how much the patient changed. Responses for the CGI-I evaluation included the following categories:~0: Not Assessed~Very much improved~Much improved~Minimally improved~No change~Minimally worse~Much worse~Very much worse" (NCT00705003)
Timeframe: Week 6

Interventionunits on a scale (Mean)
BCI-024+BCI-0492.37
BCI-0242.82
Placebo2.86

[back to top]

The Change From Baseline on the HAM-A at Week 6

"The 14-item HAM-A scale rates the patient's level of anxiety based on feelings of anxiousness, tension, and depression; any phobias, sleep disturbance, or difficulty in concentrating; the presence of genitourinary, cardiovascular, respiratory, autonomic or somatic symptoms; and the interviewer's assessment of the patient's appearance and behavior during the interview. Each item is to be scored on a 5 point scale with 0 reflecting no symptoms and 4 reflecting symptoms of maximum symptom severity (Hamilton 1960).~The items are summed to find the total score. The total minimum score is 0 units on a scale and the total maximum score is 56 units on a scale, where higher scores indicate more severe anxiety. Change from baseline is calculated as baseline score minus Week 6 score. A positive change indicates improvement." (NCT00705003)
Timeframe: Week 0 and Week 6

Interventionunits on a scale (Mean)
BCI-024 and BCI-0499.04
BCI-0246.69
Placebo6.51

[back to top]

The Change From Baseline in the Quick Inventory of Depressive Symptomatology - 16 Item Self-Report (QIDS-SR16) at Week 6

"The QIDS-SR16 is a 16 question, patient rated scale that assesses the 9 Diagnostic & Statistical Manual of Mental Disorders-IV-Text Revision criterion diagnostic symptom domains including sad mood, concentration, self criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance, decrease or increase in appetite or weight, & psychomotor agitation or retardation. Each item is measured on a scale of 0 to 3. To find total score, you enter:~highest score from items 1-4 (Sleep Items)~item 5 score~highest score from items 6-9 (appetite/weight)~item 10 score~item 11 score~item 12 score~item 13 score~item 14 score~highest score from items 15-16 (psychomotor) These 9 scores are summed to find total score. Total minimum score is 0 units on a scale & total maximum score is 27 units, where higher scores indicate more severe depression. Change from baseline is calculated as baseline score minus Week 6 score. A positive change indicates improvement" (NCT00705003)
Timeframe: Baseline and Week 6

Interventionunits on a scale (Mean)
BCI-024 and BCI-0498.57
BCI-0246.65
Placebo7.31

[back to top]

The Change From Baseline in the IDS-C30 at Week 6

The Inventory of Depressive Symptomatology is a 30-item scale that assesses criteria including mood, concentration, self criticism, suicidal ideation, interest, energy/fatigue, sleep, decrease/increase in appetite or weight, psychomotor agitation or retardation, diurnal mood variation, capacity for pleasure, sexual interest, bodily aches and pains, panic or phobic symptoms, digestive problems, interpersonal rejection sensitivity, and leaden paralysis. Items are scored on a 4 point scale with 0 reflecting no symptoms and 3 reflecting symptoms of maximum severity. The total score is calculated by summing the scores from 28 of the 30 items. Only one of items 11 or 12, and only one of items 13 or 14 are scored. The minimum score is 0 and the maximum score is 84. A score of 84 indicates maximum severity of depressive symptoms. Change from baseline is calculated as the baseline score minus the post-baseline score. A positive change indicates improvement. (NCT00705003)
Timeframe: Week 0 and Week 6

Interventionunits on a scale (Mean)
BCI-024 and BCI-04919.24
BCI-02416.35
Placebo14.42

[back to top]

The Change From Baseline in the CGI-S at Week 6

"Clinical Global Impression (CGI) is a standardized, clinician-rated assessment designed to allow the clinician to rate severity of illness, change over time, and pharmacologic treatment effects with consideration of the patient's clinical condition and the severity of side effects experienced (Guy 1976). The CGI-S is a sub-scale of the Clinical Global Impression. The Investigator was asked: Considering your total clinical experience with patients with this particular population, please assign a rating to how mentally ill the subject is at this time.~Possible responses include the following:~0: Not Assessed~Normal, not ill at all~Borderline mentally ill~Mildly ill~Moderately ill~Markedly ill~Severely ill~Among the most extremely ill patients. The change from baseline CGI-S score was calculated as the baseline CGI-S score minus the post-baseline CGI-S score, such that a positive change indicated an improvement from baseline." (NCT00705003)
Timeframe: Baseline and Week 6

Interventionunits on a scale (Mean)
BCI-024 and BCI-0491.43
BCI-024.93
Placebo0.97

[back to top]

Apnea-hypopnea Index (Number of Central and Mixed Apneas/Hour of Sleep)

(NCT00746954)
Timeframe: Overnight polysomnogram over 3 separate nights

InterventionAPNEA-HYPOPNEA/HR by drug or placebo (Mean)
BUSPIRONE32.5
ACETAZOLAMIDE31.2
PLACEBO35.7

[back to top]

Retention in the Study

Number of days subjects remained active in the study (NCT00875836)
Timeframe: participants were followed for twelve weeks

InterventionDay (Median)
Buspirone79
Placebo84

[back to top]

Percent Marijuana-negative Urine Drug Screens (UDS)

Participants submitted a urine sample weekly. Percentage of marijuana negative urine samples were calculated per group. (NCT00875836)
Timeframe: Participants provided a once-weekly urine sample for twelve weeks

Interventionpercentage of UDS (Number)
Buspirone7.2
Placebo6.4

[back to top]

Marijuana Craving

The Marijuana Craving Questionnaire (MCQ) is intended to measure marijuana craving in adults. It measures symptoms on four subscales: expectancy, purposefulness, emotionality, and compulsivity. The scale rates individual items from 1 (least craving) - 7 (most craving) with a composite scoring range of 12-84 and possible subscale scoring range of 3-21. It was administered weekly- reported here is the mean composite score across the 8 week treatment course. (NCT00875836)
Timeframe: 8 Weeks

Interventionunits on a scale (Mean)
Buspirone29.6
Placebo28.4

[back to top]

Reversal Learning as Assessed by Number of Perseverative Errors on the Reversal Learning Task

The task is a rapid-presentation, probablistic gain/loss design. Reversal learning is assessed by means of a simple computerized card game. The paradigm utilizes a visual discrimination task where subjects have to learn to respond to outcome contingencies between two stimuli (high probability gain/low probability loss vs. low probability gain/high probability loss). At an unsignaled time point halfway into testing, the contingencies are reversed; the losing card becomes the winning card and the winning card becomes the losing one. Visual feedback regarding win or loss ($0.20) is provided after each trial and the cumulative total gained/lost is also shown. Using trial-and-error feedback, subjects have to discover which of the two patterns is correct and are instructed to win as much money as possible. The duration of the task is approximately 10 minutes, consisting of 80 trials. (NCT01267292)
Timeframe: Thursday of week 1

Interventionnumber of perseverative errors (Mean)
Buspirone Plus Methylphenidate11.78154
Placebo for Buspirone Plus Methylphenidate14.13049

[back to top]

Reversal Learning as Assessed by Number of Perseverative Errors on the Reversal Learning Task

The task is a rapid-presentation, probablistic gain/loss design. Reversal learning is assessed by means of a simple computerized card game. The paradigm utilizes a visual discrimination task where subjects have to learn to respond to outcome contingencies between two stimuli (high probability gain/low probability loss vs. low probability gain/high probability loss). At an unsignaled time point halfway into testing, the contingencies are reversed; the losing card becomes the winning card and the winning card becomes the losing one. Visual feedback regarding win or loss ($0.20) is provided after each trial and the cumulative total gained/lost is also shown. Using trial-and-error feedback, subjects have to discover which of the two patterns is correct and are instructed to win as much money as possible. The duration of the task is approximately 10 minutes, consisting of 80 trials. (NCT01267292)
Timeframe: Monday of week 4

Interventionnumber of perseverative errors (Mean)
Buspirone Plus Methylphenidate10.88235
Placebo for Buspirone Plus Methylphenidate14.69598

[back to top]

Systolic Blood Pressure

"The mean score over all 44 time points is reported in this outcome measure (i.e., the summary score is reported). Each subject contributed 11 data points for each dose level of Methylphenidate (15mg, 30mg, 60mg, or 0mg), resulting in a total of 220 data points per dose level per arm.~Systolic blood pressure is the amount of pressure in the arteries during contraction of the heart muscle." (NCT01267292)
Timeframe: 11 times a day on Wednesday and Friday of week 2; 11 times a day on Monday and Wednesday of week 3

,
InterventionmmHg (Mean)
15mg Methylphenidate30mg Methylphenidate60mg Methylphenidate0mg Methylphenidate
Buspirone Plus Methylphenidate118.0856114.8396114.3904114.7914
Placebo for Buspirone Plus Methylphenidate115.9205120.4545113.6932115.6932

[back to top]

Reversal Learning as Assessed by Number of Perseverative Errors on the Reversal Learning Task

The task is a rapid-presentation, probablistic gain/loss design. Reversal learning is assessed by means of a simple computerized card game. The paradigm utilizes a visual discrimination task where subjects have to learn to respond to outcome contingencies between two stimuli (high probability gain/low probability loss vs. low probability gain/high probability loss). At an unsignaled time point halfway into testing, the contingencies are reversed; the losing card becomes the winning card and the winning card becomes the losing one. Visual feedback regarding win or loss ($0.20) is provided after each trial and the cumulative total gained/lost is also shown. Using trial-and-error feedback, subjects have to discover which of the two patterns is correct and are instructed to win as much money as possible. The duration of the task is approximately 10 minutes, consisting of 80 trials. (NCT01267292)
Timeframe: baseline

Interventionnumber of perseverative errors (Mean)
Buspirone Plus Methylphenidate14.41176
Placebo for Buspirone Plus Methylphenidate10.625

[back to top]

Rapid Response Inhibition as Assessed by the Immediate Memory Task (IMT)

"Subjects are required to respond selectively to a series of stimuli (e.g., numbers) presented briefly for 500 ms with a 500 ms intertrial interval (ITI). Increases in false alarm rates are interpreted as failures in response inhibition. Five digit numbers are presented on a computer screen every 500 ms sec. Subjects are instructed to respond when the first number of a set was repeated. A hit response is scored when a subject correctly responds. Distracters consist of five-digit numbers that are completely different from the first, and numbers in which four of the five digits match the original, with the non-matching number occurring randomly across the five digit places. A response to the number with 4 of 5 digits correct is scored as a false alarm. The a-prime value reflects the ability of the participant to discriminate between signal (Go stimulus) and noise (No-Go stimulus) and ranges from 0.5 (chance level) to 1 (perfect discrimination)." (NCT01267292)
Timeframe: Thursday of week 1

Interventiona-prime (Mean)
Buspirone Plus Methylphenidate0.8673529
Placebo for Buspirone Plus Methylphenidate0.8551562

[back to top]

Rapid Response Inhibition as Assessed by the Immediate Memory Task (IMT)

"Subjects are required to respond selectively to a series of stimuli (e.g., numbers) presented briefly for 500 ms with a 500 ms intertrial interval (ITI). Increases in false alarm rates are interpreted as failures in response inhibition. Five digit numbers are presented on a computer screen every 500 ms sec. Subjects are instructed to respond when the first number of a set was repeated. A hit response is scored when a subject correctly responds. Distracters consist of five-digit numbers that are completely different from the first, and numbers in which four of the five digits match the original, with the non-matching number occurring randomly across the five digit places. A response to the number with 4 of 5 digits correct is scored as a false alarm. The a-prime value reflects the ability of the participant to discriminate between signal (Go stimulus) and noise (No-Go stimulus) and ranges from 0.5 (chance level) to 1 (perfect discrimination)." (NCT01267292)
Timeframe: Monday of week 4

Interventiona-prime (Mean)
Buspirone Plus Methylphenidate0.8569118
Placebo for Buspirone Plus Methylphenidate0.8695347

[back to top]

Rapid Response Inhibition as Assessed by the Immediate Memory Task (IMT)

"Subjects are required to respond selectively to a series of stimuli (e.g., numbers) presented briefly for 500 ms with a 500 ms intertrial interval (ITI). Increases in false alarm rates are interpreted as failures in response inhibition. Five digit numbers are presented on a computer screen every 500 ms sec. Subjects are instructed to respond when the first number of a set was repeated. A hit response is scored when a subject correctly responds. Distracters consist of five-digit numbers that are completely different from the first, and numbers in which four of the five digits match the original, with the non-matching number occurring randomly across the five digit places. A response to the number with 4 of 5 digits correct is scored as a false alarm. The a-prime value reflects the ability of the participant to discriminate between signal (Go stimulus) and noise (No-Go stimulus) and ranges from 0.5 (chance level) to 1 (perfect discrimination)." (NCT01267292)
Timeframe: baseline

Interventiona-prime (Mean)
Buspirone Plus Methylphenidate0.8327941
Placebo for Buspirone Plus Methylphenidate0.8498438

[back to top]

Diastolic Blood Pressure

"The mean score over all 44 time points is reported in this outcome measure (i.e., the summary score is reported). Each subject contributed 11 data points for each dose level of Methylphenidate (15mg, 30mg, 60mg, or 0mg), resulting in a total of 220 data points per dose level per arm.~Diastolic blood pressure is the blood pressure when the heart muscle is between beats." (NCT01267292)
Timeframe: 11 times a day on Wednesday and Friday of week 2; 11 times a day on Monday and Wednesday of week 3

,
InterventionmmHg (Mean)
15mg Methylphenidate30mg Methylphenidate60mg Methylphenidate0mg Methylphenidate
Buspirone Plus Methylphenidate74.7272774.566847372.92513
Placebo for Buspirone Plus Methylphenidate76.7159178.5340975.562576.88636

[back to top]

Attentional Bias as Assessed by Score on the Stroop Task

"The mean score over all 4 time points is reported in this outcome measure (i.e., a summary score is reported). Each subject contributed 1 data point for each dose level of Methylphenidate (15mg, 30mg, 60mg, or 0mg), resulting in a total of 20 data points per dose level per arm.~The Stroop task assesses attentional biases to cocaine-related (drug-related) and rewarding (non-drug related) stimuli vs. neutral stimuli. Participants are instructed to respond to words shown in different colors on the screen, by pressing as quickly and accurately as possible on one of three colored buttons. Attentional bias is measured as the difference in reaction times on cocaine vs. neutral words. The reported score is a difference score in milliseconds (cocaine minus neutral), in which positive means slower to respond to cocaine and thus greater attentional bias, and negative means no attentional bias to cocaine words." (NCT01267292)
Timeframe: 1 time a day on Wednesday and Friday of week 2; 1 time a day on Monday and Wednesday of week 3

,
Interventionmilliseconds (Mean)
15 mg methylphenidate30 mg methylphenidate60 mg methylphenidate0 mg methylphenidate
Buspirone Plus Methylphenidate-13.90333-9.36126915.591674.688844
Placebo for Buspirone Plus Methylphenidate27.11815.3540723.2806341.22625

[back to top]

"Subjective Effects as Assessed by the Elated Subscale of the Visual Analogue Scale (VAS)"

"The mean score over all 44 time points is reported in this outcome measure (i.e., the summary score is reported). Each subject contributed 11 data points for each dose level of Methylphenidate (15mg, 30mg, 60mg, or 0mg), resulting in a total of 220 data points per dose level per arm.~The VAS presents 100-mm horizontal lines labeled with an adjective: stimulated, high, anxious, elated, hungry, and nauseated. The elated subscale is reported, and this sub scale is anchored by not at all (0) on the left and extremely (100) on the right, with a score range of 0-100. The higher the score, the worse the outcome." (NCT01267292)
Timeframe: 11 times a day on Wednesday and Friday of week 2; 11 times a day on Monday and Wednesday of week 3

,
Interventionunits on a scale (Mean)
15mg Methylphenidate30mg Methylphenidate60mg Methylphenidate0mg Methylphenidate
Buspirone Plus Methylphenidate11.4812828.7297314.5459521.95676
Placebo for Buspirone Plus Methylphenidate19.5344821.4204521.8114314.89017

[back to top]

"Subjective Effects as Assessed by Score on the Feel High Subscale of the Drug Effects Questionnaire (DEQ)"

"The mean score over all 44 time points is reported in this outcome measure (i.e., the summary score is reported). Each subject contributed 11 data points for each dose level of Methylphenidate (15mg, 30mg, 60mg, or 0mg), resulting in a total of 220 data points per dose level per arm.~The DEQ is a visual analog scale questionnaire that assesses the extent to which subjects experience four subjective states: Feel Drug, Feel High, Like Drug, and Want More. The Feel High subscale is reported, and this subscale is scored on a visual analogue scale (scroll bar on computer screen) ranging from 0-100. 100 represents the highest score for that subjective state, and the higher the score, the worse the outcome." (NCT01267292)
Timeframe: 11 times a day on Wednesday and Friday of week 2; 11 times a day on Monday and Wednesday of week 3

,
Interventionunits on a scale (Mean)
15mg Methylphenidate30mg Methylphenidate60mg Methylphenidate0mg Methylphenidate
Buspirone Plus Methylphenidate9.32258112.713515.88648610.39785
Placebo for Buspirone Plus Methylphenidate9.17816110.788579.8465914.508671

[back to top]

Subjective Effects as Assessed by Score on the Vigor Subscale of the Profile of Mood States (POMS)

"The mean score over all 44 time points is reported in this outcome measure (i.e., the summary score is reported). Each subject contributed 11 data points for each dose level of Methylphenidate (15mg, 30mg, 60mg, or 0mg), resulting in a total of 220 data points per dose level per arm.~The POMS is a self-rating measure of current mood, consisting of six subscales demonstrated to be sensitive to a range of acute drug effects, including amphetamine, cocaine, and caffeine. The six subscales are: depression, vigor, confusion, tension, anxiety, and fatigue. A 37-item short form of the POMS was used, which correlates highly with the full scale. The vigor subscale is reported, and the vigor subscale score ranges from 0 to 28, with 28 representing the highest score for that mood state. The higher the value, the worse the outcome." (NCT01267292)
Timeframe: 11 times a day on Wednesday and Friday of week 2; 11 times a day on Monday and Wednesday of week 3

,
Interventionunits on a scale (Mean)
15mg Methylphenidate30mg Methylphenidate60mg Methylphenidate0mg Methylphenidate
Buspirone Plus Methylphenidate4.6096269.9243244.7459466.16129
Placebo for Buspirone Plus Methylphenidate3.7701156.2685715.8742865.735632

[back to top]

Risky Decision Making as Assessed by Score on the Risky Decision Making Task

"The mean score over all 4 time points is reported in this outcome measure (i.e., a summary score is reported). Each subject contributed 1 data point for each dose level of Methylphenidate (15mg, 30mg, 60mg, or 0mg), resulting in a total of 20 data points per dose level per arm.~The risky decision making task provides subjects with three choice options on each of 100 repeated trials. Options are low, moderate, and high risk, based on variance and probability in gain/loss amounts. The low risk option is more adaptive over many trials. The outcome measure is a risk index (ranging from 0.33 to 100) that factors in tolerance for variability and amount of gains and losses across the three options. 100 is highest risk. 0.33 is lowest risk." (NCT01267292)
Timeframe: 1 time a day on Wednesday and Friday of week 2; 1 time a day on Monday and Wednesday of week 3

,
Interventionunits on a scale (Mean)
15mg Methylphenidate30mg Methylphenidate60mg Methylphenidate0mg Methylphenidate
Buspirone Plus Methylphenidate9.12666710.771678.94626311.415
Placebo for Buspirone Plus Methylphenidate10.073969.6993337.8898258.715333

[back to top]

Heart Rate

"The mean score over all 44 time points is reported in this outcome measure (i.e., the summary score is reported). Each subject contributed 11 data points for each dose level of Methylphenidate (15mg, 30mg, 60mg, or 0mg), resulting in a total of 220 data points per dose level per arm.~Heart rate is the measure of heart beats per minute." (NCT01267292)
Timeframe: 11 times a day on Wednesday and Friday of week 2; 11 times a day on Monday and Wednesday of week 3

,
Interventionbeats per minute (Mean)
15mg Methylphenidate30mg Methylphenidate60mg Methylphenidate0mg Methylphenidate
Buspirone Plus Methylphenidate66.8449266.4331666.3636463.21925
Placebo for Buspirone Plus Methylphenidate67.7556868.2613669.1306869.60795

[back to top]

Mean Score on the Hamilton Depression Rating Scale (HAM-D) at the End of the Active and Placebo Periods

The Hamilton Depression Rating Scale (HAM-D) was administered to participants at the end of each treatment period. The HAM-D is a multiple item questionnaire used to provide an indication of depression. The questionnaire is designed for adults and is used to rate the severity of their depression by probing mood, feelings of guilt, suicide ideation, insomnia, agitation or retardation, anxiety, weight loss, and somatic symptoms. Although the HAM-D form lists 21 items, the scoring is based on the first 17 items. Eight items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Nine items are scored from 0-2 with 0 = absent and 2 = frequent or severe. Scores range from 0 to 50 with a score of 0-7 representing normal and a score >/= 23 representing very severe depression. (NCT01496612)
Timeframe: Three months

Interventionscore on a scale (Mean)
Buspirone1.40
Placebo2.40

[back to top]

Mean Score on the Trail Making Test-A (TMT-A) Following 3 Months on Active Drug and 3 Months on Placebo

The Trail Making Test-A (TMT-A) measures visual scanning and rote memory. The participant is asked to draw a line between 24 consecutive numbered circles randomly arranged on a page. The TMT-A is scored by how long it takes to complete the test. An average score for TMT-A is 29 seconds and a deficient score is >78 seconds. (NCT01496612)
Timeframe: Three months

InterventionSeconds (Mean)
Buspirone47
Placebo43.8

[back to top]

Mean Score on the Trail Making Test-B (TMT-B) Following 3 Months on Active Drug and 3 Months on Placebo

The Trail Making Test-B (TMT-B) measures visual scanning and executive functioning. The participant is asked to draw a line between 24 consecutive numbered and lettered circles randomly arranged on a page. The participant is required to switch between numbers and letters in consecutive order. The TMT-B is scored by how long it takes to complete the test. An average score for TMT-B is 75 seconds and a deficient score is >273 seconds. (NCT01496612)
Timeframe: Three months

InterventionSeconds (Mean)
Buspirone43.4
Placebo46

[back to top]

Seizure Frequency in the Buspirone (Active) and Placebo Periods

Participants utilized a seizure calendar to record the number of seizures that occurred during the three month treatment period, i.e., while participants were either taking Buspirone or Placebo. Seizure frequency was calculated as the total number of seizures occurring during each three month period. For each period a mean was calculated across subjects. (NCT01496612)
Timeframe: Three months

Interventionnumber of seizures (Mean)
Buspirone33.2
Placebo31.2

[back to top]

Mean Score on the Hamilton Anxiety Rating Scale (HAM-A) at the End of the Active and Placebo Periods.

Participants were administered the Hamilton Anxiety Rating Scale (HAM-A) at the end of each three month treatment period, i.e., while participants were either on Buspirone or Placebo. The HAM-A measures an individual's severity of anxiety symptoms. The scale consists of 14 parameters, each defined by a series of symptoms. Each group of symptoms is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild anxiety, 18-24 mild to moderate anxiety and 25-30 moderate to severe anxiety. (NCT01496612)
Timeframe: Three months

Interventionscore on a scale (Mean)
Buspirone.80
Placebo2

[back to top]

Mean Score on the Beck Depression Inventory (BDI) at the End of the Active and Placebo Periods

The Beck Depression Inventory (BDI) is a 21-item test presented in multiple-choice format, which measures presence and degree of depression in adolescents and adults. The BDI evaluates 21 symptoms of depression. The 21 items cover sadness, pessimism, past failure, self-dislike, self-criticism, suicidal thoughts or wishes, crying, agitation, loss of interest, indecisiveness, worthlessness, loss of energy, changes in sleeping patterns, irritability, changes in appetite, difficulty concentrating, tiredness or fatigue, and loss of interest in sex. Each answer is scored on a scale value of 0-3 with 0 indicating absence of symptom and a 3 indicating severe symptom. The total range of possible scores is 0-63. A total score of <10 indicates no or minimal depression,10-18 indicates mild-to-moderate depression,19-29 indicates moderate-to-severe depression, and 30+ indicates severe depression. (NCT01496612)
Timeframe: Three months

Interventionscore on a scale (Mean)
Buspirone.80
Placebo1.8

[back to top]

Mean Score on the Cancellation Task Following 3 Months on Active Drug and 3 Months on Placebo

The WAIS-IV Cancellation Subtest assesses processing speed and attention. It is a timed test with two sequential forms, A & B. Each form requires the participant to scan an array of colored shapes (e.g., triangle, circle) randomly arranged. The participant is given 45 seconds to mark (i.e. cross out) as many of the two designated geometric shapes in the total array as possible. Cancellation scores are based on the number of correct responses minus the number of incorrect responses completed in the allotted time. The total correct for the two forms is converted to a single scaled score based on age-corrected normative data with a mean of 10 +/- 3 and a range of 1 to 19. The mean is 10 +/-3; thus a typical age corrected score is between 8 and 11; the higher the number the better the score. A low score (<8) is progressively more impaired, the lower the score. A high score (>12) indicates more efficiency and better attention than compared to others the same age. (NCT01496612)
Timeframe: Three months

Interventionscore on a scale (Mean)
Buspirone7.6
Placebo9.8

[back to top]

"Peak Ratings of Good Effects on the Visual Analog Scale"

"Subjects rated their feelings of Good Effects on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions." (NCT01639157)
Timeframe: Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.

,
Interventionarbitary units on a Visual Analog Scale (Mean)
0 mg Cocaine15 mg Cocaine45 mg Cocaine
Buspirone4.821.321.2
Placebo3.315.732.3

[back to top]

"Peak Ratings of Euphoric on the Visual Analog Scale"

"Subjects rated their feelings of Euphoric on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions." (NCT01639157)
Timeframe: Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.

,
Interventionarbitary units on a Visual Analog Scale (Mean)
0 mg Cocaine15 mg Cocaine45 mg Cocaine
Buspirone5.615.816.4
Placebo5.913.114.1

[back to top]

"Peak Ratings of Bad Effects on the Visual Analog Scale"

"Subjects rated their feelings of Bad Effects on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions." (NCT01639157)
Timeframe: Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.

,
Interventionarbitary units on a Visual Analog Scale (Mean)
0 mg Cocaine15 mg Cocaine45 mg Cocaine
Buspirone4.36.712.2
Placebo5.97.79.1

[back to top]

"Peak Ratings of Any Effect on the Visual Analog Scale"

"Subjects rated their feelings of Any Effect on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions." (NCT01639157)
Timeframe: Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.

,
Interventionarbitary units on a Visual Analog Scale (Mean)
0 mg Cocaine15 mg Cocaine45 mg Cocaine
Buspirone6.223.026
Placebo6.117.333.4

[back to top]

"Peak Ratings of Active, Alert, Energetic on the Visual Analog Scale"

"Subjects rated their feelings of Active, Alert, Energetic on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions." (NCT01639157)
Timeframe: Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.

,
Interventionarbitary units on a Visual Analog Scale (Mean)
0 mg Cocaine15 mg Cocaine45 mg Cocaine
Buspirone3.820.124.7
Placebo3.717.433.3

[back to top]

"Peak Ratings of Restless on the Visual Analog Scale"

"Subjects rated their feelings of Restless on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions." (NCT01639157)
Timeframe: Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.

,
Interventionarbitary units on a Visual Analog Scale (Mean)
0 mg Cocaine15 mg Cocaine45 mg Cocaine
Buspirone4.110.013.0
Placebo1.910.29.4

[back to top]

Peak Systolic Blood Pressure

Systolic blood pressure was measured with an automated monitor. Higher values represent greater systolic pressure. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions. (NCT01639157)
Timeframe: This measure was completed at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.

,
InterventionmmHg (Mean)
0 mg Cocaine15 mg Cocaine45 mg Cocaine
Buspirone120.8128.7127.1
Placebo120.6127.0131.8

[back to top]

Peak Score on Stimulant Subscale of the Adjective Rating Scale

"Subjects completed 16 items that loaded into the Stimulant Subscale of the Adjective Rating Scale. The items were rated 0-4 on a Likert-type scale and the sum for the 16 sedative items was summed to yield the Stimulant Subscale score. The maximum score for this scale was 64, the minimum was 0. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions." (NCT01639157)
Timeframe: Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.

,
Interventionarbitrary units on a Likert-type scale (Mean)
0 mg Cocaine15 mg Cocaine45 mg Cocaine
Buspirone59.811.4
Placebo4.4911.3

[back to top]

Peak Score on Sedative Subscale of the Adjective Rating Scale

"Subjects completed 16 items that loaded into the Sedative Subscale of the Adjective Rating Scale. The items were rated 0-4 on a Likert-type scale and the sum for the 16 sedative items was summed to yield the Sedative Subscale score. The maximum score for this scale was 64, the minimum was 0. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions." (NCT01639157)
Timeframe: Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.

,
Interventionarbitrary units on a Likert-type scale (Mean)
0 mg Cocaine15 mg Cocaine45 mg Cocaine
Buspirone2.94.45.6
Placebo3.64.83.1

[back to top]

"Peak Ratings of Stimulated on the Visual Analog Scale"

"Subjects rated their feelings of Stimulated on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions." (NCT01639157)
Timeframe: Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.

,
Interventionarbitary units on a Visual Analog Scale (Mean)
0 mg Cocaine15 mg Cocaine45 mg Cocaine
Buspirone4.018.725.3
Placebo4.217.932.3

[back to top]

Peak Oral Temperature

Oral temperature was measured with an automated monitor. Higher values represent greater temperature. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions. (NCT01639157)
Timeframe: This measure was completed at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.

,
InterventionDegrees Fahrenheit (Mean)
0 mg Cocaine15 mg Cocaine45 mg Cocaine
Buspirone98.298.398.1
Placebo98.398.498.4

[back to top]

Peak Heart Rate

Heart rate was measured with an automated monitor. Higher values represent greater heart rate. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions. (NCT01639157)
Timeframe: This measure was completed at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.

,
Interventionbeats per minute (Mean)
0 mg Cocaine15 mg Cocaine45 mg Cocaine
Buspirone75.979.982.8
Placebo79.779.689.3

[back to top]

Peak Diastolic Blood Pressure

Diastolic blood pressure was measured with an automated monitor. Higher values represent greater diastolic pressure. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions. (NCT01639157)
Timeframe: This measure was completed at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.

,
InterventionmmHg (Mean)
0 mg Cocaine15 mg Cocaine45 mg Cocaine
Buspirone74.375.177.6
Placebo73.374.677.6

[back to top]

Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative

The reinforcing effects of cocaine were determined using a modified progressive ratio procedure (Stoops et al., 2010) in which subjects made 6 choices between available each available cocaine dose and money (US$0.25). Reinforcing effects are measured for each cocaine dose during both buspirone and placebo maintenance. (NCT01639157)
Timeframe: One test per cocaine dose level per intervention for each participant over his/her 2 week inpatient admission

,
InterventionNumber of Cocaine Choices (Mean)
0 mg Cocaine15 mg Cocaine45 mg Cocaine
Buspirone1.005.565
Placebo1.225.334.89

[back to top]

"Peak Ratings of Willing to Take Again on the Visual Analog Scale"

"Subjects rated their feelings of Willing to Take Again on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions." (NCT01639157)
Timeframe: Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.

,
Interventionarbitary units on a Visual Analog Scale (Mean)
0 mg Cocaine15 mg Cocaine45 mg Cocaine
Buspirone3.327.734.6
Placebo3.222.143.4

[back to top]

"Peak Ratings of Willing to Pay For on the Visual Analog Scale"

"Subjects rated their feelings of Willing to Pay For on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions." (NCT01639157)
Timeframe: Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.

,
Interventionarbitary units on a Visual Analog Scale (Mean)
0 mg Cocaine15 mg Cocaine45 mg Cocaine
Buspirone3.618.631.9
Placebo3.113.931.3

[back to top]

"Peak Ratings of Talkative, Friendly on the Visual Analog Scale"

"Subjects rated their feelings of Talkative, Friendly on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions." (NCT01639157)
Timeframe: Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.

,
Interventionarbitary units on a Visual Analog Scale (Mean)
0 mg Cocaine15 mg Cocaine45 mg Cocaine
Buspirone3.211.712.1
Placebo2.011.221.8

[back to top]

"Peak Ratings of Sluggish, Fatigued, Lazy on the Visual Analog Scale"

"Subjects rated their feelings of Sluggish, Fatigued, Lazy on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions." (NCT01639157)
Timeframe: Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.

,
Interventionarbitary units on a Visual Analog Scale (Mean)
0 mg Cocaine15 mg Cocaine45 mg Cocaine
Buspirone5.313.412.9
Placebo12.912.77.7

[back to top]

"Peak Ratings of Shaky, Jittery on the Visual Analog Scale"

"Subjects rated their feelings of Shaky, Jittery on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions." (NCT01639157)
Timeframe: Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.

,
Interventionarbitary units on a Visual Analog Scale (Mean)
0 mg Cocaine15 mg Cocaine45 mg Cocaine
Buspirone4.815.118.9
Placebo2.111.417.7

[back to top]

"Peak Ratings of Rush on the Visual Analog Scale"

"Subjects rated their feelings of Rush on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions." (NCT01639157)
Timeframe: Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.

,
Interventionarbitary units on a Visual Analog Scale (Mean)
0 mg Cocaine15 mg Cocaine45 mg Cocaine
Buspirone3.618.420.1
Placebo1.912.423.3

[back to top]

"Peak Ratings of Performance Improved on the Visual Analog Scale"

"Subjects rated their feelings of Performance Improved on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions." (NCT01639157)
Timeframe: Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.

,
Interventionarbitary units on a Visual Analog Scale (Mean)
0 mg Cocaine15 mg Cocaine45 mg Cocaine
Buspirone2.78.94.7
Placebo1.95.24.8

[back to top]

"Peak Ratings of Performance Impaired on the Visual Analog Scale"

"Subjects rated their feelings of Performance Impaired on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions." (NCT01639157)
Timeframe: Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.

,
Interventionarbitary units on a Visual Analog Scale (Mean)
0 mg Cocaine15 mg Cocaine45 mg Cocaine
Buspirone2.68.812.6
Placebo4.36.318.2

[back to top]

"Peak Ratings of Nervous, Anxious on the Visual Analog Scale"

"Subjects rated their feelings of Nervous, Anxious on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions." (NCT01639157)
Timeframe: Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.

,
Interventionarbitary units on a Visual Analog Scale (Mean)
0 mg Cocaine15 mg Cocaine45 mg Cocaine
Buspirone3.613.117.2
Placebo210.212.6

[back to top]

"Peak Ratings of Nauseated, Queasy, Sick to Stomach on the Visual Analog Scale"

"Subjects rated their feelings of Nauseated, Queasy, Sick to Stomach on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions." (NCT01639157)
Timeframe: Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.

,
Interventionarbitary units on a Visual Analog Scale (Mean)
0 mg Cocaine15 mg Cocaine45 mg Cocaine
Buspirone3.88.813.4
Placebo1.610.611.1

[back to top]

"Peak Ratings of Like Drug on the Visual Analog Scale"

"Subjects rated their feelings of Like Drug on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions." (NCT01639157)
Timeframe: Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.

,
Interventionarbitary units on a Visual Analog Scale (Mean)
0 mg Cocaine15 mg Cocaine45 mg Cocaine
Buspirone3.623.930.3
Placebo2.118.336.1

[back to top]

"Peak Ratings of Irregular/Racing Heartbeat on the Visual Analog Scale"

"Subjects rated their feelings of Irregular/Racing Heartbeat on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions." (NCT01639157)
Timeframe: Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.

,
Interventionarbitary units on a Visual Analog Scale (Mean)
0 mg Cocaine15 mg Cocaine45 mg Cocaine
Buspirone3.911.120.1
Placebo2.39.114.3

[back to top]

"Peak Ratings of High on the Visual Analog Scale"

"Subjects rated their feelings of High on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each cocaine dose under both buspirone and placebo conditions." (NCT01639157)
Timeframe: Subjects completed this measure at 15 minute intervals for 45 minutes after sampling each cocaine dose under both buspirone and placebo maintenance conditions.

,
Interventionarbitary units on a Visual Analog Scale (Mean)
0 mg Cocaine15 mg Cocaine45 mg Cocaine
Buspirone5.117.921.4
Placebo3.912.727.2

[back to top]

Maximum Days of Continuous Cocaine Abstinence

The primary outcome measure selected for the present two-stage protocol is the maximum days of continuous cocaine abstinence during study weeks 4-15. The Timeline Follow-back (TLFB) procedure (Sobell and Sobell, 1992; Fals-Stewart, 2000) will be used to assess the participants' self-reported use of substances for each day of the study. A rapid UDS system that screens for drugs of abuse will be used to analyze the urine samples. (NCT01641159)
Timeframe: study week 16

InterventionDays (Mean)
Buspirone Plus TAU42.9
Placebo Plus TAU46.6

[back to top]

Cocaine-use Days

Cocaine use days during days 22-105 as assessed by UDS and self-report combined with no imputation (NCT01641159)
Timeframe: study week 16

Interventionproportion of cocaine use days (Number)
Buspirone Plus TAU0.153
Placebo Plus TAU0.134

[back to top]

Attentional Bias to Marijuana Specific Stimuli Measured Via Analysis of Eye Movements

Eye movements are analyzed using a MiraMetrix S2 Eyetracker. This outcome measure reports a ratio: [(number of anti-saccade errors with marijuana-related images) divided by (total number of anti-saccade errors with marijuana-related images or neutral images)]. Anti-saccade errors are when the subject fails to inhibit fixation onto the image. (NCT02132832)
Timeframe: week 3

Interventionratio of errors (see OM description) (Mean)
Buspirone0.5503957
Placebo0.531073

[back to top]

Attentional Bias to Marijuana Specific Stimuli Measured Via Analysis of Eye Movements

Eye movements are analyzed using a MiraMetrix S2 Eyetracker. This outcome measure reports a ratio: [(number of anti-saccade errors with marijuana-related images) divided by (total number of anti-saccade errors with marijuana-related images or neutral images)]. Anti-saccade errors are when the subject fails to inhibit fixation onto the image. (NCT02132832)
Timeframe: week 2

Interventionratio of errors (see OM description) (Mean)
Buspirone0.5517691
Placebo0.4979594

[back to top]

Attentional Bias to Marijuana Specific Stimuli Measured Via Analysis of Eye Movements

Eye movements are analyzed using a MiraMetrix S2 Eyetracker. This outcome measure reports a ratio: [(number of anti-saccade errors with marijuana-related images) divided by (total number of anti-saccade errors with marijuana-related images or neutral images)]. Anti-saccade errors are when the subject fails to inhibit fixation onto the image. (NCT02132832)
Timeframe: week 1

Interventionratio of errors (see OM description) (Mean)
Buspirone0.5795019
Placebo0.5539831

[back to top]

Anxiety as Assessed by the Zung Self-Rated Anxiety Scale

"The Zung Self-Rated Anxiety Scale is a widely-used 20 item scale that is scored on a Likert-type scale of 1-4, with 15 questions concerning increasing anxiety levels and five questions concerning decreasing anxiety levels. The scale focuses on the most common general anxiety symptoms and means of coping with stressors that produce anxiety. The range of scores is 20-80:~20-44 Normal Range~45-59 Mild to Moderate Anxiety Levels~60-74 Marked to Severe Anxiety Levels~75-80 Extreme Anxiety Levels" (NCT02132832)
Timeframe: week 3

Interventionunits on a scale (Mean)
Buspirone33.27778
Placebo31.63158

[back to top]

Anxiety as Assessed by the Zung Self-Rated Anxiety Scale

"The Zung Self-Rated Anxiety Scale is a widely-used 20 item scale that is scored on a Likert-type scale of 1-4, with 15 questions concerning increasing anxiety levels and five questions concerning decreasing anxiety levels. The scale focuses on the most common general anxiety symptoms and means of coping with stressors that produce anxiety. The range of scores is 20-80:~20-44 Normal Range~45-59 Mild to Moderate Anxiety Levels~60-74 Marked to Severe Anxiety Levels~75-80 Extreme Anxiety Levels" (NCT02132832)
Timeframe: week 2

Interventionunits on a scale (Mean)
Buspirone31.5
Placebo31.57895

[back to top]

Anxiety as Assessed by the Zung Self-Rated Anxiety Scale

"The Zung Self-Rated Anxiety Scale is a widely-used 20 item scale that is scored on a Likert-type scale of 1-4, with 15 questions concerning increasing anxiety levels and five questions concerning decreasing anxiety levels. The scale focuses on the most common general anxiety symptoms and means of coping with stressors that produce anxiety. The range of scores is 20-80:~20-44 Normal Range~45-59 Mild to Moderate Anxiety Levels~60-74 Marked to Severe Anxiety Levels~75-80 Extreme Anxiety Levels" (NCT02132832)
Timeframe: week 1

Interventionunits on a scale (Mean)
Buspirone32.44444
Placebo32.52632

[back to top]

Stress as Assessed by the Visual Analogue Stress Scale-Current (VASS-C)

"With the Visual Analogue Stress Scale - Current (VASS-C), current stress level is ranked on a 0 - 10 visual analog scale, with 0 as no stress and 10 as extreme stress, cued by the question Please rate your current stress level." (NCT02132832)
Timeframe: week 2

Interventionunits on a scale (Mean)
Buspirone3
Placebo2.789474

[back to top]

Stress as Assessed by the Visual Analogue Stress Scale-Current (VASS-C)

"With the Visual Analogue Stress Scale - Current (VASS-C), current stress level is ranked on a 0 - 10 visual analog scale, with 0 as no stress and 10 as extreme stress, cued by the question Please rate your current stress level." (NCT02132832)
Timeframe: week 3

Interventionunits on a scale (Mean)
Buspirone1.944444
Placebo2.526316

[back to top]

Stress as Assessed by the Visual Analogue Stress Scale-Current (VASS-C)

"With the Visual Analogue Stress Scale - Current (VASS-C), current stress level is ranked on a 0 - 10 visual analog scale, with 0 as no stress and 10 as extreme stress, cued by the question Please rate your current stress level." (NCT02132832)
Timeframe: week 1

Interventionunits on a scale (Mean)
Buspirone3.888889
Placebo3.631579

[back to top]

Stress as Assessed by the Perceived Stress Scale

The Perceived Stress Scale is a 10 item scale that was developed to measure the degree to which individuals appraise their life as stressful and has been widely used in health studies. The scale has a 5-point Likert response format. The total score is calculated by summing responses. The questions are general in nature and relatively content free with regard to specific population groups. The range of scores is 0-40, with 40 indicating the most stress. (NCT02132832)
Timeframe: week 3

Interventionunits on a scale (Mean)
Buspirone10.38889
Placebo14.05263

[back to top]

Stress as Assessed by the Perceived Stress Scale

The Perceived Stress Scale is a 10 item scale that was developed to measure the degree to which individuals appraise their life as stressful and has been widely used in health studies. The scale has a 5-point Likert response format. The total score is calculated by summing responses. The questions are general in nature and relatively content free with regard to specific population groups. The range of scores is 0-40, with 40 indicating the most stress. (NCT02132832)
Timeframe: week 2

Interventionunits on a scale (Mean)
Buspirone13.88889
Placebo16.42105

[back to top]

Stress as Assessed by the Perceived Stress Scale

The Perceived Stress Scale is a 10 item scale that was developed to measure the degree to which individuals appraise their life as stressful and has been widely used in health studies. The scale has a 5-point Likert response format. The total score is calculated by summing responses. The questions are general in nature and relatively content free with regard to specific population groups. The range of scores is 0-40, with 40 indicating the most stress. (NCT02132832)
Timeframe: week 1

Interventionunits on a scale (Mean)
Buspirone15.05556
Placebo18.57895

[back to top]

Changes From Baseline in Manometric Parameters: Duration of Contractions at the Distal Part of the Esophagus at Week 4

(NCT02363478)
Timeframe: before and after 4 weeks buspirone administration

Interventionsec (Mean)
Buspirone0.5

[back to top]

Changes From Baseline in Manometric Parameters: Velocity of Contractions at the Distal Part of the Esophagus at Week 4

(NCT02363478)
Timeframe: before and after 4 weeks buspirone administration

Interventioncm/sec (Mean)
Buspirone0.3

[back to top]

Changes From Baseline in Manometric Parameters: i) Amplitude of Contractions at the Distal Part of the Esophagus and ii) Resting and Residual (Lower Esophageal Pressure) LES Pressure and IRP (Integrated Relaxation Pressure) at Week 4

(NCT02363478)
Timeframe: before and after 4 weeks buspirone administration

InterventionmmHg (Mean)
amplitudeLES resting pressureLES residual pressureIRP
Buspirone0.94.50.30.4

[back to top]

Changes in the Severity of Esophageal Symptoms at Week 4

Severity of esophageal symptoms (dysphagia, heartburn, regurgitation and chest pain) was measured on a 100-point visual analogue scale (VAS) ranging from 0 (absent) to 100 (very severe). Even minor decrease in the VAS score for each symptom at week 4 considered as improvement. (NCT02363478)
Timeframe: before and after 4 weeks buspirone administration

Interventionunits on a scale (Mean)
heartburnregurgitationdysphagiachest pain
Buspirone14.913.26.91.9

[back to top]

Apnea-Hypopnea Index (AHI)

Randomized placebo-controlled cross-over study. Each subject was studied on three separate occasions: (1) Buspirone vs. Trazodone vs. placebo for 2 weeks; After the two-week treatment a polysomnogram (PSG) study was repeated to determine the AHI. (2) Cross over medication for two weeks was followed by a second PSG to determine the AHI followed by two weeks washout. (3) Cross over medication for two weeks was followed by another sleep study to determine the AHI. (NCT02458469)
Timeframe: Two weeks

InterventionEvents/Hour (Mean)
Buspirone48.7
Trazodone40.0
Placebo45.2

[back to top]

CO2 Reserve (Delta-PETCO2-AT)

Randomized placebo-controlled cross-over study. Each subject was studied on three separate occasions: (1) Buspirone vs. Trazodone vs. placebo for 2 weeks; After the two-week treatment a noninvasive nasal mechanical ventilation study was repeated to determine the hypocapnic apneic threshold. (2) Cross over medication for two weeks was followed by a second noninvasive nasal mechanical ventilation study to determine the CO2 reserve (Delta-PETCO2-AT) and hypocapnic apneic threshold followed by two weeks washout. (3) Cross over medication for two weeks was followed by another sleep study to determine the hypocapnic apneic threshold. (NCT02458469)
Timeframe: Two weeks

InterventionmmHg (Mean)
Buspirone-3.6
Trazodone-2.5
Placebo-1.8

[back to top] [back to top]

Change in Percentage of Normal Swallows Recorded in a Series of 10 Measured Swallows.

A normal swallow is defined as a swallow with a Distal Contractile Index greater than 450mm Hg (NCT02674412)
Timeframe: 14 days

Interventionpercentage of swallows (Mean)
Buspirone15
Placebo20

[back to top]

Change in Distal Contractile Index (DCI) on High Resolution Esophageal Manometry

DCI is a measure of the strength of muscle contractions in the esophagus while swallowing. It is measured in mm Hg, and values greater than 450mm Hg are considered Normal. (NCT02674412)
Timeframe: Change in the score from Baseline to 14 days

Interventionmm Hg (Mean)
Buspirone241.9
Placebo340.4

[back to top]

Mean Change in Hamilton Anxiety Rating Scale (HAM-A) From Baseline to 12 Weeks

The HAM-A assess anxiety on 0-56 scale where a higher score represents a higher level of anxiety. (NCT02803749)
Timeframe: 12 weeks

Interventionscore on a scale (Mean)
Buspirone-4.21
Placebo-3.36

[back to top]

"Number of Much Improved or Very Much Improved on Patient Global Impressions-Improvement (PGI-I) at 12 Weeks"

"The PGI-I assesses patient global impression of improvement on a 7-point scale where 1 = very much improved and 7 = very much worse." (NCT02803749)
Timeframe: 12 weeks

InterventionParticipants (Count of Participants)
Buspirone3
Placebo0

[back to top]

"Number of Much Improved or Very Much Improved on Clinical Global Impressions-Improvement (CGI-I) at 12 Weeks"

"The CGI-I assesses clinician global impression of improvement on a 7-point scale where 1 = very much improved and 7 = very much worse." (NCT02803749)
Timeframe: 12 weeks

InterventionParticipants (Count of Participants)
Buspirone5
Placebo2

[back to top]

Mean Change in Hospital Anxiety and Depression Scale (HADS) - Depression From Baseline to 12 Weeks

The HADS assesses anxiety on a scale of 0-21 and depression on a scale of 0-21 with higher scores indicating higher levels of anxiety and depression respectively. (NCT02803749)
Timeframe: 12 weeks

Interventionunits on a scale (Mean)
Buspirone-.95
Placebo.34

[back to top]

The Number of Participants Who Fail to Complete the 12-week Study on Study Drug.

(NCT02803749)
Timeframe: 12 weeks

InterventionParticipants (Count of Participants)
Buspirone7
Placebo0

[back to top]

Mean Change in Anxiety Using the Hospital Anxiety and Depression Scale (HADS)

The HADS assesses anxiety on a scale of 0-21 and depression on a scale of 0-21 with higher scores indicating higher levels of anxiety and depression respectively. (NCT02803749)
Timeframe: baseline to 12 weeks

Interventionscore on a scale (Mean)
Buspirone-1.87
Placebo-0.89

[back to top]

Mean Change in Unified Dyskinesia Rating Scale (UDysRS) From Baseline to 12 Weeks

The UDysRS assesses dyskinesias on a scale of 0-104 where a higher score represents more severe dyskinesias. (NCT02803749)
Timeframe: 12 weeks

Interventionscore on a scale (Mean)
Buspirone.72
Placebo7.78

[back to top]

Number of Responders (>50% Reduction From Baseline or Reduction to ≤7 on HAM-A) at 12 Weeks

The HAM-A assess anxiety on 0-56 scale where a higher score represents a higher level of anxiety. (NCT02803749)
Timeframe: 12 weeks

InterventionParticipants (Count of Participants)
Buspirone9
Placebo1

[back to top]

Heart Rate

Hyperarousal will be measured by heart rate during participants' time in the driving simulation. (NCT03538431)
Timeframe: Up to 6 weeks

InterventionBeats Per Minute (Mean)
Buspirone81.78
Unmedicated82.74

[back to top]

Driving Performance - Measured by Mean Off-Road Glance Duration

Driving performance will be analyzed using eye tracking in individuals with Autism Spectrum Disorder while on the anti-anxiety medication buspirone and while not on buspirone. Eye movement behavior (measured by glance duration) during the driving simulation was manually coded on a frame-by-frame basis from recorded video by trained coders for all cases where usable video recordings were available for both the medicated and non-medicated driving simulation sessions per participant. (NCT03538431)
Timeframe: Up to 6 weeks

InterventionSeconds (Mean)
Buspirone0.85
Unmedicated0.90

[back to top]

4-Week Cardiac Rhythm

This safety outcome is computed from the results of an electrocardiogram (ECG) QTc interval at 4-weeks measured in milliseconds (msec). (NCT03587142)
Timeframe: baseline and 4-weeks

Interventionmilliseconds (msec) (Least Squares Mean)
Buspirone-2.80
Placebo3.63

[back to top]

4-Week Change in Anxiety

The outcome is assessed using the self-reported Hospital Anxiety and Depression Scale (HADS) anxiety subscore, calculated as the sum of 7-items, each scored from 0 (not at all) to 3 (most of the time). The change is computed as the subscore at 4-weeks minus the baseline subscore. A negative change indicates reduced anxiety at 4-weeks. (NCT03587142)
Timeframe: baseline and 4-weeks

Interventionunits on a scale (Least Squares Mean)
Buspirone-1.27
Placebo-2.03

[back to top]

4-Week Change in Aspartate Aminotransferase (ALT)

This safety outcome is computed by subtracting the baseline level of Alanine Aminotransferase (ALT) (U/L) from the 4-week level. (NCT03587142)
Timeframe: baseline and 4-weeks

InterventionU/L (Least Squares Mean)
Buspirone0.32
Placebo1.34

[back to top]

4-Week Change in Bloating and Stomach Distention Symptoms Severity

The outcome is assessed using the self-reported bloating subscore, which is computed as the average of 2 scores for 2-items on the Gastroparesis Cardinal Symptom Index (GCSI) survey: bloating, stomach visibly larger. Each item is scored from 0 (no) to 5 (very severe) symptoms in the past 2-weeks; the subscore ranges from 0 to 5. The change is computed as the subscore at 4-weeks minus the baseline subscore. A negative value for change indicates improvement in symptoms. (NCT03587142)
Timeframe: baseline and 4-weeks

Interventionscore on a scale (Least Squares Mean)
Buspirone-1.36
Placebo-0.95

[back to top]

4-Week Change in Bloating Symptom Severity

The outcome is assessed using self-reported assessment of bloating severity in the prior 2-weeks using the Gastroparesis Cardinal Symptom Index (GCSI) survey. The item is scored from 0 (no) to 5 (very severe) symptoms; the change is computed as the score at 4-weeks minus the baseline score. A negative change indicates symptom improvement. (NCT03587142)
Timeframe: baseline and 4-weeks

Interventionscore on a scale (Least Squares Mean)
Buspirone-1.34
Placebo-0.69

[back to top]

Assessment of the Severity of Adverse Events Over 4-Weeks

This safety outcome is the frequency over the 4-weeks of the study of all reported adverse events' severity grade as classified by the NCI's Common Terminology Criteria for Adverse Events (CTCAE v5.0). For the patient with 2 AE's, the AE with the maximum severity is reported. (NCT03587142)
Timeframe: over 4-weeks

,
InterventionParticipants (Count of Participants)
No Adverse events1-mild severity2-moderate severity3-severe4-life threatening5-death
Buspirone3556100
Placebo4126000

[back to top]

Adverse Events by Body Classification System by Treatment Group During the Trial

Adverse events were reported on the Adverse Event Report form by the principal investigator at each clinic site using the CTCAE v5 classification system. (NCT03587142)
Timeframe: over 4-weeks of treatment

,
Interventionevents by body classification (Number)
GastrointestinalImmune systemInfections & infestationsInvestigationsMetabolic & nutritionNervous systemRenal & urinarySurgical & medicalMusculoskeletal & connective tissue disordersTotal
Buspirone31301310012
Placebo3012001119

[back to top]

Total Number of Hospitalizations Over 4-weeks of Treatment

Hospitalization events by treatment arm were reported on the Adverse Event Case-Report form at each visit and also at time of occurrence and tabulated at end of treatment visit for comparison between placebo and buspirone arms. (NCT03587142)
Timeframe: over the 4-weeks of the trial

Interventionhospitalizations (Number)
Buspirone1
Placebo0

[back to top]

Serious Adverse Events

Serious Adverse Event (SAE) defined by the FDA as an event meeting one or more of the following criteria; inpatient hospitalization or prolonged existing hospitalization; persistent or significant incapacity or substantial disruption of ability to conduct normal life functions; jeopardized patient and required medical or surgical intervention to prevent a serious event; or congenital anomaly or birth defect. (NCT03587142)
Timeframe: over 4 weeks of treatment

InterventionSerious adverse events (Number)
Buspirone1
Placebo1

[back to top]

Change From Baseline at 4-weeks in the Water Load Satiety Test (WLST)

The Water Load Satiety Test (WLST) is the amount of water a patient can consume until full in 5 minutes. The volume of water is recorded. The change is computed as the volume of water ingested at baseline subtracted from the amount of water ingested at 4-weeks. A positive change indicates that the patient can ingest more water at 4-weeks than at baseline. (NCT03587142)
Timeframe: baseline and 4-weeks

Interventionml (Least Squares Mean)
Buspirone-43.3
Placebo-21.8

[back to top]

Change at 4-weeks in the Intragastric Meal Distribution (IMD)

The Intragastric meal distribution (IMD) is assessed at baseline and 4-weeks during the Gastric Emptying Scintigraphy Test. The ratio of gastric counts of the meal in the proximal stomach to the distal stomach is used to compute the Intragastric meal distribution (IMD) which can be used as an indirect measure of Fundic Accommodation. (NCT03587142)
Timeframe: baseline and 4-weeks

Interventionratio (Least Squares Mean)
Buspirone-0.04
Placebo0.02

[back to top]

Assessment of Adverse Events Over 4-Weeks

This safety outcome is the frequency over the 4-weeks of the study of all reported adverse events using the v5.0 CTCAE classification system. (NCT03587142)
Timeframe: over 4-weeks

Interventionevents (Number)
Buspirone12
Placebo8

[back to top]

4-Week Change Overall Quality of Health Due to Gastroparesis Issues

The outcome is assessed using the self-reported Patient Assessment of Upper Gastrointestinal Disorders-Quality of Life (PAGI-QOL) total score which comprises 30 items scored from 0 (none of the time) to 5 (all of the time) the participant's QOL has been affected by their gastrointestinal issues in the prior two weeks. The total score is the mean of the 5 subscale scores and ranges from 0 (lowest QOL) to 5 (highest QOL) in past 2-weeks. The change is computed as the score at 4-weeks minus the baseline score. A positive change indicates improved QOL. (NCT03587142)
Timeframe: baseline and 4-weeks

Interventionscore on a scale (Least Squares Mean)
Buspirone0.43
Placebo0.64

[back to top]

4-Week Change in Weight

This safety outcome is computed by subtracting the weight (kg) at baseline from the weight (kg) at 4-weeks (NCT03587142)
Timeframe: baseline and 4-weeks

Interventionkilogram (Least Squares Mean)
Buspirone-0.34
Placebo-0.43

[back to top]

4-Week Change in Vomiting Symptom Severity

The outcome is assessed using self-reported assessment of vomiting severity in the prior 2-weeks using the Gastroparesis Cardinal Symptom Index (GCSI) survey. The item is scored from 0 (no) to 5 (very severe) symptoms; the change is computed as the score at 4-weeks minus the baseline score. A negative change indicates improvement in vomiting severity. (NCT03587142)
Timeframe: baseline and 4-weeks

Interventionscore on a scale (Least Squares Mean)
Buspirone-0.71
Placebo-0.57

[back to top]

4-Week Change in Upper Abdominal Pain Symptom Severity

The outcome is assessed using self-reported assessment of upper abdominal pain severity in the prior 2-weeks using the Patient Assessment of Upper Gastrointestinal Disorders Symptom Severity Index (PAGI-SYM) survey. The item is scored from 0 (no) to 5 (very severe) symptoms; the change is computed as the score at 4-weeks minus the baseline score. A negative change indicates symptom improvement. (NCT03587142)
Timeframe: baseline and 4-weeks

Interventionscore on a scale (Least Squares Mean)
Buspirone-0.69
Placebo-0.93

[back to top]

4-Week Change in Upper Abdominal Pain and Discomfort Symptoms Severity

The outcome is assessed using the self-reported upper abdominal pain subscore, which is computed as the average of 2 scores for 2-items on the Patient Assessment of Upper Gastrointestinal Disorders-Symptom Severity Index (PAGI-SYM) survey: upper abdominal pain, upper abdominal discomfort. Each item is scored from 0 (no) to 5 (very severe) symptoms in the past 2-weeks; the subscore ranges from 0 to 5. The change is computed as the subscore at 4-weeks minus the baseline subscore. (NCT03587142)
Timeframe: baseline and 4-weeks

Interventionscore on a scale (Least Squares Mean)
Buspirone-0.78
Placebo-0.95

[back to top]

4-Week Change in Total Overall GCSI Symptom Severity

The outcome is assessed using the self-reported Gastroparesis Cardinal Symptom Index (GCSI) total score, which is computed as the average of the 3 subscores on the GCSI survey: 3-item early satiety/postprandial fullness subscore, the nausea/vomiting subscore (average of 3-items: nausea, retching, vomiting), and bloating subscore (average of 2-items: bloating, stomach visibly larger). Each item is scored from 0 (no) to 5 (very severe) symptoms in the past 2-weeks; the total score ranges from 0 to 5. The change is computed as the total score at 4-weeks minus the baseline total score. A negative change indicates improved symptoms. (NCT03587142)
Timeframe: baseline and 4-weeks

Interventionscore on a scale (Least Squares Mean)
Buspirone-1.06
Placebo-0.86

[back to top]

4-Week Change in the Postprandial Fullness and Early Satiety Symptoms Severity

The outcome is assessed using the self-reported early satiety/postprandial fullness subscore (ES/PPF), which is computed as the average of 4 scores for 4-items on the Gastroparesis Cardinal Symptom Index (GCSI) survey: stomach fullness, inability to finish a normal-sized meal, feeling excessively full after meals, and loss of appetite. Each item is scored from 0 (no) to 5 (very severe) symptoms in the past 2-weeks; the subscore ranges from 0 to 5. The change is computed as the subscore at 4-weeks minus the baseline subscore. (NCT03587142)
Timeframe: baseline and 4-weeks

Interventionscore on a scale (Least Squares Mean)
Buspirone-1.16
Placebo-1.03

[back to top]

4-Week Change in Inability to Finish a Normal-sized Meal Symptom Severity

The outcome is assessed using self-reported assessment of inability to finish a normal-sized meal severity in the prior 2-weeks using the Gastroparesis Cardinal Symptom Index (GCSI) survey. The item is scored from 0 (no) to 5 (very severe) symptoms; the change is computed as the score at 4-weeks minus the baseline score. A negative change indicates symptom improvement. (NCT03587142)
Timeframe: baseline and 4-weeks

Interventionscore on a scale (Least Squares Mean)
Buspirone-1.27
Placebo-1.12

[back to top]

4-Week Change in Stomach Fullness Symptom Severity

The outcome is assessed using self-reported assessment of stomach fullness severity in the prior 2-weeks using the Gastroparesis Cardinal Symptoms Index (GCSI) survey. The item is scored from 0 (no) to 5 (very severe) symptoms; the change is computed as the score at 4-weeks minus the baseline score. (NCT03587142)
Timeframe: baseline and 4-weeks

Interventionscore on a scale (Least Squares Mean)
Buspirone-1.16
Placebo-1.07

[back to top]

4-Week Change in Severity of Somatic Symptoms

The outcome is assessed using the self-reported Patient Health Questionnaire 15 Somatic Symptom Severity Scale (PHQ-15) total somatization score (ranges from 0 -30, with 30 being most bothered by symptoms in prior 4-weeks), calculated as the sum of 15-items, each scored from 0 (not bothered at all) to 2 (bothered a lot) by somatic symptoms in the prior 4-weeks. The change is computed as the score at 4-weeks minus the baseline score. A negative change indicates being less bothered by the symptoms. (NCT03587142)
Timeframe: baseline and 4-weeks

Interventionunits on a scale (Least Squares Mean)
Buspirone-0.99
Placebo-2.00

[back to top]

4-Week Change in Participant's Rating of Symptom Relief

The outcome is assessed using the participant-rated Clinical Patient Grading Assessment Scale (CPGAS) score which is scored from -3 (very considerably worse) to 3 (completely better) in the past week compared to the way the participant usually feels. The change is computed as the score at 4-weeks minus the baseline score. A positive change indicates patient feeling better. (NCT03587142)
Timeframe: baseline and 4-weeks

Interventionunits on a scale (Least Squares Mean)
Buspirone0.69
Placebo0.37

[back to top]

4-Week Change in Gastric Retention

The outcome is assessed using the percent of gastric retention at 4-hours from the Gastric Emptying Scintigraphy (GES) test. The change is computed as the percent retention at 4-weeks minus the baseline percent retention. % retention is the amount of food remaining in the stomach at 4-hours of the GES test and ranges from 0% (no food) to 100% (all of the food). (NCT03587142)
Timeframe: baseline and 4-weeks

Interventionunits on a percentage scale (Least Squares Mean)
Buspirone4.24
Placebo2.87

[back to top]

4-Week Change in Overall Physical Quality of Life (QOL)

The outcome is assessed using the self-reported 36-item Short Form Health Survey (SF-36v2) physical health QOL component score. The score ranges from 0 (poorest) to 100 (highest) QOL. The change is computed as the score at 4-weeks minus the baseline score. A positive change indicates improved Physical QOL. (NCT03587142)
Timeframe: baseline and 4-weeks

Interventionunits on a scale (Least Squares Mean)
Buspirone1.10
Placebo3.17

[back to top]

4-Week Change in Overall Mental Quality of Life (QOL)

The outcome is assessed using the self-reported 36-item Short Form Health Survey (SF-36v2) mental health QOL component score. The score ranges from 0 (poorest) to 100 (highest) QOL. The change is computed as the score at 4-weeks minus the baseline score. A positive change indicates improved mental QOL. (NCT03587142)
Timeframe: baseline and 4-weeks

Interventionunits on a scale (Least Squares Mean)
Buspirone1.19
Placebo3.17

[back to top]

4-Week Change in Nausea, Vomiting and Retching Symptoms Severity

The outcome is assessed using the self-reported nausea/vomiting subscore, which is computed as the average of 3 scores for 3-items on the Gastrointestinal Cardinal Symptom Index (GCSI) survey: nausea, retching, vomiting. Each item is scored from 0 (no) to 5 (very severe) symptoms in the past 2-weeks. The change is computed as the subscore at 4-weeks minus the baseline subscore. Negative change indicates improvement in symptoms. (NCT03587142)
Timeframe: baseline and 4-weeks

Interventionscore on a scale (Least Squares Mean)
Buspirone-0.65
Placebo-0.60

[back to top]

4-Week Change in Nausea Symptom Severity

The outcome is assessed using self-reported assessment of nausea severity item from the Patient Assessment of Upper Gastrointestinal Disorders Symptom Severity Index (PAGI-SYM) in the prior 2-weeks using the Gastroparesis Cardinal Symptom Index (GCSI) survey. The item is scored from 0 (no) to 5 (very severe) symptoms; the change is computed as the score at 4-weeks minus the baseline score. (NCT03587142)
Timeframe: baseline and 4-weeks

Interventionscore on a scale (Least Squares Mean)
Buspirone-0.75
Placebo-0.70

[back to top]

4-Week Change in Loss of Appetite Symptom Severity

The outcome is assessed using self-reported assessment of loss of appetite severity in the prior 2-weeks using the Gastroparesis Cardinal Symptom Index (GCSI) survey. The item is scored from 0 (no) to 5 (very severe) symptoms; the change is computed as the score at 4-weeks minus the baseline score. A negative change indicates symptom improvement. (NCT03587142)
Timeframe: baseline and 4-weeks

Interventionscore on a scale (Least Squares Mean)
Buspirone-1.09
Placebo-0.96

[back to top]

4-Week Change in Gastrointestinal Symptoms Rating Scale (GSRS) Global Score

The outcome is assessed using the self-reported GSRS total score which is computed as the mean of the 15 item scores on the Gastrointestinal Symptom Rating Scale (GSRS) survey. Each item is scored from 1 (no discomfort) to 7 (very severe discomfort) of the symptom in the past week. The change is computed as the score at 4-weeks minus the baseline score. A negative change indicates symptom improvement. (NCT03587142)
Timeframe: baseline and 4-weeks

Interventionunits on a scale (Least Squares Mean)
Buspirone-0.63
Placebo-0.49

[back to top]

4-Week Change in Gastroesophageal (GERD) Symptoms Severity

The outcome is assessed using the self-reported GERD subscore, which is computed as the average of 7 scores for 7-items on the Patient Assessment of Gastrointestinal Disorders Symptom Severity Index (PAGI-SYM) survey: heartburn during the day, heartburn when lying down, feeling of discomfort inside chest during the day, feeling of discomfort inside chest during sleep, regurgitation or reflux during the day, regurgitation when lying down, bitter, acid or sour taste in mouth. Each item is scored from 0 (no) to 5 (very severe) symptoms in the past 2-weeks; the subscore ranges from 0 to 5. The change is computed as the subscore at 4-weeks minus the baseline subscore. (NCT03587142)
Timeframe: baseline and 4-weeks

Interventionscore on a scale (Least Squares Mean)
Buspirone-0.36
Placebo-0.45

[back to top]

4-Week Change in Fasting Glucose

This safety outcome is computed by subtracting the baseline level of glucose (mg/dL) from the 4-week level. (NCT03587142)
Timeframe: baseline and 4-weeks

Interventionmg/dL (Least Squares Mean)
Buspirone10.30
Placebo10.69

[back to top]

4-Week Change in Excessive Fullness Symptom Severity

The outcome is assessed using self-reported assessment of feeling excessively full after meals severity in the prior 2-weeks using the Gastroparesis Cardinal Symptom Index (GCSI) survey. The item is scored from 0 (no) to 5 (very severe) symptoms; the change is computed as the score at 4-weeks minus the baseline score. (NCT03587142)
Timeframe: baseline and 4-weeks

Interventionscore on a scale (Least Squares Mean)
Buspirone-1.14
Placebo-0.99

[back to top]

4-Week Change in Depression

The outcome is assessed using the self-reported Hospital Anxiety and Depression Scale (HADS) depression subscore, calculated as the sum of 7 items, each scored from 0 (not at all) to 3 (most of the time). The change is computed as the subscore at 4-weeks minus the baseline subscore. A negative change indicates reduced depression. (NCT03587142)
Timeframe: baseline and 4-weeks

Interventionunits on a scale (Least Squares Mean)
Buspirone0.42
Placebo-1.43

[back to top]

4-Week Change in Creatinine

This safety outcome is computed by subtracting the baseline level of creatinine (mg/dL) from the 4-week level. (NCT03587142)
Timeframe: baseline and 4-weeks

Interventionmg/dL (Least Squares Mean)
Buspirone0.02
Placebo-0.01

[back to top]